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Abstract  
 
Consisting of five subunits (!1-!4 and "), glycine receptors (GlyRs) orchestrate inhibitory 
neurotransmission in the central nervous system (CNS). Mutation and/or dysfunction of different 
GlyR subunits are associated with CNS diseases such as spasticity and movement disorders 
(GlyR!1), hyperekplexia (GlyR !1, GlyR!2 and GlyR"), epilepsy (GlyR!2 and GlyR!3) and 
inflammatory pain (GlyR!1 and GlyR!3). In particular, GlyR!3 has recently emerged as the target 
of choice for the treatment of chronic inflammatory pain due to its discrete distribution at the lamina 
II dorsal horn spinal cord, the pain terminal. Unfortunately, while known GlyR modulators lack 
specificity for GlyRs, that render them undrugable, little is known about GlyR modulators from 
marine natural products (MNPs), despite the important roles of MNPs in drug discovery programs. 
Together with the biomedical potential of MNPs and the unmet medical needs in treatment of CNS 
diseases, recent advances in spectroscopic and ion channel technologies strongly suggest the 
importance of MNPs in the discovery of novel, potent and specific GlyR modulators.  
Consequently, chapter 1 discusses the various potential medical benefits of GlyRs and/or MNPs in 
the search for a cure for CNS diseases, with emphasis on chronic inflammatory pain. They include:  
•     Structural diversity and pharmacological aspect of GlyRs;  
•     Possible uses of GlyR modulators in therapy;  
•   The importance of advanced technologies in discovering anti-inflammatory pain drugs from   
marine resource;  
•   MNPs as a prolific source of bioactive molecules; and  
•   The role of MNPs in the discovery of new pain relief drugs.  
Chapter 2 prioritizes marine extracts as our first step in identifying MNPs as potential GlyR 
modulators. Taking advantage of the yellow fluorescence protein (YFP) assay, we screened n-
BuOH extracts of >2,500 Australian and Antarctic marine invertebrates against GlyR!1, GlyR!2 
and GlyR!3 and compared the images for control and tested extracts. This screening yielded 27 
active extracts (3 strong, 19 moderate and 5 weak antagonist extracts). Along with this screening, 
liquid chromatography mass spectrometry (LCMS) analysis established 7 priority specimens 
described in the following three chapters.  
Chapter 3 describes 6 new (ircinialactam A (3.45), 8-hydroxyircinialactam A (3.46), 
hydroxyircinialactam B (3.47), ircinialactam C (3.48), ent-ircinialactam C (3.49) & ircinialactam D 
(3.50) and 3 known (12E,20Z,18S)-8-hydroxyvariabilin (3.51), (7E,12E,20Z,18S)-variabilin (3.52) 
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and (7E,12Z,20Z,18S)-variabilin (3.53) compounds from three Irciniidae sponges. The isomers 3.51 
and 3.52 were successfully isolated and assigned as a single pure compound without derivatisation. 
Importantly, by means of liquid chromatography-solid phase extraction nuclear magnetic resonance 
(LC-SPE-NMR), we managed to isolate and elucidate the structure of minor metabolites (3.45-
3.50). Ircinialactams (3.45-3.50) were unique in that they all featured an unusual functionality, a 
glycinyl lactam and in case of ircinialactam D, a dihydroxy diacid moiety. Using automated patch 
clamp electrophysiology (APCE), we evaluated 3.45-3.53 against !1 and !3 GlyRs and identified 
3.46 and 3.47 as strong and specific GlyR!1 potentiators with EC50 values of 1.0 µM and 0.5 µM 
respectively and 3.53 as a potent and selective GlyR!3 antagonist (IC50 = 7.0 µM).  
Chapter 4 discloses 5 novel cyclic sesterterpenes (-)-ircinianinlactam A (4.11), (-)-oxo-ircinianin 
lactam A sulfate (4.12), (-)-oxo-ircinianin A (4.13), (-)-oxo-ircinianin lactam A (4.14), and (-)-
ircinianin lactone (4.15), two known co-metabolites (-)-ircinianin (4.1) & (-)-ircinianin sulfate (4.2) 
and one synthetic derivative, ircinianin acetate (4.16). Ircinianins possessed rare functional groups 
such as the glycinyl lactam in 4.11, 4.12 and 4.14 and a modified tetronic acid in 4.13 and 4.14 with 
the latter moiety being hitherto unknown in natural products. Importantly, APCE analysis showed 
4.2 as a strong GlyR!3 antagonist (IC50 = 3.2 µM), 4.14 as a specific GlyR!1 potentiator and 4.11 
as a potent and selective GlyR!3 potentiator (EC50 = 8.2 µM). (-)-Ircinianinlactam A (4.11) was the 
first compound to exert such activity against GlyR!3 subunit, the emerging pain target.  
Chapter 5 discusses ianthellalactam A (5.66) and B (5.67) (new), ethyldictyondendrilin (5.68) 
(artefact), aplysinopsin (5.1), 8E-3#-deimino-oxoaplysinopsin (5.3), 8Z-3#-deimino-oxoaplysinopsin 
(5.4), dihydroaplysinopsin (5.10) and tubastrindole B (5.34) (known) from Ianthella cf. 
flabelliformis. Ianthellalactam A and B were the first examples of linear sesquiterpene glycinyl 
lactams. APCE analysis revealed 5.3 and 5.4 as modest GlyR!3 antagonists (IC50 = 67.0 µM) and 
5.34 as a strong GlyR!1 potentiator (1.0 µM) but a modest antagonist at high concentration (IC50 = 
25.9 µM). One pot synthesis produced two strong GlyR!1 antagonists, 8E-3#-deimino-4#-demethyl-
3#-oxoaplysinopsin (5.70) and 8Z-3#-deimino-4#-demethyl-3#- oxoaplysinopsin (5.71), with IC50 
values of 8.8 µM.  
Finally, chapter 6 describes 30 compounds discovered during this study. Apart from their status 
(new or known, natural products and/or synthetics), this chapter provides their physicochemical 
characteristics and bioactivity against GlyRs. Moreover, through a strength-weakness-opportunity-
threat (SWOT) analysis, this chapter discusses the possibility of taking the lead compounds (3.46, 
3.47, 4.11 & 4.14) to the pipeline or clinical trials. 
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CHAPTER 1 
 GENERAL  INTRODUCTION 
!
 
 
1. 1. Cys-loop ligand gated ion channels 
 
Cys-loop receptors that mediate fast excitatory and inhibitory synaptic neurotransmissions belong to ligand gated 
ion channels (LGICs)1-3, which was the third most targeted of the recent 324 approved drug targets4. Typically, 
the cys-loop receptors form a pentameric structure with a family of four ionotropic receptors—all of which are 
crucial targets for the treatments of neurological disorders—including serotonin type-3 receptors (5-HT3Rs), the 
nicotinic acetylcholine receptors (nAChRs), !-amino butyric acid type-A (GABAAR) and type-C (GABACR) and 
glycine receptors (GlyRs)1. 5-HT3Rs, and nAChRs that form cation (Ca2+ and K+) pentameric sensitive pore 
facilitate excitatory neurotransmission leading to depolarization in the cells2,3. In contrast, GABARs and GlyRs 
that construct anion (Cl- and HCO3-) permeable pore mediate rapid inhibitory neurotransmission resulting in 
hyper-polarization in the cells3,5. Both stimulatory and inhibitory synaptic transmissions have well-established 
roles in maintaining various neurological functions and whose disruptions are inflicted with neurological 
disorders and/or diseases5-7. 
5-HT3Rs and nAChRs, for example, sculpt excitatory neurotransmission in the brain, peripheral and central 
nervous system (CNS) and are targets for many neurological diseases6,7. nAChRs reside in both the CNS (highly 
expressed in the hippocampus) and peripheral nervous system (PNS) particularly at the skeletal neuromuscular 
junction and in the autonomic nervous system6. At these locations, nAChRs play a variety of crucial physiological 
functions ranging from learning memory to improving cognition through memory formation6. Dysfunctions of 
nAChRs are implicated with various neurological disorders (Alzheimer’s diseases, schizophrenia, depression, 
attention deficit, hyperactivity disorder and tobacco addiction)6. The serotonin type-3 receptors (5-HT3Rs) are 
also important excitatory neurotransmitters in the brain mainly expressed in the area postrema, the caudate 
nucleus, hippocampus and the amygdala8. These receptors are relevant targets for the treatments of CNS diseases 
such as depression9 and psychotic disorders10.  
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In contrast, the chloride channel receptors GABAARs and GlyRs are the major inhibitory neurotransmitters in the 
brain and CNS5. Specifically, GABAARs signalling orchestrates synaptic inhibition in the brain with these 
receptors being clinically relevant targets for anti-convulsant, anxiolytic, sedative-hypnotic, epileptic11, cognitive 
deficit, schizophrenic, antidepressant and substance abuse agents12. GlyRs are the major neurotransmitters in the 
CNS but with more restricted distribution than GABAARs13. GlyRs are expressed specifically in the spinal cord, 
brain stem and in particular part of the brain such as cerebellum, the retina and hippocampus5. At these sites, 
GlyRs play key roles in respiratory rhythms, motor control, muscle tone, temporal tone and epilepsy as well as 
sensory and pain processing13. The discrete distribution of GlyRs is beneficial as it provides fewer side effects as 
a pain target compared to cannabinoid receptors14 and a more localized enhancement of glycinergic inhibition13.   
 
1.2. GlyRs as A Drug Target  
Like other members of cys-loop LGICs, GlyRs feature pentameric structures (Figure 1.1) drawn from their 
homology with nAChRs, the prototypical cys-loop LGICs15. In total, five genes (GlyR"1-4 and GlyR#) of GlyRs 
have been identified in mammalian tissues with different distribution in the spinal cord, brain stem and other parts 
of the brain2. These discrete expression and distribution dictate the pharmacological profiles, with dysfunctions of 
GlyRs linked with a range of neurological diseases/disorders such as hyperekplexia16, muscle tension14, 
spasticity17, epilepsy18 and inflammatory pain1,19.  
 
1.2.1 GlyRs Structure  
Each subunit of the pentameric GlyRs contains an amino-terminal extracellular domain with a loop connected by 
disulphide bonds acting as the ligand binding site, four transmembrane domains (M1-M4) assembled together 
with the second transmembrane (M2) forming the pentameric chloride sensitive pore, a large intracellular loop 
(IL) between M3 and M4 as the intracellular modulation sites (Figure 1.1)2. M3 and M4 are linked by a large, 
poorly conserved, intracellular domain that contain phosphorylation sites and other sites mediated by cytoplasmic 
factors2. Several GlyR modulators including gingkolides, bilobalide and picrotoxins are known to modulate the 
second and the third transmembrane domain (M2-M3)20 (discussed in section 1.4.2, page 9). A very recent 
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discovery also stressed the importance of a group of polar amino acids in these two transmembranes and the 
vicinity of transmembrane domains in facilitating a hydrogen interaction between tetrahydrocannabinoids (THC) 
and modulation of GlyRs by THC respectively21.  
                   
 
 
 
 
 
 
Figure 1.1. The structure of GlyRs. (a) The topology of " subunit featuring the disulphide bridge that forms the Cys-loop signature of 
LGIC (red). (b) The mature "2#3 receptor with two copies of " subunits (transparent), three of # subunits (light blue), four 
transmembrane (M1-M4) regions (cylinders) and pore-forming domain M2 (dark brown) modified from Vannier and Triller 200922.  
 
The five GlyRs subunits ("1-"4) and # have distinct expressions and distributions depending on the period of 
embryonic development. In the early developmental stage, GlyR!2 and GlyR"4 are highly expressed in most 
CNS areas, but are totally replaced by !1" heteromer in the postnatal period2,23 with both subunits retained until 
adulthood in specific area such as retinal cells24,25. In the mature neurons, however, GlyRs comprise GlyR"1 and 
GlyR# subunits with GlyRs being expressed at high level in the spinal cord and brain stem, but at lower level in 
the thalamus and hypothalamus2. Following low levels of expression during embryonic phase, GlyR"1 and 
GlyR# accumulate and maintain high levels of expression in mature neurons with both subunits contributing to 
the ligand binding domain26. GlyR"3 mirrors expressional pattern of GlyR"1 but with limited spatial expression 
and lower concentrations than GlyR"1, except for retinal cells where GlyR"3 dominate all other subunits24.  
The pentameric GlyRs also feature distinct subunit compositions and binding sites. They can exist either as " 
homomers or "# heteromers assembled in 2"/3# stoichiometry (Figure 1.1b)22 with the glycine-binding site of 
!/" heteromeric GlyRs is jointly formed by ! and " subunits26. Although " subunits can form functional GlyRs, 
these subunits interact with gephyrin and thereby mediate synaptic clustering of GlyRs27. GlyR"1 has been 
proposed to have at least two binding sites while GlyR"1# has at least three binding sites at which allosteric 
ligands such as ivermectins exerted different effects as both antagonists and potentiators of GlyR"11.  
 
(a) (b) 
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Together, the above different subunit compositions, expressions and arrangements and binding sites determine 
pharmacological characteristics of different subunits of GlyRs. 
 
1.2.2. GlyRs  Pharmacology  
Many research groups recently reported important roles of GlyRs both in non-neuronal28 and neuronal cells1,2,20,23. 
However, due to their major functions as neurotransmitter receptors, the following focuses exclusively on the role 
of GlyRs in the CNS and part of the brain where they control excitatory neurotransmissions. Dysfunctions and 
defects of GlyRs subunits are known to underlie many intractable CNS related diseases such as muscular 
tension17, epilepsy18, spasticity17, inflammatory pain19 and hyperekplexia29.  
 
 
1.2.2.1  Hyperekplexia   
The glycinergic defects due to mutations of and/or dysfunction of GlyR"1 are associated with spasticity17,29 and 
inflammatory pain19 with the human hereditary disorder (startle diseases)30 as the most predominant case1,30. 
Hyperekplexia is a neurological disorder typified by an exaggerated response to unexpected stimuli31. For 
instance, hyperekplexia patients can suddenly jump, yell or raise their hands in response to unexpected touch or 
sound32 and in a severe case, they can even convulsively jerk in responding to light stimulus, a similar response to 
strychnine poisoning33. At least, seven points of GlyRs mutation have been related to hyperekplexia34 with 
mutations at R271L and R271Q in the extracellular M2-M3 linker of GlyR"1 being the major cause of the 
disorder (Figure 1.2)16,35.  
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Figure 1.2. Mutations of GlyR"1 related to hyperekplexia35  
 
 
 
1.2.2.2 Spasticity   
A similar hypertonic motor disorder, spasticity, has also been identified in GlyR"1 mutated mice and rats17,36. 
Spasticity is characterized by an increase in motor neuron excitability and synaptic inputs owing to muscle stretch 
triggered by hyper excitability of spinal reflexes and reduced glycinergic inhibition.17 Similar to hyperekplexia, 
spasticity can cause excessive startle reaction in addition to increasing muscle tone. In mice, spasmodic mutation 
(GlyR"1 spd) was caused by amino acid substitution (A52S) within the N-terminal domain of GlyR"1, a process 
known to affect agonist activity of the subunit37. This progressively disabling disease normally starts to appear 
one year after patients experience spinal cord injury (SPI). Spasticity is triggered by a down-regulation of 
potassium chloride co-transporter (KCC2), in the motor neurons resulting in depolarization of the chloride 
equilibrium potential thereby reducing postsynaptic glycinergic inhibition17. Since the GlyR"1 glycinergic 
inhibition is known to dampen motor neurons, these facts suggest that GlyR"1 is a promising target for treating 
spasticity38.  
GlyR"1 also mediates glycinergic inhibition in the retina39,40 and the pain pathway19. Together with the other 
GlyR subtypes, GlyR"1 has been identified in the mouse retina with 30% of this subtype co-localizing with 
GlyR"3 in amacrine cells. In addition, it is known that GlyR"1 also colocalizes with GlyR"3 in the lamina II of 
the dorsal horn CNS where pain neurons terminate.19 These facts suggest the importance of GlyR"1 in vision and 
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treatment of inflammatory pain although the absence of phosphorylation site in GlyR"1 was believed to indicate 
bigger risks of side effect than the GlyR"31,19.  
The relative abundances of GlyR"2 and GlyR"4 in the retinal cells suggest the potential of these subunits in 
vision39-41. Due to the presence of a premature stop codon, GlyR"4 is considered as a pseudo-human gene12, while 
GlyR"2 is also known to play a pivotal role in neuronal cell development switching the immature to mature 
neuron cells20, in addition to delaying the onset of hyperekplexia disease42.  
 
1.2.2.3. Epilepsy  
Another important pharmacological role of GlyRs relates to "2 and "3 GlyR splicing. Two variants of GlyR"3 
namely "3KGlyR and "3LGlyR have been discovered in highly damaged human hippocampus of intractable 
temporal epilepsy (TLE) patients, strongly suggesting the importance of "3 GlyR splicing in pathophysiology of 
the temporal lobe epilepsy18.  
 
1.2.2.4  Inflammatory Pain  
Perhaps the most interesting finding in GlyRs is the discovery of GlyR"3 in superficial layers of the spinal cord 
dorsal horn, the pain terminal19. This discovery has attracted much attention because "3 GlyRs mediates 
inhibitory neurotransmission onto spinal nociceptive neurons controlling inflammatory pain1,43,44. It has been 
proposed that injured or damaged tissues induce expression of two enzymes, COX-2 and PGE synthase, which in 
turn trigger the production of prostaglandin E2 type in the spinal cord. Because PKA phosphorylation was present 
at GlyR"3, but not GlyR"1, PGE2 via PKA-dependent phosphorylation only inhibited GlyR"3 (Figure 1.3)19,43. 
This inhibition reduces the inhibitory drive onto nociceptive projection neurons and increases the transmission of 
pain stimuli to the brain, strongly suggesting GlyR"3 subunit as an ideal target for pain treatment1,19,43,44. This 
discovery offers an interesting opportunity for scientists to discover safe and effective pain relief drugs1,19,44. 
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Figure 1.3. Model for glycinergic inhibition of GlyR"3 on dorsal horn lamina II of the central nervous system, reproduced from Zeilhofer 
200543.  
 
 
1.3. GlyR and Chronic Inflammatory Pain 
In fact, the recent ineffectiveness of and safety issues associated with pain relief drugs have stirred serious 
concerns among medical professionals45. It has been estimated that patients received only 25% pain relief even 
after proper treatment with approved analgesics such as non-narcotic analgesics, non-steroidal anti-inflammatory 
drugs (NSAIDs) antidepressants, anticonvulsants and selective cyclooxygenase-2 (COX2) inhibitors45. In addition, 
medication with opioids can have adverse side effects (euphoric effects leading to addiction and reduced efficacy 
among them) on patients.  Based on 2010 figures, these analgesics retain a high market share (from 5% to 29% of 
US$27 billion) in 7 major pharmaceutical markets (US, Japan, France, Germany, Italy, Spain and UK)45.  
 
                                                      
                    Figure 1.4.  The percentage for market sharing of approved pain relief drugs adopted Melnikova 201045 
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The above situation is not ideal and demands an ongoing improvement in the search for pain relief drugs, in 
particular the opportunity is offered by new and improved modes of action45. The marine cone snail derived pain 
drug ziconotide is an excellent example exerting its anti-inflammatory effect by modulating N-type calcium 
channels located on the primary nociceptive afferent nerves in the superficial layers of the dorsal horn of the 
spinal cord46,47. Because GlyR"3 is discretely distributed and mediates inhibitory neurotransmission in exactly the 
same area19, it is believed that GlyR"3 subunit modulators offer the prospect of being safer pain drugs than 
opioids14. We endorse the hypothesis that treatment of pain is ideally targeted at this subunit1, and that GlyRs 
represent a novel therapeutic strategy in treating pain and other CNS related diseases13.   
 
1.4. GlyR Modulators  
Today, several molecules are known to modulate GlyRs mainly through allosteric and antagonistic modulations. 
Of the allosteric modulators, tropisetron (1.5), zatosetron (1.7) and bemesetron (1.8) are considered the best 
because of their potent modulating activity, displacing GlyRs with nanomolar potency48,49, and high 
bioavailability against GlyRs1. Similarly, strychnine represents the best example of GlyR antagonist1 as this 
alkaloid is the prototypic competitive antagonist of GlyRs showing nanomolar Ki values at recombinant and 
native receptors in binding and functional assays2. Despite their promising activities, the pharmacological 
potentials of known GlyRs modulators are hampered by a lack of GlyR isoform specificity1,38. As a result, 
strychnine is known as non-specific pharmacological probe for GlyRs and no GlyR modulators (antagonists, 
agonists or potentiators) have advanced to the clinic1,44. 
 
 
1.4.1.  GlyR Allosteric Modulators  
Ivermectins (1.1-1.2), picrotoxins (1.3-1.4) and tropeins (1.5-1.10) are positive allosteric modulators of GlyRs, 
showing bifunctional activities either as potentiators or antagonists of GlyRs depending on concentration1,48,49. 
Ivermectin, a mixture of 22,23-dihydroivermectins B1a (1.1, ~85%) and 22,23-dihydroivermectins B1b (1.2, 
~15%)—potentiated "1 GlyR at low concentration (0.01 µM) but activated the heteromer 1"# GlyR at higher 
concentration (0.03 µM)50. These macrocyclic lactones were also capable of activating desensitized GlyR50 and  
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modulating GABAA, glutamate and acetylcholine receptors1,49. Picrotoxin, a mixture of picrotin (1.3) and 
picrotoxinin (1.4), acted as an allosteric GlyR with an inhibitory potency that decreased as the glycine 
concentration increased1. Howtrone and Lynch showed that picrotoxin strongly antagonized several mutan GlyRs 
with IC50 value of 0.64 to 10.3 µM by allosterically eliciting specific effects on the M2-M3 loop51. For decades, 
however, picrotoxin has been known as a potent inhibitor of both GlyRs and GABARs52. Tropeines such as 
tropisetron (1.5), LY-278,584 (1.6), zatosetron (1.7), bemesetron (1.8), granisetron (1.9) and atropine (1.10) also 
allosterically modulated GlyRs with 1.5-1.8 and 1.9-1.10 known as positive and negative GlyR agents 
respectively48. In the presence of glycine, 1.5-1.8 strongly (nanomolar) and 1.9-1.10 moderately (micromolar) 
displaced GlyRs48. In particular, 1.5 and 1.8 potently potentiated GlyRs with EC50 value of 10-1000 nM but 
inhibited the receptors at IC50 = 1-24 µM53. However, lack of specificity with cross modulation of other members 
of cys-loop LGIC (i.e. 5-HT3 and "7 of nAChRs receptors) rendered them undruggable54. 
 
 
1.4.2. Antagonists  
GlyR antagonists also show the same specificity issue. Gingkolides A-C and J (1.11-1.14) strongly antagonized 
GlyRs ("1, "2 and "1#) with IC50 value of 0.69-12 µM55 and gingkolides B (1.12) and C (1.13) potently 
antagonized native GlyRs in native hippocampal neurons with IC50 values around 273 and 269 nM 
respectively56. Unfortunately, in addition to showing other neuromodulatory properties57, the active constituents 
of Gingko biloba also activated GABAAR "1#2!2L with IC50 value of 10 µM58 and platelet activating factor 
(PAF) receptor with Ki values of 0.07 to 0.9 µM57,59. Similarly, although several cannabinoid agonists such as 
HU-308 (1.15), HU-210 (1.16), WIN-212-2 (1.17), N-arachidonyl-ethanolamine (1.18) and N-arachidonyl-
glycine (1.19) exerted strong antagonist activity against the GlyRs (10-15 µM), they strongly antagonised CB1 
and CB2 receptor38. Finally, the plant alkaloid strychnine (1.20) is known as the classical antagonist of GlyR"1 
inhibiting the subunit at IC50 =196.6 nM60. In addition to strychnine, protostrychnine (1.21), brucine 3 (1.22) and 
brucine 4 (1.23) exerted similar modulating activity against GlyR"1 although with weaker antagonistic activity 
(IC50 > 1 µM)60. However, like other known GlyR modulators, strychnine and derivatives were non specific GlyR 
modulators as they modulated GABAA, nAChR and other members of LGIC61. 
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1.4.3. Possible Uses  
Both GlyR antagonists and positive allosteric modulators have potential to be pharmacological probes and drugs. 
It has been demonstrated that potent and selective GlyR antagonists can have potential in treating convulsion and 
anxiety62. Likewise, evidence has been presented that upregulation of RNA edited GlyR"2 and GlyR"3 is a 
causal factor associated with temporal lobe epilepsy (TLE), suggesting that GlyR inhibitors could treat this 
debilitating disease18,63. However, because GlyR-mediated diseases such as inflammatory pain19, spasticity17, 
hyprekplexia16,64 are identical with diminished GlyRs activity, positive GlyR modulators are presumably 
preferable13. Unfortunately, all known GlyR modulators have been hampered by their promiscuous modulating 
activities against receptors other than GlyRs. Although several synthetic cannabinoids and anandamide effected a 
strong pharmacological discrimination between "1 and GlyR"3, these ligands were considered unsuitable for 
physiological or behavioural studies due to non-specific actions at cannabinoid receptors CB1 and CB238. 
Similarly, all GlyR positive allosteric modulators lacked receptor specificity, making them unsuitable for a 
therapeutics targeting specifically towards GlyRs1,13. The lack of specificity is even shown by strychnine, which 
remains the only known pharmacological probe for GlyRs1. These facts show the urgent need and value in 
discovering specific GlyR modulators that can serve as either pharmacological probes and/or drugs for treating 
various CNS diseases mediated by GlyRs.  
Although many GlyR modulators have been discovered through recent discovery programs, receptor specificity 
remains a serious issue, arguably due to a heavy focus on the discovery of GlyR modulators from known non-
specific modulators48,65. While strategically quick to deliver GlyR modulators, the approach seems predestined to 
fail on delivering the requisite selectivity48,54. This situation and the current high demand for novel, potent and 
specific GlyR modulators1 clearly warrant a new approach to discover GlyR modulators. One of the ways to 
achieve this is by screening GlyR modulators from a potential source of bioactive molecules including marine 
invertebrates66-68. 
Curiosuly, most marine invertebrates have soft body, are sessile and therefore are prone to predation. Yet, they 
thrive in a competive marine environment such as coral reef presumably because they have developed chemical 
defense enabling them to establish a particular niche68. Although early discovery of bioactive molecules from 
these marine invertebrates was an aferthought, recently there has been a realisation that these active compounds 
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would ultimately be useful for treatments of human diseases68. Over the years, sponge, tunicate, bryozoan and 
coral have inspired researchers to identify and discover both new pharmacological tools and marine drugs from 
these marine invertebrates66-68. In fact, these invertebrates have proven to be a very rich source of potent bioactive 
compounds many of which have advanced to Phase II/III chlinical trials in anticancer, analgesic, allergic and 
cognitive diseases, discussed in detail below68.  
 
1.5. Marine Natural Products (MNPs) as a Source of Bioactive Molecules   
The last five decades have witnessed the emergence of marine natural products as an important source of 
bioactive molecules with pharmacological potential66. Four marine derived drugs have made their way to the 
market, with thirteen MNPs being in the different stages of clinical trials and many others in pre-clinical trials66. 
With the recent technological improvements5,67,69, it is anticipated that MNPs will continue to make a significant 
contribution to the discovery of new pharmacological tools and drugs for treating many human diseases70, 
including diseases related to the dysfunction of ion channels. In addition to ziconotide, there are a number of 
MNP derived modulators of voltage gated ion channel (VGIC)71. Up to now, however, little is known about 
MNPs as LGIC modulators72. 
 
 
1.5.1. Marine Natural Product in Medical Clinic   
Ara-A (1.24), Ara-C  (1.25), ziconotide (1.26), and trabectedin (1.27) (Figure 1.5) represent four MNP derived 
drugs known today. Cytosine arabinosine or Ara-C, cytarabine or Ara-A were synthetic purine and pyrimidine 
nucleosides respectively inspired by two nucleosides isolated from the Caribbean sponge Tethya crypta. Ara-C 
and Ara-A received FDA approval in 1969 and 1976 as anticancer and antibiotic agents respectively66. Both MNP 
derived drugs have given significant impacts on antibiotic and cancer pharmacology generating 13,008 and 3640 
peer review publications respectively66. The pain relief drug, ziconotide or Prialt (1.26), successfully made to the 
market in 2004, almost three decades after the approval of Ara-A. This synthetic peptide developed from the 
peptide of a fish hunting cone snail Conus magnus73 exerts its anti-inflammatory by blocking the sodium voltage 
gated ion channel47. Three years after the approval of ziconotide, trabectedin also known as Yondelis (ET-743) 
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discovered from the Caribbean tunicate, Ecteinascidia turbinata74 received European Union’s approval as an 
anticancer drug for the treatments of soft tissue sarcoma75 and platinum sensitive ovarian cancer76. As 2011, 
trabectedin was also in the phase III of clinical trials in the US66. 
Thirteen MNPs have advanced to various levels of clinical trials (Figure 1.5). The tetrahydorisoquinoline 
alkaloid, trabectedin (1.27), peptide soblidotin (1.28) and polyether macrolide eribulin mesylate (E7389) (1.29) 
are now in the phase III clinical trials66. These molecules were originally isolated from tunicates Ecteinascidia 
turbinaria77 and Symploca sp78 and a sponge Halicondria okadai 79 respectively as anticancer agents targeting 
tubulin80. Seven marine metabolites are also now in the phase II clinical trial66. They include the peptide tasidotin 
(1.30) from a tunicate Symloca sp., cyclic peptide elisidepsin (1.31) from Elysia refuscens81, depsipeptide 
plitidepsin (1.32) from Aplidium ablicans, alkaloid PM1004 from tunicate Jeruna funerbis (1.33), 
diketopiperazine plinabulin (1.34) from marine bacteria Aspergillus sp., and alkaloid DMXBA (1.35) from a 
marine worm Ampiphorus angulatatus and diterpene glycoside pseudopterosin (1.36) from Pseudopterogorgia 
elisabethae (Figure 1.5)66. Of these, 1.30-1.34 are anticancer agents targeting tubulin, solid tumour, and DNA 
triplets, while the alkaloid DMXBA (1.35) peptide pseudopterosin (1.36) target cognition/schizophrenia and 
wound healing respectively66,82. Finally, three MNPs have entered phase I clinical trial as anticancer including 
protein inhibitor bryostatin (1.37) from bryozoans Bugula, proteasome binding salinosporamide A (1.38) from a 
marine bacterium Salinospora tropica83 and tubulin inhibitor hemiasterlin (1.39) from a sponge Hemiasterella 
minor84. 
Although the number of marine drugs and the drug discovery in the pipeline are low compared to terrestrial 
natural products, this is not a measure of relative potential but rather reflects the invaluable marine biodiscovery. 
From 1998 to 2006, hundreds of MNPs advanced to preclinical trials, including 592 molecules with anti tumour 
and cytotoxic activities and 666 compounds with antibacterial, anticoagulant, anti-inflammatory, antifungal, 
anthelmintic, antiplatelet, antiprotozoal and antiviral activities, actions on the cardiovascular, endocrine, immune 
and nervous systems as well as other miscellaneous mechanisms of actions66. By 2009, there were already 705 
Pub Med references for marine pharmacology70. As pointed out by William Fenical of the Scripps Institute of 
Oceanography “Since the field of marine natural products chemistry began in the mid 1960s, it has been clear 
that the oceans and their diverse biota represent a significant resource, perhaps the greatest resource on Earth 
(34 of the 36 phyla of life), for the discovery of new drugs. During the first decade of this science (ca. 1970–
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1980), researchers explored the oceans to discover the specific biological taxa that would yield bioactive 
molecules. Hundreds of structurally novel, bioactive molecules were discovered proving that marine organisms 
had the potential to be developed into drugs in many areas of human therapy”70.  
 
Figure 1.5. Examples of MNPs that have been approved as drugs and advanced to different stages of clinical trials modified from Mayer et 
al  2010 66  
 
Early MNP researchers emphasized the discovery of novel chemical entities, while latter researchers have shifted 
the emphasis to bioactivity66. Traditionally, the discovery of bioactive MNPs were guided by phenotype-oriented 
bioassays such as cytotoxicity and/or antimicrobial tests85. Mechanism of actions targeted approach to drug 
discovery was not introduced to MNPs until recently85. An important challenge to developing MNP drugs is 
supply66-68,86,87. For example, to supply 2.0 gram of trabectedin68 or 18.0 gram bryostatin required the harvest of 1 
ton tunicate Ecteinascidia turbinata and 13 tons of bryozoans Bugula nerita respectively86. In the words of David 
Newman of the National Cancer Institute (NCI) “In retrospect, this is one of the major reasons that the field 
evolved slowly. Discovery of a given compound was easy in relative terms, but development, which required large 
amounts, was, and still is, not simple”68.  
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1.5.2. The role of technology  
Despite the challenge faced by MNP chemistry, recent technological improvements have significantly propelled 
the development of MNPs66,67,70,87. In the case of trabectedin, the supply issue has been successfully overcome by 
synthesis of trabectedin from its intermediate safracin B obtained from Pseudomonas fluoresens68. Although it is 
still work in progress, similar approaches also seem promising for bryostatins66. Structure elucidations of very 
limited MNPs (nanomole scale)88 have been assisted by high temperature superconducting Nuclear Magnetic 
Resonance (NMR) cryoprobe88 and limited, unstable as well as lacking UV-vis MNPs by LC-SPE-NMR89,90,91. 
Several molecules having complex structures have also been successfully synthesized69 with (+)-discordemolide 
featuring 13 stereogenic centres and high degree of chemical sensitive functionality as an excellent example92. 
Moreover, MNPs profit from the recent developments in mass spectrometry technique simplifying the lengthy 
and complicated processes in identifying bioactive molecules through combination with other techniques such as 
multitarget affinity/specificity screening (MASS) and frontal affinity chromatography (FAC)69. Similarly, MNPs 
benefits from the discovery of myriad novel drug targets including ion channel receptors (Figure 1.6)67, which 
were ranked third (LGIC) and fourth (VGIC) out of the 324 most approved drug targets4. Coupled with currently 
introduced automated patch clamp technology93 and interdisciplinary collaboration66, ion channel drug can be 
advanced by MNPs.  
 
              
Figure 1.6.  Top ten approved drug target revealing ligand gated ion channel (LGIC) as the third more popular approved drug target 
adopted from Overington 20064. 
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1.5.3. Ion Channel Modulators  
Many scientists have explored the potential of MNPs as modulators of receptors belonged to voltage gated ion 
channel (VGICs). In addition to the peptide ziconotide66 and many other marine toxins72, several small molecules 
were capable of modulating VGIC receptors including 2!,3"-epitaondiol (1.40), flabellinol (1.41) and 
flabellinone (1.42), jamaicamide A (1.43), jamaicamide B (1.44), jamaicamide C (1.45), kalkitoxin (1.46), 
clathrodin A (1.47) and dibromosceptrin (1.48). The meroditepeneoids (1.40-1.42) isolated from brown algae 
Stypopodium flabelliforme act on sodium channel with the IC50 values of 0.7, 2.0 and 7.0 µM respectively94,95. The 
dinoflagellate Lyngbya majuscula produce three polyketide-peptide neurotoxins (1.43-1.45) that antagonize 
sodium channel with IC50 value of 5 µM96. The thiazole containing lipopeptide (1.46) from the Caribbean L. 
majuscula potently block sodium channel with an IC50 of 1.0 µM97. Two metabolites of genus Agelas, clathrodin 
A (1.47) and dibromosceptrin (1.48), also modulate NaV channels by different mechanism with the monomer 
(1.47) activating and the dimer (1.48) inhibiting the sodium channel98,99.  
Up to now, however, little is known about the modulators for receptors members of LGIC superfamily other than 
anabaseine, an alkaloid isolated from a marine worm Amphiporus lactifloreus100. Anabaseine has been reported to 
activate the acetylcholine receptors in various animal species especially the neuromuscular "12!1#$ (embryonic) 
or "12!1#% (adult) and "7 nAChRs100. Inspired by this activity, 200 analogues were synthesized resulting in the 
discovery of 2,4-dimethoxy-benzylidine anabaseine (DMXBA) (1.35, Figure 1.4). This anabaseine derivative 
improved memory in animal models and is now in clinical trial for cognitive problems related with 
schizophrenia100. Today, however, almost nothing is known about GlyR modulator from MNPs notwithstanding 
the potentials of GlyRs as an emerging drug target for treatments of CNS diseases5,21.  
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The emergence of GlyRs as a new drug target for treating CNS diseases5, the lack of receptor specificity among 
existing GlyR modulators1,44,101, the absence of GlyR modulators from MNPs despite being important source of 
bioactive molecules and the current high demand for high affinity and specificity GlyR modulators1,20,44 
encouraged us to explore the potential of MNPs as a new source of novel, potent and specific GlyR modulators. 
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      CHAPTER 2 
MARINE EXTRACT SCREENING 
 
In order to discover MNP GlyR modulators, we screened >2,500 southern Australian and Antarctic marine 
invertebrate extracts using two assays, the yellow fluorescence protein (YFP) assay and automated patch clamp 
electrophysiology (APCE). While the YFP was used to screen crude marine extracts in order to detect priority 
samples, the APCE was employed to evaluate bioactivity of pure compounds of corresponding extracts previously 
observed in YFP analysis.  
 
2.1. Yellow Fluorescence Protein (YFP)   
The YFP assay takes advantage of yellow fluorescence protein sensitivity towards anion quenching. This assay is 
capable of reporting anionic influx into HEK293 cells102. In practice, an extract/compound is considered as an 
agonist when it opens (agonises) GlyRs allowing the influx of iodide ions and quenching YFP (Figure 2.1, (A1). 
Control (Figure 2.1, (A2) left) and test (Figure 2.1, (A2) right) images were taken and compared with quenching 
(changed in tested images) suggesting a GlyR agonist. In the same way, a potentiator opens (agonises) the GlyR. 
Unlike an antagonist, which can activate the receptor both in the presence and in the absence of glycine, a 
potentiator agonises the receptor only in the presence of low dose of glycine (Figure 2.1 (B1) but not in the 
absence of glycine. The control image (Figure 2.1 (B2) left) and the test image (Figure 2.1(B2) right) were taken 
and compared with the absence of quenching (no change in test image) suggesting potentiator of GlyRs. In 
contrast, an extract or a molecule is considered as an antagonist when it blocks the receptor, preventing the anion 
from quenching the YFP (Figure 2.1 (C1). The control images (Figure 2.1 (C2) left) and test image (Figure 
2.1(C2) right) were also taken and compared with no difference between control and test images indicating the 
absence of YFP quenching or an antagonist activity. This activity was later confirmed by screening pure 
compound(s) isolated from corresponding active extract(s) against different GlyR subunits using an automated 
patch clamp electrophysiology.  
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Figure 2.1.  Illustration of agonist (A1), potentiator (B1) and antagonist (C1) with corresponding control images  (A2), (B2) and (C2) 
respectively. 
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2.2. Electrophysiology (Automated patch clamp)  
Patch clamp technique is one of the choices for secondary screening or lead optimization and is considered the 
gold standard in validating ion channel modulators93,103. In particular, the automated patch clamp has recently 
revolutionized the discovery of ion channel modulators through its capacity in performing high-throughput high 
sensitivity screening103. This automated technique has bridged the longstanding gap between the primary 
screening and secondary screening93, a quality that may benefit MNPs whose active compounds are frequently 
only available in a very low yield69.  
 
 
 
 
 
 
 
Figure 2.2. Illustration of agonist, potentiator and antagonist of GlyR (Electrophysiology). Doted line is the transition of 
conductance for glycine. Spikes above the transition conductance (3.0-100 µM) represent antagonist activity while spikes 
below the doted line (0.1-1.0 µM) suggests an agonist or a potentiator activity with the previous occurring both in the 
presence and in the absence of glycine while the latter taking place only in the presence of low dose of glycine. 
 
Hence, this technique was used in our secondary screening to evaluate the biological activity of all pure 
compounds successfully obtained from the fractionation and purification of all priority extracts. Figure 2.2 
illustrates patch clamp recording with doted line representing the transition of conductance for glycine, spikes 
below the transition of conductance (e.g. 0.1 and 1.0 µM) suggesting an antagonist activity and those above the 
transition conductance (e.g. 3.0-100 µM) suggesting either an antagonist or a potentiator activity. As previously 
described for YFP test, agonist activity occurs both in the presence and in the absence of glycine while potentiator 
takes place only in the presence of low dose glycine (Figure 2.2).  
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2.3. Marine Diversity Library 
The above ion channel technologies were employed to screen a library of >2500 marine invertebrate and alga 
samples, collected from intertidal, coastal and deep-sea locations across southern Australia and Antarctica. The 
specimens were processed to generate an extract library suitably formatted for medium to high throughput 
bioassay. A portion (7.0 mL) of the archived EtOH extract of each marine sample was decanted, concentrated in 
vacuo, weighed and partitioned into n-BuOH (2.0 mL) and H2O (2 mL). This pre-processing achieves a >10 fold 
concentration of “drug-like” small molecules, while simultaneously desalting and simplifying the solubility 
characteristics of, the n-BuOH soluble. Aliquots (1.0 mL) of both n-BuOH and H2O phases were transferred to 
deep 96-well plates, to generate a set of extract library plates. These plates were subsequently used to prepare 10- 
and 100-fold dilution plates. 
 
 
2.4. Biological Profiling 
Primary screening was performed in two steps. In the first round screening, the EtOC extracts of >2,500 
specimens were screened for antagonist activity against GlyR"1, leading to the identification of 27 hits (Table 
2.1). As previously described for antagonist activity in YFP test (pages 19-20) and shown in Figure 2.3 (page 23), 
the hits were defined by comparing control and test images of corresponding extracts. For example, both test and 
control images for CMB-03344 extract were identical, indicating the absence of quenching during the test. As a 
result, this extract was assigned as having a strong antagonist activity (Figure 2.3, red). In contrast, there was a 
considerable difference between the control and test images of CMB-03322 with slightly lesser cells observed in 
the test image compared to the control, indicative of a modest quenching or a moderate antagonist activity (Figure 
2.3, orange). Furthermore, a sharp contrast was observed between control and test images of CMB-02718 with 
much lesser cells observed in the test image, suggesting a strong quenching or a weak antagonist activity (Figure 
2.3, yellow). In similar manner, we assigned in total 27 hits consisting of 3 strong, 19 moderate and 5 weak hits 
(Table 2.1) in the first round screening of 2,500 Australian and Antarctic marine invertebrates.  
 
Chapter 2: Marine Extract Screening 
 
    23 
Following partition of the EtOH extract into n-BuOH and water-soluble extracts, we screened n-BuOH and water 
soluble against GlyR"1-GlyR"3. This screening resulted in 10, 5 and 7 GlyR"1, GlyR"2 and GlyR"3 
antagonists for n-BuOH part as well as 3 and 1 GlyR"1 and GlyR"3 antagonists for water-soluble part. In order 
to determine priority extracts, the10 extracts were further subjected to chemical profiling (described in Table 2.2).  
 
Figure 2.3. Control and test images of weak (yellow), moderate (orange) and strong (red) hits. Comparison of control image of  
CMB-02718    
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Table 2.1. Hits resulted from highthroughput screening of more than 2,500 specimens 
 
 HITS 
Butanol Extracts Water Extracts 
  Primary   
  Screening  
  (EtOH)  
  extracts) 
"1 "2 "3 "1 "2       "3 
    CMB-01008             
    CMB-01064             
    CMB-01457             
    CMB-01510             
    CMB-01940             
    CMB-02433             
    CMB-02694             
    CMB-02709             
    CMB-02718             
    CMB-02816             
    CMB-02830             
    CMB-02858             
    CMB-03023             
    CMB-03102             
    CMB-03105             
    CMB-03174             
    CMB-03199             
    CMB-03200             
    CMB-03020       
    CMB-03022             
    CMB-03023       
    CMB-03231             
   CMB-03322             
   CMB-03344             
   CMB-03363             
   CMB-03590             
CM
B 
M
ar
ine
 G
lyR
 
Sc
re
en
ing
 
   CMB-03608             
Note: red, orange and yellow mean strong, moderate and weak activities while "1, "2 and "3 indicated (GlyR"1$"3) respectively.  
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2.5. Chemical Profiling  
The n-BuOH soluble fractions were sequentially triturated into hexane, dichloromethane (DCM), methanol 
(MeOH) and water (H2O). Likewise, water-soluble fractions were sequentially triturated into MeOH and H2O 
soluble (Scheme 2.1). Further purification of active fraction was achieved by various combination of 
chromatography with an emphasis on HPLC.  
 
              
               
            Scheme 2.1. Extract fractionation through solvent partition and trituration followed by chromatography.   
 
 
 
Chemical profiling identified four-structure classes of extracts common to nine priority extracts. Online database 
(Marinelit) searching against spectroscopic data (m/z) coupled with 1H NMR data analysis indicated the 
likelihood of at least four different structure classes as suggested by molecular weights (Table 2.2). 
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Table 2.2. Chemical and biological profiling on prioritized extracts and associated fractions.   
LRESIMS and Bioassay Guided Fractionation on Nine Potential Specimens 
 
                    n-BuOH Fraction 
                mass (mg)/bioactivity  LRESIMS 
Petrol        DCM       MeOH H2O 
        5.6    590.7          109.3             5.3 
      tR (min) ESI(+)MS ESI(-)MS MW 
 ! !           9.50 490 (M+ H) 488 (M-H) 489 
 ! !          9.80 472 (M+ H) 470 (M-H) 471 
 ! !        10.50 490 (M+ H) 488 (M-H) 489 
 ! !        10.70 406 (M+H) 404 (M-H) 405 
 ! !        14.50 413 (M+H) 468 (M-H) 416 
    
    
 C
M
B-
01
06
4 
 ! !           17.00 429 (M+H) 427 (M-H) 398 
Petrol DCM MeOH H2O 
1.4        75.3            43.4 - 
      tR (min) ESI(+)MS ESI(-)MS MW 
 ! !        11.50 406 (M+H) 404 (M-H) 405 
CM
B-
 
03
23
1 
 ! !        12.20 552 (M+H) 550 (M-H) 551 
Petrol DCM MeOH H2O        tR (min) ESI(+)MS ESI(-)MS MW 
        8.4          267.8          208.1           41.4     
 ! !          6.75 472 (M+ H) 470 (M-H) 471 
 ! !          7.25 490 (M+ H) 488 (M-H) 489 
 ! !          7.50 406 (M+H) 404 (M-H) 405 
 ! !          7.75 452 (M+H) 550 (M-H) 551 
 ! !          9.80 413 (M+H) 468 (M-H) 416 
    
 C
M
B-
03
36
3 
 ! !        13.90 429 (M+H) 427 (M-H) 398 
Petrol DCM MeOH H2O 
              5.6 590.7 109.3            5.3 
      tR (min) ESI(+)MS ESI(-)MS MW 
 ! !          9.25  547 (M-H) 547 
 ! !         10.67 470 (M+H) 468 (M-H) 469 
 ! !         11.76  475 (M-H) 475 
 ! !        12.78 413 (M+H) 411 (M-H) 412 C
M
B-
01
00
8 
 ! !        14.84 397 (M+H) 395 (M-H) 396 
Petrol DCM MeOH H2O 
3.0 75.9 20.9 - 
     tR (min) ESI(+)MS ESI(-)MS MW 
 ! !             6.5  485 (M-H) 485 
 ! !         10.52 429 (M+H) 427 (M-H) 428 
 ! !        13.10 457 (M+H) 455 (M-H) 456 
  C
M
B-
02
85
8 
 ! !         14.12 413 (M+H) 411 (M-H) 412 
Petrol DCM MeOH H2O 
    0.6 255.0 74.6           3.3 
     tR (min) ESI(+)MS ESI(-)MS MW 
 ! !         10.34 470 (M+H) 468 (M-H) 469 
 ! !         11.16  475 (M-H) 475 
 ! !        12.28 413 (M+H) 411 (M-H) 412 
  C
M
B-
03
34
4 
 ! !        14.38 397 (M+H) 395 (M-H) 396 
Petrol DCM MeOH H2O       tR (min) ESI(+)MS ESI(-)MS MW 
             52.7 283.0 74.6            3.3     
 ! !            5.60 509 (M+H) 507 (M-H) 508 
 ! !          5.67 257 (M+ H) 255 (M-H) 256 
 ! !          9.13 254 (M+H) 253 (M-H) 254 
 ! !          9.49 256 (M+ H) 254 (M-H) 255 
 ! !        10.73 292 (M+H) 290 (M-H) 291 
 ! !        11.21 292 (M+H) 290 (M-H) 291     
    
CM
B-
03
32
2 
 ! !        14.18 251 (M+H) 249 (M-H) 250 
Petrol DCM MeOH H2O 
 8.2 24.8 92.5            9.8 
     tR (min) ESI(+)MS ESI(-)MS MW 
 ! !         9.06 380 (M+H) 378 (M-H) 379 
    
 C
M
B-
 
    
 0
14
57
 
 ! !         9.30 394 (M+H) 392 (M-H) 393 
Petrol DCM MeOH H2O 
19.6 74.2 115.1            9.7 
    tR (min) ESI(+)MS ESI(-)MS MW 
 ! ! !        9.23 394 (M+H) 392 (M-H) 393 
 ! !         9.55 394 (M+H) 392 (M-H) 393 
 ! !        15.00 329 (M+H) 327 (M-H) 328 
 
   C
M
B-
01
51
0 
 ! !        16.00 283 (M+H) 222 (M-H) 281 
Note: red, orange and yellow for fractions mean strong, moderate and weak activities while on the molecular weight (MW) blue and red 
indicated known and unknown molecular weights. LCMS condition: Zorbax C3/C8/C18 analytical columns (150 x 4.6 mm) eluted with 90% 
H2O/MeCN to MeCN with 0.5% HCO2H modifier.  
LRESIMS = low resolution electrospray ionisation mass spectrometry  
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Chemical profiling on extracts from three sponges coded CMB-01064, CMB-03231 and CMB-03363 showed 
very similar profiles (Table 2.2) with both known and likely new molecular features.  The three specimens were 
collected in the Great Australian Bight, off The Pinnacles Reef and off Port Phillip Heads, Victoria, Australia and 
identified as Psammocinia sp., and Ircinia spp. respectively, two of the three main members of Irciniidae 
family104. Apart from Sarcotragus105-107, these two genera are also known for furanoterpene tetronic acids108-112. 
LRESIMS analysis showed that CMB-01064 and CMB-03363 contained virtually the same molecular weights 
(398, 416, 405, 471, 489, Table 2.2), two of which (398 and 416) were consistent with the known 
furenosesterterpene tetronic acid variabilins. This assumption was supported by 1H NMR and HRESIMS analysis, 
comparison to our authentic sample of variabilin113 and online search on the Marinelit focusing on known 
members of variabilin structure class and metabolites of Ircinia spp. and Psammocinia sp. These profiling efforts 
confirmed the presence of known variabilin type compounds and several unreported co-metabolites with 
molecular weights of 405, 471, 489 and 551 in CMB-01064 and CMB-03363 (Table 2.2). Of these, 405 and 521 
were also observed in CMB-03231 (Table 2.2), which upon 1H NMR and HRESIMS analysis proved to be similar 
molecules to those in CMB-01064 and CMB-03363. These structural resemblances placed these three priority 
extracts (CMB-03363, CMB-01064 and CMB-03231) in the first group. Also, as the fractions for the unknown 
metabolites showed strong modulation activity against GlyR"1 and GlyR"3, they strongly encouraged more 
detail chemical analysis. 
In the same way, chemical and biological profiling allowed CMB-01008, CMB-02858 and CMB-03344 to be 
assembled into a second group. These three specimens were collected off Durras New South Wales, off Port 
Phillip Heads, Victoria and off Barwon Heads, Victoria respectively and were all identified as Psammocinia spp. 
LRESIMS revealed similar molecular weights for DCM and MeOH fractions. Again, the close similarity of 
molecular weights and 1H NMR in these three specimens (CMB-01008, CMB-02858 and CMB-03344) suggested 
their structural similarity, which was further confirmed by a single ion extraction shown in detailed in Supporting 
Information in Chapter 4 of this thesis. Of interest, a minor fraction at tR = 10.34 min from CMB-03344 showed 
selective potentiating activity against GlyR"3 with little or no such effect on GlyR"1.   
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Unlike the other groups, there is only one specimen in the third group (CMB-03322) collected from Lonsdale Port 
Phillip Heads, Victoria Australia and identified as Ianthella cf. flabelliformis. This specimen contained two-
distinctive structure classes distributed in DCM and MeOH fractions (Table 2.2) as shown by their different 
molecular weights (Table 2.2). Although the DCM fraction was inactive against GlyRs, this fraction contained 
two unreported identical molecular weights 291 suggesting the presence of new compounds. Although MeOH 
fraction contained known pseudomolecular ions, bioassay confirmed that there was GlyR modulators (Table 2.2) 
while known pseudomolecular corresponded to monomer (tR = 5.67-9.49 min.) and dimer aplysinopsins (tR = 
5.60 min., Table 2.2). Our GlyR bioassay revealed indole alkaloid fractions as the active component of the 
Australian Ianthella cf. flabelliformis. In particular, a fraction (tR = 5.60 and 9.13 min., Table 2.2) corresponding 
to molecular weights of 508 and 254 (dimer and monomer aplysinopsins) showed potent potentiating activity 
against GlyR"1. These data have encouraged us to study the metabolites of Ianthella cf. flabelliformis as new 
source of novel, potent and selective GlyR modulators. The following paper details our discovery of new terpenes 
and novel GlyR modulators from Australian marine sponge, Ianthella cf. flabelliformis.  
The final group consists of two specimens (CMB-01045 and CMB-01510) whose pseudomolecular ions also were 
very similar (in particular the peaks corresponding to m/z 393) with online database search showed very few hits. 
Unfortunately, the limited amount of material made further chemical analysis impractical (at this time).  
Following on from the analysis of the 27 extracts detected in the primary screening of >2,500 Australian and 
Antarctic marine invertebrates and algae against the GlyRs, only 7 specimens were prioritized for chemical 
analysis including CMB-01064, CMB-01008, CMB-02858, CMB-03231, CMB-03322, CMB-03344 and CMB-
03363, clustered into three groups: Group 1 (CMB-01064, CMB-03231 and CMB-03363)  (Chapter 3); Group 2 
(CMB-01008, CMB-02858 and CMB-03344) (Chapter 4); and Group 3 (CMB-03322) (Chapter 5).  
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CHAPTER 3 
IRCINIALACTAMS  
 
 
3.1. Declaration  
 
This chapter describes three known sesterterpene tetronic acids from the variabilin structure class and new co-
metabolites named ircinialactams discovered from three Australian sponges of the family Irciniidae, three of the 
seven previously described priority specimens. Of these, three metabolites showed promising bioactivity potently 
and specifically modulating GlyR"1 and GlyR"3 with a paper describing the discovery published in Bioorganic 
& Medicinal Chemistry in 2010101. This was the first of three papers published between the Capon Group of the 
Institute for Molecular Bioscience (IMB) and the Lynch Group of Brain Institute (QBI) of The University of 
Queensland Australia.  
The two-research groups contributed equally to the publication of the ircinialactam paper. I was responsible for 
chemical investigation (isolation, purification and structure elucidation) of all metabolites discovered from three 
Australian Irciniidae sponges (CMB-01064, CMB-03231 and CMB-03363). During my lab work at the IMB, I 
received technical assistance (lab work and data analysis) from Dr. Hua Zhang and Dr. Andrew M. Piggott and 
was supervised by Professor Robert J. Capon as the head of chemistry lab. Similarly, the other co-authors have 
contributed to the work on ircinialactams paper. Dr. Robiul Islam performed bioassays (Yellow Fluorescence 
Protein and Patch Clamp assays) at the QBI. He received technical assistance from Dr. Daniel F. Gilbert, Dr. 
Frank Fontaine and Dr. Timothy I. Webb and was under the supervision of Professor Joseph W. Lynch as the 
head of pharmacology lab. The contributions of all co-authors to the publication of ircinialactams paper are listed 
in the table given below.   
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Balansa, W.; Islam, R.; Fontaine F.; Piggott, A. M.; Zhang, H.; Webb, T. I.; Gilbert, D.; Lynch, J. W.; Capon, R. 
J. Ircinialactams: Subunit-Selective Glycine Receptor Modulators from Australian Sponges of the Family 
Irciniidae. Bioorg. Med. Chem. 2010, 18, 2912–2919. 
 
Contributor Statement of contribution 
Balansa, Walter Responsible for chemistry (100% working) 
Islam, Robiul Responsible for bioassay  (100% working) 
Fontaine, Frank Assisted with lab work and data analysis 
Zhang, Hua Assisted with lab work and data analysis 
Piggott, Andrew M. Assisted with lab work and data analysis 
Webb, Timothy. Assisted with lab work and data analysis 
Gilbert, Daniel Assisted with lab work and data analysis 
Lynch, Joseph W. Head of pharmacology lab.  
Capon, Robert J. Head of chemistry lab.  
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3.2. Introduction  
 
3.2.1 Variabilin Structure and Diversity  
Members of Irciniidae family represent the most prolific source of sesterterpene tetronic acids such as variabilin 
(3.1)105,109,112,114,115. First reported by Faulkner from Ircinia variabilis, the antimicrobial variabilin was typified by a 
#-substituted furan %H (6.25, 7.18 and 7.31) and a conjugated tetronic acid %H (1.81 and 5.41) moieties attached to 
the opposite end of a linear polyisoprenoid that features &7,12 double bond configuration109. Structure of this type 
but with &8,13 configuration named strobilinin (3.2) was also reported by Rothberg and Subiak from a sponge I. 
strobilina in 1975 as an antibiotic agent against Staphylococcus aureus and Bacillus subtilis116. None of these 
original reports, however, addressed the geometry of trisubstituted or conjugated double bonds or the 
stereochemistry (C-18).  
Subsequently, in 1983 Gonzales et al assigned the stereochemistry of the trisubstituted double bonds of variabilin 
with upfield chemical shifts 1H (<1.5 ppm) and 13C (<20.0 ppm) of the olefinic methyls being consistent with an E 
geometry while downfield chemical shifts 1H (>1.5 ppm) and 13C (>20.0 ppm) were consistent with Z geometry110. 
When studying the metabolites of a New Zealander Sarcotragus sp. in 1989, Barrow et al assigned the 
stereochemistry of conjugated double bond (C-20) with a shielded chemical shift (< 120.0 ppm) consistent with E 
geometry and a deshielded chemical shift (>120.0 ppm) being consistent with a Z configuration105. Following 
these empirical NMR rules, in 1994 Davis and Capon reassigned the reported single pure compound strobilinin 
(3.2) as a mixture of two geometric isomers 8E-13E-20Z-strobilinin (3.3) and 8E-13Z-20Z-strobilinin (3.4)117. The 
authors used molecular rotation to assign 18S and 18R configurations to variabilin and strobilinins respectively 
and went on to apply this same approach to assign 18S configurations to ircinin-1 (3.5) and ircinin 2 (3.6)113. 
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Ever since, these above approaches have been widely applied in assigning the stereochemistry of variabilin and its 
related metabolites. These include the stereochemical assignments of variabilin and its geometric isomers isolated 
from a Maltese I. oros by Conig et al in 1997111, from three Ircinia spp. by Martinez et al in 1997112, from a South 
African nudibranch Hypselorides capensis by Coetzee et al in 1998118, from a Smenonspongia in 1998119 by Shin 
et al and from several Sarcotragus spp. by Jung et al and Shin et al in eight years period from 2001 to 
2009107,108,114,115.  
Of note, variabilin type compounds and their geometric isomers were known to resist purification in HPLC (high 
performance liquid chromatography) arguably due to their overlapping peaks112. In most cases, these 
furanosesterterpene geometric isomers were assigned as a mixture or purified as acetylated analogues as noted in 
reports of variabilin related metabolites from a number of Korean sponges of the genera Smenospongia and 
Sarcotragus, from an Australia I. strobilina117 and a Maltese I. oros111.  By contrast, this derivatization approach 
was not effective in assisting purification of a mixture of variabilins, strobilinins and flexinins from three 
Colombian I. felix, I. strobilina and I. campana112.  
In addition to geometric isomers, variations on variabilin structure class also arise from the modifications to the 
furan and tetronic acid termini. Examples include a series of metabolites isolated from Korean Sarcotragus spp. 
reported during last decade featuring unconjugated or truncated tetronic acids in place of conjugated tetronic acid 
O O
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and hydroxybutenolide, dimethoxy or amino acid derivatives including leucine, isoleucine, glycine or 
phenylalanine in exchange of furan.  
For example in 2001, Shin et al reported sarcotragin A and B from a Korean Sarcotragus sp. consisting of 
trinorsesterterpene and phenylethilamine lactam moiety120. Apart from the unusual ",#-unsaturated lactam, 
sarcotragins (3.7, 3.8) were also unique in that the tetronic acids functional group has been replaced by an "-
hydroxy methyl ester.  In 2002 and 2003, Liu et al reported a series of closely related structures named sarcotrines 
A-F (3.9-3.18) featuring coupling between terpene and amino acid derivatives such as leucine, isoleucine, glycine 
or phenylalanine from another two Sarcotragus spp.114,115. While sarcotines A-E (3.9-3.17) contain unconjugated 
tetronic acid, this moiety is replaced by ",#-hydroxymethoxybutanone and ",#-dihydroxybutenone moieties in 
sarcotragins A-B (3.7 and 3.8) and sarcotines F (3.18-3.19) respectively. Variations among sarcotines also derive 
from epimerism such as in sarcotines A-C (3.9-3.14), isomerism such as in sarcotines E-F (3.16-3.19) and lactam 
regiochemistry such as in sarcotines E-F.  Of interest, the chemical shifts of an olefin and a quaternary carbon at 
lactam moiety could be used to differentiate lactam regiochemistry with downfield resonances (~6.74 (H-2), 
~137.6 (C-2) and ~140.2 (C-3) ppm attributed to an "-substituted lactam and less shielded resonances (~5.7 (H-
2), ~ 121.0 (C-2) and 136.0 (C-3)) ppm attributed to a #-substituted lactam114,115. In 2004, Choi et al reported 
psammocinins A1-B (3.20-3.22) from another Korean Sarcotragus sp. lacking a methyl substituent in the 
conjugated tetronic acid of psammocinin A1 and A2 (3.20-3.21) as well as the replacement of the furan with an 
oxidized dimethylacetal moiety in psammocinin B (3.22)108.  
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In 2008, Wang et al discovered a series of sesterterpenes containing furan, !-lactone, !-lactam or methyl acetal at 
one termini and tetronic acids, carboxylic acid or dimethyl diester moieties at the other termini of a linear terpene 
from a Korean Sarcotragus sp (3.23-3.41)107.  
Three of the metabolites (3.23-3.25) share a very close structure with variabilin except that furan moiety in the 
3.23-3.25 has been replaced by ",#-substituted regioisomeric hydroxy !-lactones. Although !-hydroxybutenolide 
has been commonly reported to co-occur with furan in marine terpenes such as the luffarins121 and 
spongiabutenolides122, to date 3.23-3.25 represent the only hydroxybutenolides known for variabilin structure 
class107. Faulkner and co-workers reported regioisomeric hydroxybutenolides through a singlet oxidation of 3 or 
3,4122 substituted furans and Barrow et al obtained hydroxybutenolide as one of the major products in an 
autoxidation study of variabilin123.  
Four of these linear terpenes (compounds 3.26-3.29) feature furan and carboxylic acid at the opposite end of a 
linear terpene. The C21 linear terpene was previously reported by Barrow et al from a New Zealand Sarcotragus 
sp105. Biogenetically, it was proposed by Faulkner that hydrolysis of a tetronic acid gave rise to an "-diketone 
which in turn underwent oxidation, losing four-carbon fragment to deliver the carboxylic acid (Scheme 3.1)124. 
Compounds 3.30-3.37 contain furan and dimethyl diester moieties connected by a linear terpene. The latter 
functionality was previously reported as a product of acid treatment and has never been reported as natural 
product until the 2009 report by Shin et al107. It was proposed that the dimethyl diester functionality also 
underwent hydrolysis to yield an "-diketone which upon a rearrangement resulted in dimethyl diester moiety 
(Scheme 3.2)124. Interestingly, from the same sponge, the authors isolated different isomers of the dimethyl 
diesters distinguishable from their differing optical rotation properties. Together with compounds 3.26-3.30, they 
represent the only known molecules bearing dimethyl diester functional group.  
In addition to being dimethyl diesters, compounds 3.38-3.41 also contain the glycinyl lactam functional group, a 
functional group reported only from haumanamide isolated from a Hawaiian sponge125 and spongolactams C 
isolated from a Japanese Sponge Spongia sp126 and several nitrogenous terpenes from Korean Sarcotragus 
spp107,114,115,120. It has been previously proposed that the formation of the lactam from a furan moiety was enzyme 
catalyzed. In a nucleophilic attack of ethanolamine to an electron deficient, ring fission and formation of an 
aldehyde took place, which through concomitant cyclisation and oxidation could deliver the target lactam 
(Scheme 3.2 (A)127. However, a few synthetic studies have reported that instead of cyclisation such lactamization 
Chapter 3: Ircinialactam Declaation and Introduction  
 
    36 
required intermediate lactones and amino acids128. These data along with the fact that hydroxybutenolides are 
known to be produced by singlet oxidation122 and as auto oxidation of variabilin123 suggest an alternative plausible 
transformation of furan to lactam proceeding via oxidation of the furan to regioisomeric hydroxybutenolides, 
which undergo conjugation with glycine to yield the target glycinyl lactam (Scheme 3.2 (B).  
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 Scheme 3.1. The formation of carboxylic acid and dimethyl diester from tetronic acid adopted from Gonzales et al 198397 
 
 Scheme 3.2. Plausible formation of glycinyl lactam from furan proposed earlier by Hamman et al 1999127 (A) and our plausible formation  
                     of furan to butenolide to lactam (B).  
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3.2.2. Synthesis of Variabilin and Glycinyl Lactam 
Indeed, the same process has been shown in synthesis of spongolactams and derivatives from their corresponding 
furan by Mori et al in 2009126. The authors obtained regioisomeric hydroxybutenolides from their respective furan 
and conjugated them with a range of amino acids including histamine, glycine and phenylalanine followed by 
reduction of the hydroxy group to produce a range of " and # !-lactam containing metabolites. The synthesis of 
variabilin was also reported by Takabe el al by means of asymmetric synthesis employing enzymatic 
desymmetrization129.  
 
3.2.3. Ecological Consideration 
In addition to structural variations and synthesis efforts, a few papers have addressed the ecological role of 
variabilin. Pawlik et al have reported that variabilin isolated from Caribbean sponges of the genus Ircinia was 
capable of deterring the wrasse Thalassoma bifasciatum at concentration of 0.5 mg/ml in aquarium fish feeding 
assay130. Similarly, Epifanio et al have also found that variabilin and derivatives isolated from the Western 
Atlantic sponge Ircinia strobilina produced fish predation deterrent131.  
 
3.2.4 Biological Activity  
Variabilin and its oxidative derivatives were also known to be active in many bioassays. As mentioned before, 
variabilin was first reported as an antimicrobial agent109. Subsequently, variabilin derivatives have been reported 
to exert a range of biological activities including antiviral and antibacterial105,106, antitumor, cytotoxic against 
K562 cell line107 and SK-MEL-2 (human tumor cell line) inhibitors of isocitrate lyase and DNA replication108 and 
a dual inhibitor of human secretory and cytosolic Phospholipase A2132. Unlike variabilin and its oxidative 
derivatives, to date known linear sesterterpene glycinyl lactams have proved to be inactive both in antibacterial107 
and cytotoxic107,114 assays.  
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In contrast, chemical and biological profiling suggested that the active components for three Australian Irciniidae 
concentrated in two fractions at tR = 9.50-10.70 (CMB-01064); tR = 11.50-12.20 (CMB-03231) and tR = 6.5-7.5 
(CMB-03363) which HPLC-MS analysis confirmed to contain likely new nitrogenous molecules (Table 2.2). 
These results encouraged us to investigate the metabolites of these three Australian Irciniidae sponges as a source 
of potentially new GlyR modulators.  
Described in the following paper is the discovery of six novel linear glycinyl lactams including ircinialactam A 
(3.45), 8-hydroxyircinialactam A (3.46), 8-hydroxyircinialactam B (3.47), ircinialactam C (3.48), ent-
ircinialactam C (3.49) and ircinialactam D (3.50) as well as three known compounds such as 
7E,12E,18R,variabiln (3.51), 7E,12Z,18R-variabilin (3.52) and 12E,20Z-18S-8-hydroxyvariablin (3.53). While 
geometrically isomeric variabilins were normally reported as a mixture or acetylated derivatives107,112,114,115, 
compounds 3.50 and 3.51 were isolated by HPLC without derivatisation. Importantly, all glycinyl lactams except 
3.47 and 3.49 were successfully isolated by SPE-LC-NMR. Together with 7,8-dihydroisopalinurin (3.52) and 
cometin A (3.53), 3.45-3.51 were evaluated against GlyRs in a structure activity relationship (SAR) study. Of 
these, 3.46, 3.47 and 3.53 were active against GlyR"1 and GlyR"3 with 3.53 strongly modulating both GlyR"1 
and GlyR"3 while 3.46 and 3.47 only potently potentiang GlyR"1 suggesting 3.46 and 3.47 specific GlyR"1 
potentiators.  
 
*Note that the numbering system for ircinialactams and variabilins in this introduction and conclusion of this thesis is 
different from those used in the ircinialactam paper and its supporting information. 
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a b s t r a c t
Screening an extract library of >2500 southern Australian and Antarctic marine invertebrates and algae
for modulators of glycine receptor (GlyR) chloride channels identified three Irciniidae sponges that
yielded new examples of a rare class of glycinyl lactam sesterterpene, ircinialactam A, 8-hydroxyircini-
alactam A, 8-hydroxyircinialactam B, ircinialactam C, ent-ircinialactam C and ircinialactam D. Struc-
ture–activity relationship (SAR) investigations revealed a new pharmacophore with potent and subunit
selective modulatory properties against a1 and a3 GlyR isoforms. Such GlyR modulators have potential
application as pharmacological tools, and as leads for the development of GlyR targeting therapeutics to
treat chronic inflammatory pain, epilepsy, spasticity and hyperekplexia.
! 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Glycine-gated chloride channel receptors (GlyRs) play a pivotal
role in orchestrating inhibitory neurotransmission in the central
nervous system.1 Although they are generally known to be concen-
trated at the post-synaptic densities of neurons in the spinal cord,
brainstem and retina, GlyRs are also located pre-synaptically at
several synapses.2–4 GlyRs are members of the Cys-loop ion chan-
nel receptor family and comprise a family of five subunits, a1–a4
and b. Functional GlyRs can be formed either as pentameric a sub-
unit homomers or as ab subunit heteromers.1,5 The a1–a4 sub-
units exhibit differential central nervous system distribution
patterns that are particularly evident in the superficial dorsal horn
of the spinal cord,6 and the retina.7–9 On the other hand, the b sub-
unit is broadly distributed throughout the brain. The physiological
consequences of the differential a subunit distribution patterns are
difficult to establish, as there are currently few pharmacological
probes that can selectively inhibit specific GlyR isoforms.10,11
Although several synthetic cannabinoid agonists (e.g., HU-210,
HU-308 and WIN-55,212-2) effect a strong pharmacological dis-
crimination between a1-containing and a3-containing GlyRs,12
these ligands are generally unsuitable for physiological or behav-
ioural studies due to non-specific actions at cannabinoid receptors
CB1 and CB2. As such, small molecule subunit selective modulators
of GlyRs would have significant value as pharmacological tools.
A further reason for identifying novel GlyR subunit-specific li-
gands is to identify therapeutic lead compounds for muscle relax-
ation, inflammatory pain, immunomodulation and epilepsy. As a1b
GlyRs mediate inhibitory neurotransmission onto spinal motor
neurons,1 increasing a1b GlyR activity dampens motor neuron
activity and hence reduces muscle contractility. Although gener-
ally sparsely distributed, the a3 subunit is strongly expressed in
glycinergic synapses on nociceptive sensory neurons in the super-
ficial layers of the spinal cord dorsal horn.6 A variety of evidence13
indicates that inflammatory pain sensitisation is caused by a pros-
taglandin E2-mediated down-regulation of a3-mediated glyciner-
gic inhibitory currents in nociceptive neurons. This could
produce ‘disinhibition’ of nociceptive projection neurons, resulting
in the increased transmission of pain impulses to the brain, thereby
explaining inflammatory pain sensitisation. Agents that restore
(i.e., potentiate) glycinergic currents could therefore have potential
as analgesics for chronic inflammatory pain. Although a1 is also
expressed in nociceptive neurons, the a3 GlyR is considered a more
promising therapeutic target as its sparse distribution outside the
dorsal horn implies a reduced risk of side-effects.11,13,14
Functional GlyRs are also present in a variety of immune cells,
including macrophages and leucocytes, where they are thought
to mediate the anti-inflammatory effects of glycine.15,16 Thus, the
systemic administration of enhancing agents specific for a1- or
a2-containing GlyRs could limit the damage inflicted by the
inflammatory immune response on essential biological molecules,
cells and organs. Finally, RNA-edited high-affinity transcripts of a2
and a3 GlyRs are upregulated in human temporal lobe epilepsy
0968-0896/$ - see front matter ! 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2010.03.002
* Corresponding author. Tel.: +61 7 3346 2979; fax: +61 7 3346 2090.
E-mail address: r.capon@imb.uq.edu.au (R.J. Capon).
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and there is evidence for a causative relationship between this
upregulation and the condition.17,18 Thus, antagonists selective
for high-affinity a2- or a3-containing GlyRs may be useful for
treating this chronic and debilitating neurological disorder. Con-
sidering all this information, it would be potentially useful to iden-
tify novel compounds with potent and specific potentiating or
inhibitory effects on any individual GlyR isoform.
The aim of this study was to identify novel GlyR subunit-spe-
cific modulators from marine natural products with potential
either as therapeutic leads or as pharmacological probes for unrav-
elling glycinergic mechanisms in the central nervous system and
immune system.
2. Results
2.1. Fluorescence-based screening
A collection of >2500 southern Australian and Antarctic mar-
ine invertebrates and algae were initially screened against
recombinantly expressed a1 and a3 GlyRs using a yellow fluo-
rescent protein (YFP)-based anion influx assay as described in
Section 5. While the fluorescence assay employed was robust,
some problems associated with autofluorescence of the extracts
were encountered. These problems were largely overcome by
using cell selection masks during quantitative microscopy to only
measure fluorescence specifically associated with cell cytoplasms.
In addition, some extracts resulted in false positives due to
disruption of cellular membranes and leakage of YFP. Conse-
quently, the cellular morphology in all active wells had to be
assessed to ensure membrane integrity had been maintained. Fi-
nally, all active fractions were subjected to a second round of
screening, yielding 27 marine extracts with confirmed antagonis-
tic activity.
2.2. Isolation and structure elucidation
Chemical investigation of active extracts derived from three
sponges of the Family Irciniidae yielded the known sponge metab-
olites (7E,12E,20Z,18S)-variabilin (1), (7E,12Z,20Z,18S)-variabilin
(2) and (12E,20Z,18S)-8-hydroxyvariabilin (3), along with new
examples of a rare class of glycinyl lactam sesterterpenes, ircini-
alactam A (4), 8-hydroxyircinialactam A (5), 8-hydroxyircinialac-
tam B (6), ircinialactam C (7), ent-ircinialactam C (8) and
ircinialactam D (9) (Scheme 1). All these metabolites belong to a
common biosynthetic family, collectively known as sesterterpene
tetronic acids, with the archetypal example being 1. It is notewor-
thy that the ircinialactams were present at 10–100-fold lower con-
centrations in the sponge extracts than the corresponding
variabilins, necessitating the use of HPLC–SPE–NMR for structure
elucidation.
(7E,12E,20Z,18S)-Variabilin (1) was first reported from the mar-
ine sponge Ircinia variabilis in 1973,19 and its full stereostructure
described in 1994.20 Over the last 25+ years several dozen variabi-
lins have been reported, featuring differing levels of oxidation, ste-
reochemistry and double bond regiochemistry. These include 2
from a Maltese Ircinia oros21 and 3 from a New Zealand Sarcotragus
sp.22 Samples of 1–3 recovered during this current investigation
were identified by spectroscopic analysis, with configurations
Scheme 1. Marine natural products investigated for GlyR modulating properties.
W. Balansa et al. / Bioorg. Med. Chem. 18 (2010) 2912–2919 2913
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about D7,8 and D12,13 defined by the 13C NMR chemical shifts for
the corresponding olefinic methyls (E !16 ppm, Z !23 ppm), and
configuration about D20,21 defined by the 13C NMR chemical shift
for C-20 (E !121 ppm, Z !117 ppm).22 Double bond regiochemist-
ry was determined from 2D NMR correlations, and absolute
configuration by ½a#D measurements20,22–24 and biogenetic consid-
erations. Full 1D and 2D NMR (methanol-d4) data for 1–3 are pre-
sented in the Supplementary data.
The remaining metabolites 4–9 are noteworthy in that the pre-
cursor furan moiety has undergone modification to the rare glyci-
nyl lactam functionality. Such sesterterpene glycinyl lactams are a
relatively recent addition to the scientific literature, having been
described from Korean Sarcotragus spp.25–27 Diagnostic NMR reso-
nances consistent with conversion of a furanyl to a glycinyl lactam
include replacement of a-furan methines (H-1 and H-4) with res-
onances for glycinyl (10-H2, dH !4.2) and lactam (1-H2 or 4-H2 dH
!4.0) methylenes, and the appearance of a lactam carbonyl (C-4
or C-1, dC !174).26 The 1H NMR chemical shift for H-2 is also diag-
nostic of lactam regiochemistry, (1-H2, dH !6.8; 4-H2, dH !5.8).26
Metabolites 7–8 are glycinyl lactams further modified by biosyn-
thetic truncation of the carbon skeleton (C25–C21) with concomi-
tant transformation of the tetronic acid to a carboxylic acid. Such
C21 furanoterpenes have been reported as co-metabolites with
sesterterpene tetronic acids from a Spanish Ircinia sp.,28 as well
as both New Zealand22 and Korean27 Sarcotragus spp. Metabolite
9 is a glycinyl lactam further modified by ring opening and rear-
rangement of the tetronic acid functionality, to return a distinctive
dihydroxy diacid (ester) terminus. The first reported examples of
such a dihydroxy diacid (as the dimethyl ester) appeared as re-
cently as 2008, as co-metabolites with sesterterpene tetronic acids
from a Korean Sarcotragus sp.27 A more detailed account of the
structure proofs of 4–9 is presented below.
(+)HRESIMS analysis of ircinialactam A (4) returned a pseudo-
molecular ion [M+Na]+ consistent with a molecular formula
(C27H37NO6, Dmmu 0.5) requiring ten double bond equivalents
(DBE) and indicative of a glycinyl lactam analog of 1. Analysis of
the NMR data (Table 1) revealed diagnostic resonances for config-
urations about D7,8 (C-9, dC 16.0, E), D12,13 (C-14, dC 15.9, E) and
D20,21 (C-20, dC 115.9, Z), and the glycinyl lactam regiochemistry
(H-2, dH 6.88). Excellent correlations between the 13C NMR data
for 4 with that of 1, particularly across the C-12 to C-25 structure
fragment, together with analysis of the complete 1D and 2D NMR
data and a $ve ½a#D, supported the assigned structure.
(+)HRESIMS analysis of 8-hydroxyircinialactam A (5) returned a
pseudomolecular ion [M+Na]+ consistent with a molecular formula
(C27H39NO7, Dmmu 0.6) requiring nine DBE and indicative of a
glycinyl lactam analog of 3. Analysis of the NMR data (Table 2) re-
vealed diagnostic resonances for configurations about D12,13 (C-14,
dC 15.7, E) and D20,21 (C-20, dC 115.7, Z), and the glycinyl lactam
regiochemistry (H-2, dH 6.93). Excellent correlations between the
13C NMR (methanol-d4) data for 5with that of 3, particularly across
the C-12 to C-25 structure fragment, together with analysis of the
complete 1D and 2D NMR data and a $ve ½a#D, supported the as-
signed structure. The configuration about C-8 remains unassigned.
The isomeric co-metabolite 8-hydroxyircinialactam B (6) displayed
excellent NMR comparisons to 5, with resonances diagnostic for
configurations about D12,13 (C-14, dC 15.7, E) and D20,21 (C-20, dC
115.8, Z), and for the alternative glycinyl lactam regiochemistry
(H-2, dH 5.88). Analysis of the complete 1D and 2D NMR data
(Table S4, Supplementary data) and a $ve ½a#D, supported the as-
signed structure.
(+)HRESIMS analysis of ircinialactam C (7) returned a pseudo-
molecular ion [M+Na]+ consistent with a molecular formula
(C23H35NO5, Dmmu 0.6) requiring seven DBE, suggestive of the
glycinyl lactam of C21 furanoterpene analogue of 1. Analysis of
the NMR data (Table 3) revealed diagnostic resonances for config-
urations aboutD7,8 (C-9, dC 16.1, E) andD12,13 (C-14, dC 15.9, E), and
the glycinyl lactam regiochemistry (H-2, dH 6.89). Excellent corre-
lations between 13C NMR data for 7 and 4, particularly across the
C-1 to C-19 structure fragment, together with analysis of the com-
plete 1D and 2D NMR data and a $ve ½a#D, supported the assigned
Table 1
NMR data (600 MHz, methanol-d4) for ircinialactam A (4)
# dH (mult, J Hz) dCa COSY HMBC (1H–13C)
1 4.05 (br s) 52.9 2 2, 3
2 6.88 (br s) 138.7 1 1, 4
3 139.2
4 174.2
5 2.28b 26.8 3, 6
6 2.26b 27.0 7 3, 5, 7, 8
7 5.14 (br t, 6.5) 124.5 6 5, 9, 10
8 137.2
9 1.59 (br s) 16.0 7, 8, 10
10 1.99 (t, 7.3) 40.7 11 8, 9, 11, 12
11 2.08 (m) 27.4 10, 12 10, 12, 13
12 5.10 (br t, 6.5) 125.6 11 11, 14, 15
13 135.9
14 1.56 (br s) 15.9 12, 13, 15
15 1.96 (m) 40.4 16 12, 13, 14, 16
16 1.39c 26.8 15 17
17a 1.39c 37.5 16, 18 16
17b 1.31 (m) 16
18 2.75 (m) 31.8 19, 20
19 1.06 (d, 7.0) 21.6 18 17, 18, 20
20 5.28 (d, 10.1) 115.9 18 17, 19, 21, 22
21 144.9
22 164.2
23 99.2
24 173.3
25 1.75 (s) 6.1 22, 23, 24
10 4.22 (s) 44.3 1, 4, 20
20 172.3
a 13C assignments supported by HSQC experiment.
b,c Overlapping signals.
Table 2
NMR data (600 MHz, methanol-d4) for 8-hydroxyircinialactam A (5)
# dH (mult, J Hz) dCa COSY HMBC (1H–13C)
1 4.06 (br s) 52.9 2, 5 2, 3
2 6.93 (br s) 138.6 1 1, 3, 4, 5
3 139.4
4 174.3
5 2.27 (br t, 7.3) 27.2 1, 6 2, 4, 6
6 1.62 (m) 23.1 5, 7 5
7 1.50 (m) 42.2 6 6
8 73.2
9 1.14 (s) 26.7 7, 8, 10
10 1.45 (m) 42.7 11 8, 11
11 2.01 (m) 23.5 10, 12 10, 12, 13
12 5.13 (br t, 7.1) 126.0 11, 14 11, 14, 15
13 135.9
14 1.58 (br s) 15.7 12, 13, 15
15 1.96 (br t, 7.0) 40.4 16 16
16 1.39b 26.7 15 17
17a 1.39b 37.5 17b 16
17b 1.31 (m) 17a
18 2.75 (m) 31.8 19, 20
19 1.06 (d, 6.7) 21.0 18 17, 18, 20
20 5.28 (d, 10.2) 115.7 18 17, 19, 21, 22
21 145.0
22 164.6
23 98.9
24 173.5
25 1.75 (s) 6.1 22, 23, 24
10 4.22 (s) 44.3 1, 4, 20
20 172.6
a 13C assignments supported by HSQC experiment.
b Overlapping signals.
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structure. The isomeric metabolite ent-ircinialactam C (8) dis-
played identical NMR data (Table S5, Supplementary data) to 7,
with resonances diagnostic for configurations about D7,8 (C-9, dC
16.3, E) andD12,13 (C-14, dC 16.1, E), and for the glycinyl lactam reg-
iochemistry (H-2, dH 6.88). Analysis of the complete 1D and 2D
NMR data, and more significantly a +ve ½a"D, supported the as-
signed structure.
(+)HRESIMS analysis of ircinialactam D (9) returned a pseudo-
molecular ion [M+Na]+ consistent with a molecular formula
(C29H45NO9, Dmmu 0.3) requiring eight DBE, suggestive of a glyci-
nyl lactam of 1 in which the tetronic acid moiety had undergone
ring opening and rearrangement. Analysis of the NMR data
(Table S6, Supplementary data) revealed diagnostic resonances
for configurations about D7,8 (C-9, dC 16.1, E) and D12,13 (C-14, dC
16.0, E), and the glycinyl lactam regiochemistry (H-2, dH 6.89), as
well as resonances for an ethyl ester (dH 4.19/4.22, m, CO2CH2CH3;
dH 1.29, t, CO2CH2CH3; dC 176.6, CO2CH2CH3) and a carboxylic acid
(dC 175.2, CO2H). Excellent correlations between NMR data for 9
and 7, particularly across the C-1 to C-19 structure fragment, as
well as 9 and published data for a known dimethyl ester ana-
logue,27 together with analysis of the complete 1D and 2D NMR
data, supported the structure as shown. While the relative config-
urations at C-21 and C-23 were not resolved, an 18S configuration
was assigned on the basis of the known co-metabolites (1–3) and
biogenic considerations.
2.3. Bioassay
The metabolites 1–9 represent known and new examples of the
‘variabilin’ family of marine sponge sesterterpenes. To further
broaden our structure–activity relationship (SAR) investigations
we also had access to authentic samples of the marine sponge
metabolites 7,8-dihydroisopalinurin (10)23 from a Psammocinia
sp. and cometin A (11)29 from a Spongia sp. All compounds were
screened against recombinant a1 and a3 GlyRs using whole cell
patch-clamp electrophysiology. The standard electrophysiological
protocol involved voltage-clamping a1 or a3 GlyR-expressing
HEK293 cells at #40 mV and inducing an inward current flux by
applying an EC20 glycine concentration (i.e., a concentration that
activates 20% of the saturating glycine-gated current). For a1 and
a3 GlyRs, this corresponded to glycine concentrations of 15 and
100 lM, respectively. Unless otherwise indicated, GlyRs were first
activated with a 2 s pulse of glycine alone and then with the same
concentration of glycine plus a defined concentration of test
compound. Usually a 1 min period elapsed between successive gly-
cine plus compound applications. Under these experimental condi-
tions, the known sesterterpene tetronic acids 1 and 2 had no
significant effect on either a1 or a3 GlyRs at concentrations up
to 100 lM (Table 4). However, the 8-hydroxy analogue 3 produced
potent potentiation of a1 GlyRs. Examples of the effects of increas-
ing concentrations of 3 at the a1 GlyR are shown in Figure 1A, with
an averaged dose–response presented in Figure 1B. As summarised
in Table 4, this compound exhibited a mean EC50 of 1.2 ± 0.2 lM
and a maximum potentiation magnitude of 215 ± 39% (both n = 3
cells). It is apparent that a slowly-developing inhibition can also
be observed at concentrations >30 lM, although this was not
quantified. In contrast, 3 potently inhibited a3 GlyRs with a mean
IC50 of 7.0 ± 1.5 lM (n = 3). Given this subunit-specific activity, we
also tested the effects of 3 on transiently expressed a2 GlyRs using
conventional whole cell patch-clamp recording, as described previ-
ously.12 Receptors were activated with an EC20 (50 lM) glycine
concentration and 3 applied at a concentration of 10 lM. Averaged
from six cells, we found that this resulted in weak inhibition, to
87 ± 2% of control current magnitude.
As summarised in Table 4, the glycinyl lactam analogue 4 was a
moderate potentiator of a1 GlyRs, producing an enhancement of
140 ± 12% (n = 7) at a concentration of 100 lM. Analogue 4 was
also a modest inhibitor of a3 GlyRs (Table 4). Combining structural
features of 3 and 4, the 8-hydroxy glycinyl lactam 5 had no signif-
icant effect on a3 GlyRs at concentrations up to 100 lM, but was
an effective potentiator of a1 GlyRs, with potentiation being signif-
icant at 1 lM and reaching 217 ± 15% (n = 6) at 100 lM, the highest
concentration tested. However, as the potentation did not saturate
by 100 lM, an EC50 could not be measured. By contrast, the isomer
6was an exceptionally strong potentiator of a1 GlyRs. Examples of
the effects of increasing concentrations of 6 at the a1 GlyR are
shown in Figure 2A, with an averaged dose–response presented
Table 4
Summary of the potentiation (EC50) and antagonism (IC50) of GlyRs
Compound Potentiation Antagonism
a1 GlyR a3 GlyR a1 GlyR a3 GlyR
EC50 (lM) MP (%) EC50 (lM) MP (%) IC50 (lM) IC50 (lM)
1 — — — —
2 — — — —
3 1.2 ± 0.2
215 ± 39
— — 7.0 ± 1.5a
4 No saturation
140 ± 12
— — 30–100
5 No saturation
217 ± 15
— — —
6 0.5 ± 0.3b
330 ± 28
No saturation
183 ± 19
— —
7 — — — 30–100
8 — — — 30–100
9 — — — 30–100
10 — — — —
11 — — — —
MP = maximum potentiation expressed as a percentage of EC20 glycine current. A
dash (—) indicates no activity was observed. No saturation = no current saturation
was observed at drug concentrations up to 100 lM and hence EC50 values could not
be calculated. All mean data were averaged from 3–7 cells.
a Hill coefficient (nH) = 0.9 ± 0.15 lM.
b Hill coefficient (nH) = 0.5 ± 0.3 lM.
Table 3
NMR data (600 MHz, methanol-d4) for ircinialactam C (7)
# dH (mult, J Hz) dCa COSY HMBC (1H–13C)
1 4.05 (s) 52.9 2 2
2 6.89 (br s) 138.7 1 1, 4, 5
3 d
4 174.2
5 2.30b 26.9 2, 6
6 2.27b 27.0 7 5, 7, 8
7 5.16 (br t, 6.6) 124.5 6 5, 9, 10
8 137.1
9 1.61 (br s) 16.1 7, 8, 10
10 2.01 (br t, 7.9) 40.8 11 7, 8, 9, 11
11 2.09c (m) 27.6 10, 12 10, 12, 13
12 5.11 (br t, 6.6) 125.5 11 14, 15
13 136.0
14 1.59 (br s) 15.9 12, 13, 15
15 1.97 (br t, 8.0) 40.7 16 12, 13, 14, 16, 17
16 1.44 (m) 26.3 15
17a 1.31 (m) 37.5
17b 1.17 (m)
18 1.92 (m) 31.4 19, 20a
19 0.94 (d, 5.7) 20.1 18 17, 18, 20
20a 2.27b 42.6 18, 20b 17, 18, 19, 21
20b 2.07c 20a 17, 18, 19, 21
21 177.0
10 4.22 (s) 44.3 1, 20 , 4
20 172.9
a 13C assignments supported by HSQC experiment.
b,c Overlapping signals.
d Not observed.
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in Figure 2B. As summarised in Table 4, the dose–response was fit-
ted with a mean EC50 of 0.5 ± 0.3 lM and a maximum potentiation
magnitude of 330 ± 28% (both n = 5 cells). Compound 6 also poten-
tiated a3 GlyRs with much weaker potency. The mean potentiation
elicited by 100 lM of 6 was 183 ± 19% (n = 6). These data support
the proposition that the 8-hydroxy and glycinyl lactam functional-
ities are key elements of the GlyR potentiating pharmacophore.
Negligible to at best modest antagonist activity (30–100 lM)
associated with 7–9 highlights the significance of the conjugated
tetronic acid moiety (Table 4). These observations on the pharma-
cophore are further confirmed by the absence of significant activity
associated with 10–11.
3. Discussion
Analogs 3, 5 and 6 all modulated GlyRs in the sub-micromolar
to low-micromolar range and exhibited differential effects on a1
and a3 GlyRs. Analog 3 exhibited the strongest subunit-specificity.
At a 10 lM concentration, 3 strongly potentiated a1 GlyRs, had lit-
tle effect on a2 GlyRs and potently inhibited a3. This is the first a3
specific inhibitor yet identified. Until now, the only compounds
known to exhibit strong subunit-specific inhibition of GlyRs were
the synthetic cannabinoids (HU-210, HU-308 and WIN-55,212-2).
These compounds all inhibited both a2 and a3 GlyRs with affini-
ties ranging from 50 nM to 1 lM, while having little or no inhibi-
tory effect on a1 GlyRs up to 30 lM.12 HU-210 did, however,
produce strong potentiation of a1 GlyRs. Of course, the synthetic
cannabinoids have numerous off-target actions that render them
unsuitable as pharmacological probes or GlyR-targeted therapeu-
tics. Provided 3 does not exhibit off-target actions, it may be useful
as a pharmacological probe for identifying the presence of a3-con-
taining GlyRs and for investigating their contribution to glycinergic
signalling on spinal nociceptive sensory neurons. Due to its ability
to selectively inhibit a3 GlyRs, 3 may also be a promising starting
point for the development of lead compounds to treat temporal
lobe epilepsy.17,18
Analogs 3, 5 and 6 selectively and dramatically potentiated a1
GlyR currents at sub- to low-micromolar concentrations. As 5
and 6 had little effect on a3 GlyRs in this concentration range, they
can thus be considered as a1 GlyR-specific potentiators. To date
only a few a1 GlyR-specific potentiators have been identified.
NV-31, a gingkolide derivative, exhibits an a1 GlyR-specific poten-
tiating action at 1–10 lM, although the magnitude of its effect
(135%) is small.30 While some dihydropyridine and tropeine
derivatives selectively potentiate a1 GlyRs over other GlyR sub-
types,31–35 both compound classes have well-known, clinically
important effects on other ion channels. Finally, pregnenolone, an
endogenous steroid, potentiates a1 but not a2 GlyRs in the 2–
20 lM range,36 although it has much higher potencies at GABA-A
receptors.37 Thus, all previously identified GlyR a1-specific poten-
tiators have either weak activity or potent off-target actions. If 5
and 6 prove to be highly specific as a1 GlyR enhancers, they could
be useful as therapeutic leads for movement disorders such as
spasticity and hyperekplexia.38
Literature reports of novel natural products can prompt total
syntheses targeting both the natural products themselves, and
the structure class in general. In addition to developing valuable
new methodology, synthetic studies are typically justified by the
claim that an effective synthesis can be essential for supplying
the material needed for pharmacological investigation. This claim
is particularly accurate in the case of marine sponge metabolites,
where recollection and resupply is often problematic or impossi-
ble, isolated yields are low, and poor stability can limit the dura-
tion of access to a particular metabolite, often precluding or at
least curtailing biological assessment. The value of successful total
Figure 1. Effects of 3 on a1 and a3 GlyRs. (A) Effects of indicated concentrations of
3 on currents activated by EC20 glycine concentrations a1 and a3 GlyRs (upper and
lower panels, respectively). Unfilled bars denote glycine applications and filled bars
denote compound applications. (B) Averaged dose–response of 3 at a1 GlyRs (n = 3
cells). (C) Averaged dose–response of 3 at a3 GlyRs (n = 3 cells). Mean parameters of
best fit to dose–response curves are given in the text.
Figure 2. Effects of 6 on a1 and a3 GlyRs. (A) Effects of indicated concentrations of
6 on currents activated by EC20 glycine concentrations a1 and a3 GlyRs (upper and
lower panels, respectively). Unfilled bars denote glycine applications and filled bars
denote compound applications. (B) Averaged dose–response of 6 at a1 GlyRs (n = 5
cells). Mean parameters of best fit to dose–response curves are given in the text.
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syntheses notwithstanding, choice of target is frequently driven by
factors other than pharmacological imperative. In the absence of
knowledge of its unique effect on GlyRs, it is hardly surprising that,
despite being known for two decades, the sesterterpene tetronic
acid 3 failed to attract the attention of synthetic chemists. Our
findings reveal that sesterterpene tetronic acids, such as 3, 5 and
6, embody an exciting new pharmacophore worthy of synthetic
attention. Future synthetic studies could provide a library of natu-
ral products and analogues for both in vitro and in vivo evaluation,
defining the importance of the glycinyl lactam, 8-hydroxy and con-
jugated tetronic acid moieties to the pharmacophore, characteris-
ing requirements for subunit selectivity, and differentiating the
molecular basis behind antagonism versus potentiation.
4. Conclusion
In this investigation, we successfully challenged a library of
>2500 marine extracts to focus attention on three geographically
distinct sponges of the Family Irciniidae that in turn yielded an ar-
ray of sesterterpene tetronic acids, examples of which were shown
to be potent subunit-selective GlyR modulators. The glycinyl
lactam pharmacophore identified during this investigation may in-
spire the development of new pharmacological tools capable of
probing the distribution and function of GlyR isoforms, potentially
advancing the development of GlyR targeting therapeutics to
treat chronic inflammatory pain, epilepsy, spasticity and/or
hyperekplexia.
5. Experimental
5.1. Equipment
Chiroptical measurements (½a"D) were obtained on a JASCO P-
1010 polarimeter in a 100 # 2 mm cell. UV spectra were acquired
from a Cary 50 UV–vis spectrophotometer. NMR spectra were ob-
tained on a Bruker Avance DRX600 spectrometer equipped with a
3 mm HPLC–SEI 1H–13C/D Z-GRD flow probe in the solvents indi-
cated and referenced to residual 1H signals in the deuterated sol-
vents. HPLC–DAD–SPE was performed using an Agilent 1100
Series Separations Module equipped with a Bruker Diode Array
Detector coupled to a Spark Prospekt2 SPE unit. All NMR data
was acquired in methanol-d4 unless otherwise specified. Electro-
spray ionisation mass spectra (ESIMS) were acquired using an Agi-
lent 1100 Series separations module equipped with an Agilent
1100 Series LC/MSD mass detector in both positive and negative
ion modes. High-resolution ESIMS measurements were obtained
on a Bruker micrOTOF mass spectrometer by direct infusion in
MeCN at 3 lL/min using sodium formate clusters as an internal
calibrant. HPLC was performed using an Agilent 1100 Series sepa-
rations module equipped with Agilent 1100 Series diode array and/
or multiple wavelength detectors and Agilent 1100 Series fraction
collector, controlled using ChemStation Rev.9.03A and Purify ver-
sion A.1.2 software.
Fluorescence experiments were performed using an automated
imaging system with a robot-controlled liquid handling system
constructed in the laboratory. The 384-well plates were placed
onto a motorised stage (Prior ProScan II, GT Vision, Hagerstown,
MD, USA) of an Olympus IX51 inverted microscope and cells were
imaged with an Olympus 10# objective (UPlanFLN, N.A. 0.30). Illu-
mination to excite YFP fluorescence was provided by an Osram
100W mercury short arc lamp (HBO 103/2), passing through an
Olympus YFP dichroic mirror (86002V2 JP4 C76444). Emitted fluo-
rescence passed through a magnifier lens (diopter 8, mineral glass),
and was then imaged by a Photometrics CoolSNAP CF monochrome
camera (Roper Scientific GmbH, Ottobrun, Germany) and digitised
onto a personal computer. The final resolution of the images was
696 # 520 pixels. The maximum image acquisition rate used in
these experiments was 1.25 Hz. Liquid-handling was performed
with an LC PAL autosampler (CTC Analytics, Zwingen, Switzerland)
using a 100-lL syringe. A suite of LabView 8.2.1 software (National
Instruments Corp, Austin, Texas, USA) routines purpose-written in
the laboratory were used for hardware control, image acquisition,
storage, image analysis and data quantification. Whole cell
patch-clamp recordings were performed using an automated pla-
nar patch-clamp device (Patchliner, Nanion Technologies GmbH,
Munich, Germany).
5.2. Marine extracts library
A library of >2500 marine invertebrate and alga samples, col-
lected from locations across southern Australia and Antarctica,
including intertidal, coastal and deep sea locations, were acquired
(Capon) over a period of 25+ years. Individual samples were docu-
mented, diced and steeped in EtOH at $30 !C for prolonged stor-
age. A portion (7 mL) of each EtOH extract was decanted into a
labelled, tared screw cap vial (8 mL) and the solvent evaporated
in vacuo. The residue was weighed (25–50 mg) and partitioned
in situ by addition of n-BuOH (2 mL) and H2O (2 mL). Typically,
the biomass partitioned 10–20% into n-BuOH and 80–90% into
H2O. Aliquots (1 mL) of both n-BuOH and H2O phases were trans-
ferred to deep 96-well plates, to generate a set of extract library
plates. These plates were subsequently used to prepare 10- and
100-fold dilution plates. The full set of extract and dilution plates
represented a resource to support screening programs against a di-
verse array of bioassays.
For the initial screening, an aliquot (90 lL) of each 100-fold di-
luted n-BuOH partition was transferred into 384-well plates and
each well was dried under a stream of nitrogen. The plates were
stored at $30 !C, protected from light, until required. On the day
of the assay, Ringer buffer (30 lL) was added to each well of the
plates and an aliquot (10 lL) of each solution was transferred onto
cells pre-incubated in Ringer buffer (15 lL). Assays were per-
formed in horizontal duplicate. For the hit confirmation, an aliquot
(24 lL) of each 10-fold diluted n-BuOH partition was transferred
into 384-well plates, which were dried and stored as described
previously. On the day of the assay, extracts were resuspended in
Ringer buffer (80 lL) and aliquots (17 or 10 lL) were then trans-
ferred in horizontal duplicate onto cells pre-incubated in Ringer
buffer (15 lL). The concentration dependence assisted in ranking
extract potency for later prioritisation. Isolated pure compounds
were prepared as 100 mM DMSO stock solution (10 lL), and were
tested with patch-clamp at concentrations ranging from 10–
300 lM final.
5.3. Extraction and isolation
A portion of the aqueous EtOH extract of specimen CMB-01064
(genus Ircinia; Museum Victoria Registry Number MVF 166265)
was decanted and concentrated in vacuo, and the residue (2.25 g)
partitioned between H2O and n-BuOH. The n-BuOH soluble fraction
was concentrated in vacuo (876.0 mg) and the residue was further
triturated with light petroleum (19.9 mg), DCM (473.7 mg), MeOH
(343.4 mg) and water (25.5 mg). A portion of the DCM soluble frac-
tion (60.0 mg) was subjected to HPLC fractionation (Zorbax C18,
5 lm 250 # 9.4 mm column, 4 mL/min gradient elution, 10–100%
MeCN/H2O with isocratic 0.01% TFA modifier) over 25 min to yield
a mixture of 1 and 2 (6.5 mg, 5.9%), 3 (2.1 mg, 1.9%), 4 (4.0 mg,
3.6%), 5 (3.2 mg, 2.9%) and 6 (1.3 mg, 1.2%) (Scheme S1, Supple-
mentary data). Yields calculated as a percentage of n-BuOH soluble
fraction.
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A portion of the aqueous EtOH extract of specimen CMB-03363
(genus Ircinia; Museum Victoria Registry Number MVF 166224)
was decanted and concentrated in vacuo, and the residue (1.68 g)
was partitioned between H2O and n-BuOH. The n-BuOH soluble
fraction was concentrated in vacuo (526.9 mg) and the residue fur-
ther triturated with light petroleum (8.4 mg), DCM (267.8 mg),
MeOH (208.1 mg) and water (41.4 mg) soluble. The DCM soluble
fraction was subjected to HPLC (Zorbax C8, 5 lm, 250 ! 9.4 mm
column, 4 mL/min gradient elution, 10–100% MeCN/H2O with iso-
cratic 0.01% TFA modifier over 25 min) to yield three fractions (I–
III). Fraction II was essentially pure and was identified as 3
(10.0 mg, 1.9%). HPLC separation of a portion (3.2 mg) of fraction
III (Zorbax C3, 5 lm, 150 ! 4.6 mm column, 1 mL/min gradient elu-
tion 50–100% MeCN/H2O with isocratic 0.01% TFA modifier over
25 min) yielded 1 (1.2 mg, 3.7%) and 2 (1.4 mg, 4.4%). HPLC separa-
tion of fraction I (Zorbax C8, 5 lm, 150 ! 4.6 mm column, 1 mL/
min gradient elution 10–100% MeCN/H2O with isocratic 0.01%
TFA modifier over 25 min) yielded 4 (0.3 mg 0.057%), 5 (0.2 mg,
0.037%), 7 (0.3 mg, 0.057%) and 9 (0.3 mg, 0.057%) (Scheme S2,
Supplementary data). Yields calculated as a percentage of n-BuOH
soluble fraction.
A portion of the EtOH extract of the third specimen, CMB-03231
(genus Psammocinia; Museum Victoria Registry Number MVF
166220), was also decanted and concentrated in vacuo and the res-
idue (238.1 mg) was partitioned between H2O and n-BuOH. The n-
BuOH soluble fraction was concentrated in vacuo and the residue
(124.8 mg) triturated with petroleum (1.4 mg), DCM (75.3 mg)
and MeOH (43.4 mg). The DCM soluble fraction was subjected to
HPLC fractionation (Zorbax C8, 5 lm, 250 ! 9.4 mm column,
4 mL/min gradient elution, 10–100% MeCN/H2O with isocratic
0.01% TFA modifier over 25 min) yielded 8 (0.7 mg, 0.6%) (Scheme
S3, Supplementary data). Yields calculated as a percentage of n-
BuOH soluble fraction.
5.4. Characterisation of compounds
5.4.1. (7E,12E,20Z,18S)-Variabilin (1)
Colourless oil. ½a#D $24.8 (c 0.06, MeOH); UV–vis (MeOH) kmax
(log e) 203 (4.27), 257 (3.93) nm; NMR data see Supplementary
data Table S1; (+)HRESIMS m/z 421.2356 (calcd for C25H34O4Na
421.2349).
5.4.2. (7E,12Z,20Z,18S)-Variabilin (2)
Colourless oil. ½a#D $27.1 (c 0.05, MeOH); UV–vis (MeOH) kmax
(log e) 202 (4.19), 249 (3.98), 308 (3.74) nm; NMR data see Supple-
mentary data Table S2; (+)HRESIMS m/z 421.2356 (calcd for
C25H34O4Na 421.2349).
5.4.3. (12E,20Z,18S)-8-Hydroxyvariabilin (3)
Colourless oil. ½a#D $37.4 (c 0.34, MeOH); UV–vis (MeOH) kmax
(log e) 203 (4.33), 253 (4.27) nm; NMR data see Supplementary
data Table S3; (+)HRESIMS m/z 439.2462 (calcd for C25H36O5Na
439.2455).
5.4.4. Ircinialactam A (4)
Colourless oil. ½a#D $20.5 (c 0.03, MeOH); UV–vis (MeOH) kmax
(log e) 203 (4.40), 250 (4.14) nm; NMR data see Table 1; (+)HRE-
SIMS m/z 494.2508 (calcd for C27H37NO6Na 494.2513).
5.4.5. 8-Hydroxyircinialactam A (5)
Colourless oil. ½a#D $19.5 (c 0.02, MeOH); UV–vis (MeOH) kmax
(log e) 203 (4.33) nm; NMR data see Table 2; (+)HRESIMS m/z
512.2626 (calcd for C27H39NO7Na 512.2632).
5.4.6. 8-Hydroxyircinialactam B (6)
Colourless oil. ½a#D $12.0 (c 0.02, MeOH); UV–vis (MeOH) kmax
(log e) 202 (4.40) nm; NMR data see Supplementary data Table
S4; (+)HRESIMS m/z 512.2630 (calcd for C27H39NO7Na 512.2632).
5.4.7. Ircinialactam C (7)
Colourless oil. ½a#D $30.8 (c 0.03, MeOH); UV–vis (MeOH) kmax
(log e) 203 (4.27) nm; NMR data see Table 3; (+)HRESIMS m/z
428.2413 (calcd for C23H35NO5Na 428.2407).
5.4.8. ent-Ircinialactam C (8)
Colourless oil. ½a#D +28.3 (c 0.03, MeOH); UV–vis (MeOH) kmax
(log e) 201 (4.33) nm; NMR data see Supplementary data Table
S5; (+)HRESIMS m/z 428.2404 (calcd for C23H35NO5Na 428.2407).
5.4.9. Ircinialactam D (9)
Colourless oil. ½a#D $19.9 (c 0.03, MeOH); UV–vis (MeOH) kmax
(log e) 203 (4.48) nm; NMR data see Supplementary data Table
S6; (+)HRESIMS m/z 574.2990 (calcd for C29H45NO9Na 574.2987).
5.4.10. 7,8-Dihydroisopalinurin (10)
Colourless oil. ½a#D +9.9 (c 0.09, MeOH); UV–vis (MeOH) kmax
(log e) 204 (4.20) nm; NMR data see Supplementary data Table
S7; (+)HRESIMS m/z 423.2507 (calcd for C25H36O4Na 423.2506).
5.4.11. Cometin A (11)
Colourless oil. ½a#D $11.5 (c 0.05, CHCl3); UV–vis (EtOH) kmax
(log e) 240 (3.85) nm; (+)HRESIMS m/z 433.1988 (calcd for
C25H30O5Na 433.1985). NMR data consistent with published
data.29
5.5. GlyR Bioassay
The first round of screening of marine extracts was performed
using a YFP-based anion flux assay as described in detail previ-
ously.39 Briefly, the cDNAs for YFP-I152L40 and the human a1, a2
and a3L GlyR were subcloned separately into the pcDNA3.1 plas-
mid vector. HEK293 cells were transfected with the cDNAs for
YFP-I152L plus one of the GlyR cDNAs using a calcium phosphate
precipitation method. After termination of this procedure, cells
were plated into wells of a 384-well plate at a density of around
3000 cells per well. Experiments were performed 24–48 h later.
Around an hour before experiments, the culture medium in each
well was replaced by 15 lL of Na gluconate solution containing
(in mM): Na gluconate 140, KCl 5, CaCl2 2, MgCl2 1, HEPES 10, glu-
cose 10, pH 7.3/NaOH. An aliquot (10 lL) of each fraction (contain-
ing 300 lg/mL dried material) was added to each well 30–45 min
before experiments were commenced. Individual fractions were
tested in duplicate. The experiments were performed using an
automated imaging system with a robot-controlled liquid handling
system constructed in the laboratory. The experimental protocol
involved adding 50 lL of NaI solution (containing (in mM): NaI
140, KCl 5, CaCl2 2, MgCl2 1, HEPES 10, glucose 10, pH 7.3/
NaOH) + 1 mM glycine to cells in each well to yield a final glycine
concentration of %670 lM. The chloride-induced fluorescence
change was monitored 5–10 s later. Typically, 100–200 fluorescent
GlyR-expressing cells were imaged per well. Fractions producing
significant changes to either the resting or glycine-stimulated fluo-
rescence levels were re-tested to confirm activity.
5.6. Generation of stably-expressing HEK293 cell lines
The human a1 and a3L GlyR subunit cDNAs in the pcDNA3.1
plasmid vector were linearized using ScaI and transfected into
HEK293 cells using a calcium phosphate method and then main-
tained for 10–14 days in selection medium containing 1 mg/mL
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G-418 and 10 lM strychnine for a1 GlyR and 500 lg/mL G-418 for
a3 GlyR cell lines. From thenceforth, the two respective cell lines
were always cultured in these selective media. Surviving transfec-
ted colonies were isolated and grown in the same media in 96-well
plate for two weeks. Any large monoclonal colonies were screened
for functional response to 10 mM glycine using the YFP-based
chloride flux assay described above. In these experiments, several
clones of either a1 or a3 GlyRs that exhibited a significant fluores-
cence quench to glycine exposure were identified and one clonal
cell line of each subunit was selected for further characterisation
using both patch-clamp and YFP assays.
5.7. Electrophysiology
We employed a Nanion Patchliner automated planar chip
patch-clamp device (NPC-16A, Nanion Technologies GmbH, Mu-
nich, Germany) to perform whole cell recordings on up to 8 cells
simultaneously. In addition to increasing throughput, this device
permits complete exchange of the solution bathing the cells with
25 lL of new solution. For Patchliner experiments, the stable a1
and a3 GlyR-HEK293 cells were suspended in the standard exter-
nal solution containing (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2,
10 HEPES/NaOH and 5 glucose (pH 7.4) at a density of 1 ! 106–
5 ! 107 cells/mL. The cell suspension, the pre-prepared internal
solution [(in mM) 50 KCl, 10 NaCl, 60 KF, 2 MgCl2, 10 HEPES/
KOH (pH 7.2), and 20 EGTA], the external solution and the com-
pound-containing solutions are all placed at pre-defined positions
on the workstation and were applied to cells via robotic control.
For dose–response experiments, cells were voltage-clamped at
"40 mV at room temperature (20–24 !C). Compounds to be tested
were dissolved in DMSO and kept at "20 !C, with solutions for
experiments prepared from these stocks on the day of recording.
Results are expressed as mean ± SEM of three or more indepen-
dent experiments. The Hill equation was used to calculate the
half-maximal concentration (EC50) and Hill coefficient (nH) values
for activation. A similar equation was also used to calculate the
half-maximal concentrations for inhibition (IC50) and nH values for
inhibition. All curves were fitted using a non-linear least squares
algorithm (Sigmaplot 9.0, Jandel Scientific). Statistical significance
wasdeterminedbyunpaired Student’s t-testwith P<0.05 represent-
ing significance.
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The ethanolic extract from three priority specimens (CMB-03363, CMB-03231 and CMB-01064) were 
concentrated in vacuo and subjected to trituration into n-hexane, dichloromethane, methanol and water. Aliquots 
of 25–50 #g/mL were prepared from respective CMB-03363, CMB-03231 and CMB-01064 partitions and were 
tested against the glycine gated chloride channel receptors (GlyRs) using a yellow fluorescence assay. Observed 
inhibitory effects were attributed in part to metabolite(s) in the CH2Cl2 and MeOH partitions where several HPLC 
fractionations were performed. In the case of CMB-03231, CMB-01064 and CMB-03363, HPLC fractionations 
led to the discovery of 9 linear sesterterpene tetronic acids consisting of 3 known and 6 new variabilin type 
compounds shown in detailed at Figure 3S1, 3S2 and 3S3 and whose detailed discovery process is as follows.  
 
 
 
Collection and Taxonomy of Sponge CMB-03363 
 
An Ircinia sp. (CMB-03363) (Class Demospongiae, Order Dictyoceratida, Family Irciniidae) was collected in 
2001 during scientific SCUBA operations off the Nepean Wall, in The Rip, Port Phillip Heads, Victoria (Latitude 
38° 18.13’ Longitude 144° 38.12’). Growth form irregular lamellate-lobate; colour in EtOH grey; texture 
compressible but very tough to tear; oscules discrete; surface opaque, glossy, conulose; spicules none; ectosome 
collagenous; choanosome a reticulation of spongin fibres forming fascicles and cored with detritus. Collagen a 
mass of tangled fibrils with ampules clearly visible, some detritus scattered (Museum Victoria Registry Number 
MVF 166224).  
Isolation and purification of the metabolites of CMB-03363 were focused on three fractions: (1) eluted at 6 to 8 
min (red), (2) at 9 to min 10 (blue) and (3) at 13.5 to 14.5 min (pink). At the first purification stage, only fraction 
tR = 9 min (blue) was pure identified as the known 12E,20Z,18S-hydroxyvariabilin (3), while the less polar 
fraction tR = 6 min (red) and the more polar fraction tR = 13.5 to 14.5 min (pink) existed as mixtures, posing a 
challenge in isolation and purification of these two fractions.  
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Scheme 3S1. Extraction and Purification of CMB-03363 
(a). Partition [n-BuOH (-1) and H2O (-2)]; 
(b). Trituration on n-BuOH soluble (Petrol (-1-1), DCM (-1-2), MeOH (-1-3) and H2O (-1-4)] 
(c). Trituration on water soluble [MeOH (-2-1) and H2O (-2-2)]; 
(d-f, h). HPLC Zorbax C8 (250 ' 9.4 mm) 4.0 mL/min 10-100% MeCN/H2O with isocratic 0.01% TFA modifier over 25 minutes; 
(i, j). LC-SPE-NMR Zorbax C8 (150 ' 4.6 mm) 1.0 mL/min 0-100% MeCN/H2O over 15 minutes); 
(l). HPLC Zorbax (C3, 150 ' 4.6 mm) 1.0 mL/min 50% MeCN/H2O over 15 minutes. 
CMB-03363
     1.68 g
n-BuOH H2O
Petrol DCM MeOH H2O MeOH H2O
(a), (b)
(c) (d)
526.9 mg (-1) 1.15 mg (-2)
565.6 mg
  (-2-1)
582.8 mg
  (-2-2)
8.4 mg 267.8 mg
  (-1-2)
208.1 mg 41.4 mg(-1-1) (-1-3) (-1-4)
 280.5 mg
(-1-2-1)*
9.6 mg
(-1-2-2)
10.0 mg
(-1-2-3)
11.0 mg
(-1-2-4)
75.6 mg
(-1-2-5)
  0.4 mg
(1-2-2-2)
 0.8 mg
(1-2-2-4)
 7.3 mg 
(1-2-2-5)
  0.2 mg
(1-2-2-2-1)
   0.1 mg
(1-2-2-2-2)    0.3 mg(1-2-2-2-3)
   0.3 mg
(1-2-2-2-4)
(f)
(i)
(j) (k)
(l)
   0.3 mg 
(-1-2-3-1)
  0.8 mg 
(-1-2-3-2)
  6.7 mg 
(-1-2-3-3)
 1.2 mg
(-1-2-5-1)
 1.4 mg
(-1-2-5-2)
 7.8 mg
(-1-2-5-3)
   0.3 mg
-1-2-3-2-1
   0.2 mg    0.3 mg-1-2-3-2-1
   0.2 mg
-1-2-3-2-1
15.0 mg
(-1-2) + (-1-3) (e)
(g) (h)
(3)
(1) (2)
(4)
(7) (9)
(5)
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Although the less-polar HPLC fraction collected at 13.5 to 14.0 minutes appeared to be a single pure compound (Figure 3S1), 
1H NMR analysis revealed this fraction as comprising two isomers, 7E,12E,20E,18R-variabilin (1 ) and 7E,12Z,20E,18R-
variabilin (2). As mentioned before in the introduction of this chapter, such isomers have previously been reported as 
inseparable mixture and characterized on the mixture107,115. Even after derivatisation, Fujimoto et al only managed to purify 
one of five mixture of 7E,12E,20E,18R-variabilin, 8Z,13Z,20Z-strobilinin, 8E,13Z,20Z-strobilinin and 7E,13Z,20Z-felexinin, 
7E,13E,20Z-felixinin112. In our hands, the mixture of 7E,12E,20E,18R-variabilin (1 ) and 7E,12Z,20E,18R-variabilin (2) 
isomers were successfully resolved (Zorbax C3, 5 µm, 150 ' 4.6 mm column, 1 mL/min gradient elution 50-100% MeCN/H2O 
with isocratic 0.01% TFA modifier over 25 min) and characterized. 
 
 
Figure 3S1. HPLC chromatogram of CMB-03363-1-2 (Zorbax C18 (250 x 9.4 mm) 4.0 mL/min 10-100% MeOH/H2O with isocratic 0.01% 
TFA modifier over 15 minutes. 
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Purification of trace metabolites yielded four compounds (Figure 3S1 and Scheme 3S1). In order to obtain enough 
of the metabolites, the combined DCM and MeOH fractions were purified to yield fractions -1-2-2 and -1-2-3 
(~20 mg), which were further purified to obtain individual semi-pure compounds (-1-2-2-2), (-1-2-2-4), (-1-2-3-
1) and (-1-2-3-2) (Scheme 3S1). Due to the close retention time of the metabolites in this fraction, we employed 
LC-SPE-NMR. Figure 3S2 displays an overlay chromatogram of four metabolites after separation with LC-SPE-
CMR (Zorbax C8, 5 µm, 150 ' 4.6 mm column, 1 mL/min gradient elution 10-100% MeCN/H2O with isocratic 
0.01% TFA modifier over 25 min). The metabolites isolated through this process included ircinialactam A (4), 
hydroxyircinialactam (5),  ircinialactam C (7) and ircinialactam D (9).  
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Figure 3S2. Overlay of HPLC chromatogram of pure compounds 4-5, 7 and 9 [Zorbax C8 (150 x 4.6 mm) 1.0 mL/min 50-100% MeCN/H2O with isocratic 
0.01% TFA modifier] over 15 minutes, resolved by LC-SPE-NMR with careful peak shriving.  
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Collection and Taxonomy of Sponge CMB-01064  
An Ircinia sp. (CMB-01064) (Class Demospongiae, Order Dictyoceratida, Family Irciniidae) was collected in the 
Great Australian Bight, during commercial trawling operations aboard the FV Comet, in May 1990. Growth form 
massive-irregular; colour on deck not seen, colour in EtOH is grey; texture compressible but arenaceous and 
tough to tear; oscules not seen; surface opaque; conulose; spicules none; ectosome indistinct, collagenous; 
choanosome a mass of collagen fibrils with terminal ampules and detritus obscuring fiber reticulation (Museum 
Victoria Registry Number MVF 166265). 
 
 
 
  Scheme 3S2. Extraction and Purification of sponge CMB-01064 
 
 
CMB-01064
     2.25 g
n-BuOH H2O
Petrol DCM MeOH H2O MeOH H2O
(a)
(b) (c)
876.0  mg (-1) 1.24 g (-2)
565.6 mg
  (-2-1)
582.8 mg
  (-2-2)
19.9 mg 473.7  mg
  (-1-2)
343.4 mg 25.5 mg
(-1-1) (-1-3) (-1-4)
 3.2 mg
(-1-2-3)
4.0 mg
(-1-2-4)
 1.2 mg
(-1-2-5)  6.5 mg(-1-2-6)
 0.9 mg
(-1-2-1)
35.5 mg* 
(-1-2-7)
(a). Partition [n-BuOH (-1) and H2O (-2);
(b). Trituration on n-BuOH soluble (Petrol (-1-1), DCM (-1-2), MeOH (-1-3) and H2O (-1-4)]
(c). Trituratin on water soluble [MeOH (-2-1) and H2O (-2-2)];
(d). HPLC [Zorbax C18 (250 x 9.4 mm) 4.0 mL/min 90% H2O/MeCN to MeCN + 0.01 TFA over 25 minutes 
 *   Uninvetistigated
(d) 60.0 mg
1.3 mg
(-1-2-2)
(6) (4) (5) (7) (3) (1,2)
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The isolation and characterization of the metabolites of CMB-01064 were focused on six fractions including 4 
(green), 5 (yellow), 5 (pink), 7 (black), 3 (blue), 1 and 2 (red), five of which (4, 5-7 and 9) were already pure. 
Apart from 6, other compounds have been isolated from CMB-03363 (Figure 3S3) as shown by spectroscopic 
data analysis and comparison with the metabolites isolated from CMB-03363. Chemical profiles (NMR and 
HRESIMS data) of metabolites isolated from CMB-01064 showed close similarity to those obtained from CMB-
03363. The only exception was that CMB-01064 did not produce 9 but instead this specimen contained a new 
metabolite, 8-hydroxyircinialactam A (6) (Scheme 3S2).  
 
 
 
Figure 3S3. HPLC chromatogram of CMB-01064-1-2 (Zorbax C18 (250 x 9.4 mm) 4.0 mL/min 10-100% MeOH/H2O with isocratic 0.01% 
TFA modifier over 15 minutes.  
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Collection and Taxonomy of Sponge CMB-03231 
 
A Psammocinia sp. (CMB-03231) (Class Demospongiae, Order Dictyoceratida, Family Irciniidae) was collected 
off The Pinnacles Reef, offshore Point Lonsdale, Victoria (Latitude 38° 17.50’ Longitude 144° 35.20’. Growth 
form massive-irregular; colour in EtOH sandy; texture spongy but tough to tear; oscules scattered with 
membranous lip; surface translucent, wrinkled; spicules none; ectosome a distinct layer of detritus 300-400 µm 
thick; choanosome-spongin bound tracts of detritus in dense mass of collagen fibrils (Museum Victoria Registry 
Number MVF 166220). 
Although the last specimen (CMB-03231) yielded only low levels of sesterterpenes, we managed to isolate one new 
molecule ent-ircinialactam (8) from this specimen (Figure 3S4 and Scheme 3S3), the enantiomer of ircinialactam 
C (7) recovered from CMB-03363 and CMB-01064. Identification of this molecule and all metabolites isolated 
from CMB-01064 and CMB-03363 are described in detail in the following pages.  
 
                                                           
 
Figure 3S4. HPLC chromatogram of CMB-03231-1-2 (Zorbax C18 (250 x 9.4 mm) 4.0 mL/min 10-100% MeOH/H2O 
CO2H
N O
CO2H
ircinialactam C (8)
! -!
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  Scheme 3S3. Extraction and Purification of sponge CMB-03231 
 
 
 
 
 
 
 
 
 
 
 
 
CMB-03231
  238.1 mg
n-BuOH H2O
Petrol DCM MeOH MeOH H2O
(a)
(c)
124.8  mg (-1) 110.6 mg (-2)
72.7 mg
  (-2-1)
32.6 mg
  (-2-2)
0.5 mg 70  mg
  (-1-2)
3.1 mg
(-1-1) (-1-3)
0.7 mg
(-2-2)
3.1 mg*
(-1-2-3)
 0.4 mg*
(-1-2-4)
0.4 mg*
(-1-2-5)
52.5 mg *
(-1-2-6)0.5 mg*-1-2-1
(b)
(d)
(a). Partition [n-BuOH (-1) and H2O (-2);
(b). Trituration on n-BuOH soluble (Petrol (-1-1), DCM (-1-2), MeOH (-1-3) and H2O (-1-4)];
(c). Trituratin on water soluble [MeOH (-2-1) and H2O (-2-2)];
(d). HPLC [Zorbax C18 (250 x 9.4 mm) 4.0 mL/min 90% H2O/MeCN to MeCN + 0.01 TFA over 25 minutes;
 Red indicates new compound while * means univestigated.
8
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Table 3S1: NMR (600 MHz, CD3OD) data for (7E,12E,20Z,18S)-variabilin (1) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.36 (t, 1.7)  143.9 2 2, 3, 4 
2 6.29 (br s)  112.2 1 1, 3, 4 
3  125.7   
4 7.24 (br s)  140.2 5 1, 2, 3 
5 2.43 (t, 7.5) 26.1 4, 6 2, 3, 4, 6 
6 2.23 (dt, 7.5, 7.5) 29.8 5, 7 5, 7, 8 
7 5.16 (br t, 7.5) 125.4 6 5, 6, 9, 10 
8  136.7   
9 1.57 (br s)  16.3  7, 8, 10 
10 1.98B  40.9 11 7, 8, 9, 11 
11 2.08 (dt, 7.3, 7.3)  27.6 10, 12 12, 13, 15 
12 5.09 (br t, 7.2) 125.4 11 10, 11, 14 
13  136.0   
14 1.56 (br s) 16.0  12, 13, 15 
15 1.95B 40.6 16 12, 13, 14, 16, 17 
16 1.38C 27.0 15, 17a 17 
17a 
17b 
1.39C 
1.31 (m)  
37.8 
 
16 16 
16 
18 2.74 (m) 32.0 19, 20  
19 1.05 (d, 8.5) 21.3 18 17, 18, 20 
20 5.26 (d, 10.5) 115.3 18 17, 19, 21, 22 
21  145.7   
22  166.8   
23  97.5   
24  174.2   
25 1.72 (s)  6.2  21, 22, 23, 24 
A 13C NMR assignments supported by HSQC experiment. B,C overlapping signals within the column. 
O O
OH
O
(7E,12E,20Z,18S)-variabilin (1)
1
4
7 12 20
9 14 19
25
24
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Table 3S2. NMR (600 MHz, CD3OD) data for (7E,12Z,20Z,18S)-variabilin (2) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.36 (t, 1.7) 143.9 2 2, 3, 4 
2 6.29 (br s) 112.2 1 1, 3, 4 
3  126.4   
4 7.24 (br s) 140.3 5 1, 2, 3 
5 2.44 (br t, 7.4) 26.2 4, 6 2, 3, 4, 6, 7 
6 2.24 (dt, 7.2, 7.2) 29.8 5, 7 5, 7, 8 
7 5.15 (br t, 7.5) 125.5 6 5, 6, 9, 10 
8  136.7   
9 1.55 (br s) 16.1  7, 8, 10 
10 1.95B 40.8 11 7, 8, 11, 12 
11 1.97B 27.2 10, 12 12, 13 
12 5.11 (br t, 7.5) 126.0 11 11, 14, 15 
13  137.0   
14 1.65 (br s) 23.8  12, 13, 15 
15 1.93B 32.4 16 16, 17 
16 1.43 (m) 27.5 15 13 
17 
 
a 1.47 (m) 
b 1.35 (m) 
38.9  16, 18, 19, 20 
16, 18, 19, 20 
18 2.74 (m) 32.0 19, 20  
19 1.06 (d, 6.8) 21.4 18 17, 18, 20 
20 5.28 (d, 10.1) 115.4 18 17, 19, 21, 22 
21  145.4   
22  165.8   
23  98.1   
24  173.8   
25 1.73 (s) 6.3  21, 22, 23, 24 
A 13C NMR assignments supported by HSQC experiment. B overlapping signals within the column. 
 
 
O
O
OH
O(7E,12Z,20Z,18S)-variabilin (2)
1
4
7 12
9
19
20
25
24
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Table 3S3. NMR (600 MHz, CD3OD) data for (12E,20Z,18S)-8-hydroxyvariabilin (3) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.38 (t, 1.6)  144.1 2 2, 3, 4 
2 6.30 (br s) 112.0 1 1, 3, 4 
3  126.5   
4 7.26 (br s)  140.2 5 1, 2, 3 
5 2.41 (br t, 7.3) 26.3 4, 6 2, 3, 4, 6, 7 
6 1.60 (m)  25.8 5, 7 7 
7 1.47B     42.3 6  
8  73.4   
9 1.13 (s)  27.0  7, 8, 10 
10 1.45B 42.8 11 8, 9 
11 2.00C 23.7 10, 12 10, 12, 13 
12 5.12 (br t, 7.0) 126.2 11 11, 14, 15 
13  135.9   
14 1.57 (br s)  15.9  12, 13, 15 
15 1.97C 40.6 16 12, 13, 14, 16, 17 
16 1.39D  26.9 15 17 
17 
 
a 1.39D 
b 1.32 (m) 
37.7 
 
17b 
17a 
 
16 
18 2.75 (m)  32.0 19, 20  
19 1.06 (d, 6.8) 21.2 18 17, 18, 20 
20 5.28 (d, 10.1) 116.0 18 17, 19, 21, 22 
21  144.1   
22  164.7   
23  99.2   
24  173.6   
25 1.75 (s)  6.3  22, 23, 24 
A 13C NMR assignments supported by HSQC experiment. B-D overlapping signals within the column. 
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OH
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Table 3S4. NMR (600 MHz, CD3OD) data for 8-hydroxyircinialactam B (6) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1  174.7   
2 5.88 (br s) 121.1 4 1, 3, 4, 5 
3  164.7   
4 4.13 (br s)  56.4 2 2, 3 
5 2.45 (br t, 7.4) 30.9 6 2, 3, 4, 6, 7 
6 1.66 (m) 23.0 5, 7   
7 1.50 (m) 42.1 6  
8  73.2   
9 1.16 (s) 26.4  7, 8, 10 
10 1.46 (m) 42.7 11 11 
11 2.03 (m) 23.4 10, 12 10, 12, 13 
12 5.14 (br t, 7.1)  126.0 11 11, 14, 15 
13   135.8   
14 1.58 (br s) 15.7  12, 13, 15 
15 1.97 (br t, 7.1) 40.4 16 14, 16 
16 1.39B 26.6 15 17 
17 
 
a 1.40B 
b 1.32 (m) 
37.5 
 
18 
  
18 2.75 (m) 31.8 17a, 19, 20  
19 1.06 (d, 6.7) 20.9 18 17, 18, 20  
20 5.28 (d, 10.1) 115.8 18 19, 21, 22 
21  144.9   
22  164.1   
23  99.1   
24  173.2   
25 1.75 (s) 6.0  22, 23, 24 
1( 4.19 (s) 43.9  1, 4, 2( 
2(  172.3   
A 13C NMR assignments supported by HSQC experiment. B overlapping signals  
 
N O
OH
O
CO2H
OH
O
8-hydroxyircinialactam B (6)
1
4
7 12 20
9 14 19
25
24
1'
2'
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Table 3S5. NMR (600 MHz, CD3OD) data for ent-ircinialactam C (8)  
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C)  
1 4.05 (br s) 53.1 2 2 
2 6.88 (br s) 138.8 1 1, 4, 5 
3  *   
4  174.4   
5 2.30B  27.1  2, 6 
6 2.28B 27.2 7 5, 7, 8 
7 5.16 (br t, 6.7) 124.8 6 5, 9, 10 
8  137.3   
9 1.61 (br s) 16.3  7, 8, 10 
10 2.01 (br t, 7.7) 41.0 11 7, 8, 9, 11 
11 2.09C 27.7 10, 12 10, 12, 13  
12 5.11 (br t, 7.1) 125.7 11 11, 14, 15 
13  136.1   
14 1.59 (br s) 16.1  12, 13, 15 
15 1.97 (br t, 8.1) 41.0 16 12, 13, 14, 16, 17 
16 1.44 (m) 26.5 15  
17 
 
a 1.32 (m) 
b 1.18 (m) 
37.5  
 
 
18 1.92 (m) 31.6 19, 20a  
19 0.95 (d, 6.7) 20.3 18 17, 18, 20 
20 
 
a 2.26B 
b 2.07C 
42.8 18, 20b 
20a 
17, 18, 19, 21 
17, 18, 19, 21 
21  177.2   
1( 4.20 (s) 45.0  1, 2(, 4 
2(  173.1   
A 13C NMR assignments supported by HSQC experiment. B,C overlapping signals within the column. * Not observed 
CO2H
N O
CO2H ent-ircinialactam C (8)
1
20
21
1'
2'
4
7 12
9 14 19
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Table 3S6. NMR (600 MHz, CD3OD) data for ircinialactam D (9) 
 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 4.05 (br s) 52.9 2 3 
2 6.89 (br s) 138.8 1 1, 4 
3  139.6   
4  174.2   
5 2.29B 26.9  3, 6 
6 2.27B 27.0 7 3, 5, 7, 8 
7 5.16 (br t, 6.6) 124.5 6 5, 9, 10 
8  137.2   
9 1.61 (br s) 16.1  7, 8, 10  
10 2.00C 40.9 11 7, 8, 9, 11 
11 2.09 (m) 27.5 10, 12 10, 12, 13 
12 5.10 (br t, 6.9) 125.4 11 14, 15 
13  136.2   
14 1.58 (br s) 16.0  12, 13, 15 
15 1.93 (br t, 7.2) 40.8 16 12, 13, 14, 16, 17 
16 1.37 (m) 26.3 15  
17 
 
a 1.24 (m) 
b 1.11 (m) 
38.9 17, 18 
 
 
18 1.47 (m) 30.9 19, 20a, 20b  
19 0.96 (d, 6.5) 22.1 18 17, 18, 20 
20 
 
a 1.97C 
b 1.84 (dd, 14.2, 7.7) 
40.6 18 
18 
 
18, 19, 21, 22 
21  83.6   
23  81.3   
25 1.49 (s) 21.1  21, 23, 24 
22  176.6   
24  175.2   
CO2CH2CH3 a 4.22 (m) 
b 4.19 (m) 
62.5 CO2CH2CH3  
CO2CH2CH3 1.29 (t, 7.2) 14.4 CO2CH2CH3 26 
1( 4.23 (s) 44.3  1, 2(, 4 
2(  172.4   
A 13C NMR assignments supported by HSQC experiment. B,C overlapping signals within the column. 
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Table 3S7. NMR (600 MHz, CD3OD) data for 7,8-dihydroisopalinurin (10) 
 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.37 (t, 1.7) 144.0 2 2, 3, 4 
2 6.27 (m) 112.1 1 1, 3, 4 
3  126.5   
4 7.23 (m) 140.1 5 1, 2, 3 
5 2.39 (td, 7.3, 3.4) 25.8 4, 6 2, 3, 4, 6 
6 1.52B 29.2 5, 7a 5 
7 a 1.44C 
b 1.14 (m) 
36.9 
 
6, 7b 
7a, 8 
 
8 1.75 (m) 31.0 7b, 9, 10a  
9 0.97 (d, 6.7) 21.0 8 7, 8, 10 
10 a 1.87 (ddd, 14.4, 7.5, 3.0) 
b 1.31D 
41.0 
 
8, 10b 
8, 10a, 11a 
7, 8, 9 
7, 8 
11 a 1.52B 
b 1.43C 
26.1 
 
10b, 11b, 12 
11a, 12 
10, 13 
12 2.04 (m) 41.0 11a, 11b 11, 13, 15 
13  137.0   
14 1.72 (d, 1.1) 16.6 15 12, 13, 15 
15 5.78 (br d, 10.7) 126.6 14, 16 12, 14, 16, 17 
16 6.20 (ddd, 15.0, 10.7, 0.8) 126.5 15, 17 13, 15, 18 
17 5.38 (dd, 15.0, 8.2) 139.2 16, 18 15, 16, 18, 19 
18 2.17 (m) 38.4 17, 19 16, 17, 19, 20 
19 0.99 (d, 6.7) 21.6 18 17, 18, 20 
20 a 1.34D 
b 1.29D 
38.0 
 
21 
21 
17, 18, 21 
17, 18, 21 
21 4.63 (brd, 9.5) 79.3 20a, 20b 24 
22  179.4   
23  94.8   
24  181.1   
25 1.63 (d, 0.9) 6.1  22, 23, 24 
A 13C NMR assignments supported by HSQC experiment. B-D overlapping signals within the column. 
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Figure 3S5. 1H NMR (600 MHz, CD3OD) data for (7E,12E,20Z,18S)-variabilin (1) 
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Figure 3S6. 1H NMR (600 MHz, CD3OD) data for (7E,12Z,20Z,18S)-variabilin (2) 
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Figure 3S7. 1H NMR (600 MHz, CD3OD) data for (12E,20Z,18S)-8-hydroxyvariabilin (3) 
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Figure 3S8. 1H NMR (600 MHz, CD3OD) data for ircinialactam A (4) 
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Figure 3S9. 1H NMR (600 MHz, CD3OD) data for 8-hydroxyircinialactam A (5) 
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Figure 3S10. 1H NMR (600 MHz, CD3OD) data for 8-hydroxyircinialactam B (6) 
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Figure 3S11. 1H NMR (600 MHz, CD3OD) data for ircinialactam C (7) 
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Figure 3S12. 1H NMR (600 MHz, CD3OD) data for ent-ircinialactam C (8) 
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Figure 3S13. 1H NMR (600 MHz, CD3OD) data for ircinialactam D (9) 
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Figure 3S13. 1H NMR (600 MHz, CD3OD) data for 7,8-dihyrdopalinurin (10) 
 
 
 
 
Figure 3S14. 1H NMR (600 MHz, CD3OD) data for 7,8-dihyroisopalinurin (10) 
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CHAPTER 4 
           IRCINIANINS 
 
 
  
 
 
 4.1. Declaration  
 
This chapter describes a series of rare cyclic sesterterpene tetronic acids ircinianins discovered from three priority 
Australian Psammocinia spp. Our collaborative study identified two rare cyclic sesterterpene tetronic acids and 
new co-metabolites from three Australian sponges of the genus Psammocinia, two of which potently modulated 
GlyR"1 and GlyR"3. A paper describing the discovery of this new structure class of GlyR modulators was 
recently published in Organic and Biomolecular Chemistry133. This was the second paper published so far from 
research collaboration on GlyR modulators from Australian Marine Resource between the Capon Group of 
the Institute for Molecular Bioscience (IMB) and the Lynch Group of the Queensland Brain Institute (QBI) of 
The University of Queensland Australia.  
The two-research groups contributed equally to the publication of the ircinianins paper. As in the first paper I was 
responsible for chemical investigation (isolation, purification and structure elucidation) of all metabolites 
discovered from three Australian Psammocinia spp (CMB-01008, CMB-02858 and CMB-03344). During my lab 
work at the IMB, I received technical assistance (lab work and data analysis) from Dr. Hua Zhang, Dr. Andrew 
M. Piggott and Dr. Xiao Xue and was supervised by Professor Robert J. Capon as the head of chemistry lab. 
Similarly, other co-authors have contributed to the work. Dr. Robiul Islam performed bioassays (Yellow 
fluorescence Protein and Patch Clamp assays) at the QBI The University of Queensland. He received technical 
assistance from Dr. Daniel F. Gilbert, Dr. Frank Fontaine and Dr. Timothy I. Webb and was under the supervision 
of Professor Joseph W. Lynch as the head of pharmacology lab. The contributions of all co-authors to the 
publication of ircinialactams paper were listed in the table given below.   
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Balansa, W.; Islam, R.; Fontaine, F.; Piggott, A. M.; Zhang, H.; Xue, X.; Timothy, I. Webb.; Gilbert, D.F.; Lynch, J. W.; 
Capon, R. J. Sesterterpene glycinyl-lactams: a new class of glycine receptor modulator from Australian marine sponges of 
the genus Psammocinia. Org. Biomol. Chem. 2013, 11, 4695-4072. 
 
Contributor Statement of contribution 
Balansa, Walter Responsible for chemistry (100% working)  
Islam, Robiul Responsible for bioassay (100% working) 
Fontaine, Frank Assisted with lab work and data analysis 
Zhang, Hua Assisted with lab work and data analysis 
Piggott, Andrew M. Assisted with lab work and data analysis 
Xiao Xua Assisted with lab work and data analysis 
Webb, Timothy. Assisted with lab work and data analysis 
Gilbert, Daniel Assisted with lab work and data analysis 
Lynch, Joseph W. Head of pharmacology lab.  
Capon, Robert J. Head of chemistry lab.  
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4.2. Introduction  
4.2.1. Structure and Diversity  
Sponges of the genus Ircinia are known to produce a range of furanosesterterpene tetronic acids101,107,114,115,134. 
These include linear furanosesterterpene tetronic acids such as variabilin and its unusual cyclic counterparts 
including the tetracyclic (+)-ircinianin135 and pentacyclic (+)-wistarin133,134,136,137. While structural variations are 
well known in linear furanosesterterpene tetronic acids (described in detail in Chapter 3), little is known about 
such molecular features in cyclic sesterterpene tetronic acids. So far, only four members of this structure class are 
known in the literature including ($)-ircinianin (4.1)135, ($)-ircinianin sulfate (4.2)134, (+)-wistarin (4.3)137 and ($)-
wistarin (4.4)138, all of which, except ($)-wistarin (4.4), were reported from Australian Ircinia spp. indicative of 
the rarity of the ircinianin structure class133,134.  
 
  
 
 
 
 
 
Structurally, members of ircinianin structure class can be classified into two groups. The first group features a 
tetracyclic structure with a bicyclo[4.3.0]nonane ring attached to a tetronic acid or sulfate ester through a spiro 
junction ring and connected to a furan moiety through an isoprene unit such as in ($)-ircinianin (4.1) or ircinianin 
sulfate (4.2). The second group displays a pentacylic structure with a tetrahydropyran attached to hexahydroindan 
ring and !-lactone and connected to furan such as in (+)-wistarin (4.3) and ($)-wistarin (4.4).   
O
H
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($)-Ircinianin (4.1) was first reported by Hofheinz and Schonholzer in 1977 from an Australian Ircinia wistarii 
collected from Wistarii Reef with structure determined by X-ray analysis135. Subsequently, the tetracylic 
furanosesterterpene was re-isolated from I. wistarii from several locations around Australia including Heron 
Island, Swain Reef on the Great Barrier Reef, Lamont Reef the Great Barrier Reef and the Great Australian 
Bight134. The pentacylic (+)$wistarin (4.3)137 was first reported by Gregson and Ouvrier from a Gladstone 
Queensland I. wistarii in 1982 co-existing with ($)-ircinianin sulfate (4.2) as a major unstable metabolite in 
CDCl3. In addition to discovering 4.2, Coll et al also reported the occurrence of wistarin and ircinianin from an 
Australian Ircinia/Psammocinia sp. in 1997134.  Two years later, Fontana et al discovered ($)-wistarin (4.4) from 
a Red Sea Ircinia sp, representing the first case of enantiomeric sesterterpene138.  
The recurrent co-occurrence of wistarin and ircinianin in Australian I. wistarii has raised contradictive 
speculations regarding the formation of wistarin and biosynthetic relationship between linear and cyclic 
furanosesterterpene tetronic acids.  In the original report, Gregson and Ouvrier proposed that ($)-ircinianin 
underwent in vivo cyclisation to form (+)-wistarin based on a molecular model137. Even though in that report the 
treatment of ($)-ircinianin with acid, Lewis acid or bases did not result in cyclisation of ($)-ircinianin to (+)-
wistarin137, Coll et al successfully recovered 18% (+)-wistarin from treating ($)-ircinianin sulfate with CDCl3 
leading to a claim that cyclisation of (+)-wistarin was pH catalized134, a claim further supported by Uenishi et al 
through a base catalysed reaction136. Following this approach, both the racemate ($)-wistarin have been 
synthesized in the manner that suggests they are biosynthetically derived from putative linear precursor via Diels 
Alder cycloaddition136. It was assumed that ircinianin was biogenetically derived by the action of a Diels Alderase 
acting on an acyclic precursor 8,11,13,20-tetraene (4.5) (Scheme 4.1)138. Supportive of this proposal was the 
thermal transformation of ircinianin from its acyclic precursor 8,11,13,20-tetraene (4.5) shown by Uenishi and co-
workers136.  
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      Scheme 4.1. Plausible biosynthetic relationship between linear and cyclic furanosesterterpene tetronic acids adopted from  
                            Cimino et al138.  
 
4.2.2. Synthesis and Bioactivity  
Although the ircinianin structure class has been known for more than three decades, and members are 
synthetically accessible, little is known of their biological activity. In 1997, Uenishi et al successfully synthesized 
(+)$wistarin and (-)$ircinianin in a 17-step total synthesis providing the access to biological studies and allowing 
the assignment of the absolute stereochemistry of ircinianin type compounds136. This stereochemical assignment 
revised previously proposed stereochemistry for (+)-wistarin136,138 but confirmed the relative stereochemistry for 
($)-ircinianin assigned earlier by an X-ray analysis135,136. Of interest, both results consistently showed ($)-
ircinianin as having negative molecular rotation values ["]D = $232 obtained from X-ray134 and ["]D = $235 from 
synthetic analysis135,136. Also, in the same report Uenishi et al obtained three isomeric ircinianin methyl eters (4.7-
4.9). Two of these isomers had positive optical rotation values ["]D = +124 and ["]D = +45 and were assigned as 
(+)-ircinianin methyl ether (4.8) and  (4.9) while the remaining isomer (4.7) with ["]D = -167 was assigned as ($)-
ircinianin methyl eter (4.7). This assignment was consistent with the assignment of absolute stereochemistry for 
($)-ircinianin (3.1) by X-ray (["]D = $232)135 and synthetic (["]D = $235) methods136. Surprisingly, 16 years after 
the synthetic triumph, no biological activity has been described for ircinianin structure class, standing in stark 
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contrast to the linear counterpart variabilins whose members have been intensively studied over the years 
(discussed in detail in Chapter 3).     
 
                                                          
  
 
 
 
Figure 4.1. Three Ircinianin methyl eter isomers with different molecular rotation values synthesized by Uenishi et al 1999136.  
 
Chemical profiling on the extracts of two Australian Psammocinia spp. (CMB-01008, CMB-02858 and CMB-
03344) revealed molecular weights consistent with the known ircinianin and ircinianin sulfate as well as a series 
of new compounds (Table 2.2). Mass spectrometry analysis and online study (Marinlit) and 1H NMR comparison 
to authentic sample for ircinianin (CMB-library) confirmed the presence of both known and new cyclic 
sesterterpene tetronic acids. Importantly, in YFP assay, minor metabolites of two extracts (CMB-02858 and 
CMB-03344) strongly modulated either GlyR"1 or GlyR"3. These observations encouraged further study of the 
metabolites of three Australian sponges of the genus Psammocinia leading to the discovery of six new cyclic 
sesterterpenes including ($)-ircinianin lactam A (4.11), ($)-ircinianinlactam A sulfate (4.12), ($)-oxoircinianin 
(4.13), ($)-oxoircinianin lactam A (4.14), ircinianin lactone (4.15), one semisynthetic derivative ircinianin acetate 
(4.16), and two known molecules, ircinianin (4.1) and ircinianin sulfate (4.2). Of these 4.11 and 4.14 potently and 
specifically modulated GlyR"1 and GlyR"3 respectively whose details are described in the following paper.  
 
*Note that the numbering system in this introduction and conclusion of this thesis is different from the ones in the paper and 
supporting information.  
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Sesterterpene glycinyl-lactams: a new class of glycine
receptor modulator from Australian marine sponges of
the genus Psammocinia†
Walter Balansa,a Robiul Islam,b Frank Fontaine,a Andrew M. Piggott,a Hua Zhang,a
Xue Xiao,a Timothy I. Webb,b Daniel F. Gilbert,b,c Joseph W. Lynch*b,d and
Robert J. Capon*a
Bioassay guided fractionation of three southern Australian marine sponges of the genus Psammocinia,
selected for their ability to modulate glycine-gated chloride channel receptors (GlyRs), yielded the rare
marine sesterterpenes (−)-ircinianin (1) and (−)-ircinianin sulfate (2), along with the new biosynthetically
related metabolites (−)-ircinianin lactam A (3), (−)-ircinianin lactam A sulfate (4), (−)-oxoircinianin (5),
(−)-oxoircinianin lactam A (6) and (−)-ircinianin lactone A (7). Acetylation of 1 returned (−)-ircinianin
acetate (8). Whole cell patch-clamp electrophysiology on 1–8 established 3 as an exceptionally potent
and selective α3 GlyR potentiator, and 6 as a selective α1 GlyR potentiator. The discovery and characteri-
zation of sesterterpenes 1–8, and in particular the glycinyl-lactams 3 and 6, provide valuable new insights
into GlyR pharmacology. These insights have the potential to inform and inspire the development of
new molecular tools to probe GlyR distribution and function, and therapeutics to treat a wide array of
GlyR mediated diseases and disorders.
Introduction
As members of the Cys-loop ion channel receptor family,
glycine-gated chloride channel receptors (GlyRs) play a pivotal
role in orchestrating inhibitory neurotransmission in the
spinal cord, brainstem and retina.1 The α1–α4 and β-GlyR sub-
units exhibit differential central nervous system distributions
that are particularly evident in the superficial dorsal horn of
the spinal cord2 and the retina.3 Notwithstanding the biologi-
cal importance of GlyRs, the physiological consequences of
differential distribution are difficult to establish as there are
currently few pharmacological probes that can selectively
inhibit GlyR isoforms.4 As a consequence, small-molecule
isoform-selective GlyR modulators would have great value both
as pharmacological tools, and as drug lead candidates for
inflammatory pain,2,5 opioid-induced breathing disorders,6
epilepsy7 and movement disorders.8
In an attempt to address this need, we screened a library of
>2500 southern Australian and Antarctic marine invertebrates
and algae to detect extracts and metabolites displaying GlyR-
modulating properties. In a preliminary report, we described
the ircinialactams from three southern Australian sponges of
the Family Irciniidae, as exemplars of a rare and promising
new class of GlyR modulator.9 More recently we reported on
the GlyR modulating properties of indolo-alkaloids from a
southern Australian sponge, Ianthella cf. flabelliformis.10 This
current report extends earlier findings, describing our analysis
of three southern Australian sponges of the genus Psammoci-
nia, leading to the discovery of the ircinianin glycinyl-lactams
(3 and 6) as the most promising new class of tunable isoform-
selective GlyR potentiators we have discovered to date.
(−)-Ircinianin (1) was first isolated in 1977 from a Great
Barrier Reef marine sponge Ircinia wistarii, and its structure
(with relative configuration) assigned by X-ray analysis.11 A
1982 re-isolation of 1 from another Australian I. wistarii speci-
men reported the isomeric “co-metabolite” (+)-wistarin,12
while a subsequent 1997 re-isolation of 1 from a Great Barrier
Reef Ircinia (Psammocinia) wistarii described the new co-meta-
bolite (−)-ircinianin sulfate (2).13 This latter study also
†Electronic supplementary information (ESI) available: 1H NMR spectra and
tabulated 2D NMR data for all compounds, sponge taxonomy, chemical pro-
filing, fractionation schemes and electrophysiology results. See DOI:
10.1039/c3ob40861b
aInstitute for Molecular Bioscience, The University of Queensland, St. Lucia,
QLD 4072, Australia. E-mail: r.capon@uq.edu.au; Fax: +61-7-3346-2090;
Tel: +61-7-3346-2979
bQueensland Brain Institute, The University of Queensland, St. Lucia, QLD 4072,
Australia. E-mail: j.lynch@uq.edu.au; Fax: +61-7-3346-6301; Tel: +61-7-3346-6375
cInstitute of Medical Biotechnology, Department of Chemical and Biological
Engineering, Friedrich-Alexander University Nuremberg-Erlangen, Germany
dSchool of Biomedical Sciences, The University of Queensland, St. Lucia, QLD 4072,
Australia
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confirmed that (+)-wistarin was an acid-catalyzed handling
artifact of 2. In 1997, the structure and absolute configuration
of 1 was confirmed by total synthesis,14 while a 1999 account
of (−)-wistarin from a Red Sea Ircinia sp. raised the prospect
that ircinianins may exist in nature in both enantiomeric
forms.15 Although the ircinianin sesterterpene scaffold has
been known for >35 years, structure diversity and access
remains remarkably limited. Significantly, in the absence of a
practical natural or synthetic source, this enigmatic class of
marine sponge metabolite has eluded any biological evalu-
ation – existing merely as molecular curios in the virtual
chemical space that is the scientific literature. Our investi-
gations reveal for the first time that new natural product ana-
logues of the ircinianin scaffold exhibit very significant and
valuable GlyR pharmacology.
Results and discussion
Bioassay-guided fractionation of three southern Australian
Psammocinia spp. yielded the known sesterterpenes (−)-ircinia-
nin (1) and (−)-ircinianin sulfate (2), with structure assign-
ments confirmed by detailed spectroscopic analysis and
comparisons to literature data (Tables 1 and 2 and ESI Tables
S1 and S2†). Further fractionation of Psammocinia sp.
(CMB-03344), collected in 2001 off Port Phillip Heads, Victoria,
yielded (−)-ircinianin lactam A (3) and (−)-oxoircinianin (5).
Psammocinia sp. (CMB-01008), collected in 1986 off Durras on
the mid-south coast of New South Wales, yielded (−)-ircinianin
sulfate lactam A (4), while Psammocinia sp. (CMB-02858), col-
lected in 1999 off Barwon Heads, Victoria, yielded (−)-oxo-
ircinianin lactam A (6) and trace amounts of (−)-ircinianin
lactone A (7). Structures for the new ircinianin analogues 3–7
(Fig. 1) were assigned by detailed spectroscopic analysis.
HRESI(+)MS analysis of 3 established a molecular formula
(C27H35NO6) which, based on our earlier characterization of
ircinialactams9 and ianthellalactams,10 was consistent with a
glycinyl-lactam analogue of 1. Comparison of the NMR (metha-
nol-d4) data for 1 with 3 (Tables 1 and 2 and ESI Tables S1 and
S3†) attributed the only significant difference to replacement
of the furanyl in 1 with a glycinyl-lactam moiety in 3. A
deshielded 1H NMR chemical shift for H-2 (δH 6.89),9
supported by diagnostic 2D NMR correlations, permitted
identification of (−)-ircinianin lactam A (3) as shown.
HRESI(−)MS analysis of 4 established a molecular formula
(C27H34NO9S) consistent with a sulfate analogue of 3. Compari-
son of the NMR (methanol-d4) data for 3 with 4 (Tables 1 and
2 and ESI Tables S3 and S4†) revealed the only significant
differences being a deshielding/shielding of 13C NMR reso-
nances for C-22 (ΔδC −1.8), C-23 (ΔδC +5.3) and C-25 (ΔδC +3.6),
comparable with differences observed between the tetronic
acid 1 and its sulfate 2 [C-22 (ΔδC −1.8), C-24 (ΔδC −6.6) and
C-25 (ΔδC +3.3)]. A deshielded 1H NMR chemical shift for H-2
(δH 6.92),9 supported by diagnostic 2D NMR correlations, per-
mitted identification of (−)-ircinianin sulfate lactam A (4) as
shown.
Table 2 Selected 1H NMR data (600 MHz, methanol-d4) for 1–7
Pos.
δH (mult, J (Hz))
1 2 3 4 5 6 7
1 7.38 (dd, 1.7, 1.7) 7.35 (dd, 1.6, 1.6) 4.07 (br s) 4.05 (s) 7.38 (dd, 1.6, 1.6) 4.07 (td, 1.7, 1.7) 4.83 (td, 1.8, 1.6)
2 6.30 (m) 6.32 (br s) 6.89 (br s) 6.92 (s) 6.32 (m) 6.96 (tt, 1.7, 1.7) 7.37 (tt, 1.6, 1.6)
4 7.26 (m) 7.26 (br s) 7.29 (m)
5 2.41 (br t, 7.6) 2.37 (m) 2.26 (m) 2.23 (m) 2.42 (br t, 7.4) 2.26 (br t, 7.7) 2.26 (m)
6 1.68 (m) 1.73 (m) 1.71 (m) 1.80 (m) 1.67 (m) 1.67 (m) 1.71 (m)
9 1.57 (d, 1.3) 1.57 (br s) 1.58 (d, 1.4) 1.59 (s) 1.57 (d, 1.3) 1.58 (d, 1.3) 1.58 (d, 1.4)
14 1.71 (dd, 2.8, 1.4) 1.71 (br s) 1.71 (dd, 2.9, 1.4) 1.71 (s) 1.73 (dd, 2.7, 1.4) 1.73 (dd, 2.8, 1.4) 1.71 (dd, 2.9, 1.4)
19 0.92 (d, 6.3) 1.00 (d, 6.4) 0.92 (d, 6.3) 1.01 (d, 6.6) 0.84 (d, 6.3) 0.83 (d, 6.2) 0.92 (d, 6.3)
25 1.64 (s) 2.00 (s) 1.64 (s) 2.01 (s) 1.39 (s) 1.38 (s) 1.64 (s)
1′ 4.07 (br s) 4.03 (s) 4.23 (s)
Table 1 13C NMR data (150 MHz, methanol-d4) for 1–7
Pos.
δC
1 2 3 4 5 6 7
1 144.0 143.8 53.0 54.4 144.0 53.1 72.2
2 112.1 112.3 138.0 137.8 112.1 139.0 148.0
3 126.5 126.8 139.0 139.3 126.6 140.1 134.6
4 140.3 140.2 173.2 173.4 140.4 174.5 177.2
5 25.3 25.7 25.8 26.6 25.0 26.3 25.8
6 29.5 29.2 26.9 26.8 29.3 26.9B 26.9
7 40.5 40.7 40.4 40.5 40.3 40.4 40.4
8 136.5 137.1 135.1 137.1 137.9 137.8 136.1
9 16.3 16.5 16.2 16.4 16.5 16.5 16.2
10 125.1 124.3 125.5 124.2 121.6 124.1 125.5
11 48.7 49.0 48.6 49.3 48.2 48.2 48.6
12 123.6 124.1 123.5 123.8 123.9 121.6 123.5
13 137.1 137.2 137.2 137.1 137.2 137.2 137.2
14 20.8 20.5 20.74A 20.4 21.3 21.3 20.74C
15 46.2 46.5 46.2 46.4 45.7 45.6 46.2
16 27.3 27.3 27.3 27.0 26.9 26.8B 27.3
17 33.6 33.8 33.6 33.6 34.1 34.1 33.6
18 33.2 33.4 33.2 33.0 33.0 33.0 33.2
19 20.7 21.0 20.66A 21.0 20.8 20.8 20.66C
20 52.0 52.3 51.9 52.0 52.0 52.0 51.9
21 86.9 87.5 ND 87.5 ND 92.9 86.9
22 179.5A 177.7 179.5 177.7 208.1 208.1 179.5D
23 97.2 102.6 97.4 102.7 70.2 70.2 97.4
24 177.7A 171.1 ND 171.0 175.8 175.7 177.7D
25 6.1 9.4 6.1 9.7 19.8 19.8 6.1
1′ 47.1 46.8 44.5
2′ ND 173.0 172.5
ND Not detected; A–D assignments interchangeable.
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HRESI(+)MS analysis of 5 established a molecular formula
(C25H32O5) consistent with an oxidized analogue of 1. Com-
parison of the NMR (methanol-d4) data for 1 with 5 (Tables 1
and 2 and ESI Tables S1 and S5†) revealed the only significant
differences as being centered on the tetronic acid moiety, with
C-22 (δC 208.1) being indicative of a ketone carbonyl, and C-23
(δC 70.2) and C-25 (δH 1.39; δC 19.8) a tertiary alcohol moiety.
Collectively these observations supported identification of
(−)-oxoircinianin (5) as the oxidized analogue of 1, as shown –
incorporating an unprecedented C-21 to C-25 oxidized tetronic
acid motif.
HRESI(+)MS analysis of 6 established a molecular formula
(C27H35NO7) consistent with a glycinyl-lactam analogue of 5.
Comparison of the NMR (methanol-d4) data for 5 with 6
(Tables 1 and 2 and ESI Tables S5 and S6†) supported this
hypothesis, with differences being comparable to those
observed between 1 and 3 (discussed above). A deshielded 1H
NMR chemical shift for H-2 (δH 6.96),9 supported by diagnostic
2D NMR correlations, permitted identification of (−)-oxo-
ircinianin lactam A (6) as shown.
HRESI(+)MS analysis of 7 established a molecular formula
(C27H32O5) isomeric with 5, consistent with an oxidized ana-
logue of 1. Comparison of the NMR (methanol-d4) data for 1
with 7 (Tables 1 and 2 and ESI Tables S1 and S7†) attributed
the only significant difference to replacement of the furanyl in
1 with a 2-alkyl-γ-butenolide (lactone) moiety in 5. A
deshielded 1H NMR chemical shift for H-2 (δH 7.37),9 sup-
ported by diagnostic 2D NMR correlations, permitted identifi-
cation of (−)-ircinianin lactone A (3) as shown.
The fact that the new sesterterpenes 3–7 were co-meta-
bolites with the known metabolites 1 and 2 (whose relative and
absolute configurations had been fully assigned by a combi-
nation of X-ray analysis,11 total synthesis14 and chemical
interconversion13), permitted assignment of a common absol-
ute configuration. An exception to this assignment is the con-
figuration about C-23 in 5 and 6, which remains unassigned.
In proposing a plausible biosynthetic relationship between 1–7,
we suggest that (−)-ircinianin (1) is the progenitor of this struc-
ture class, undergoing sulfation and oxidation of the tetronic
acid to deliver 2 and 5, and oxidation of the furan to yield 7.
Conjugation of the lactone 7 with glycine would yield the glyci-
nyl-lactam 3, which in turn undergoes sulfation and oxidation
to deliver 4 and 6 (Fig. 2). Although we could only isolate
subsets of 1–7 from each of the three Psammocinia specimens,
careful analysis of the HPLC-DAD-MS data sets using a single
Fig. 1 Structures for 1–8 with selected 2D NMR correlations.
Fig. 2 Plausible biosynthetic relationship between 1–7.
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ion extraction approach succeeded in detecting 1–7 in all three
extracts (see ESI†). Consistent with this biosynthetic proposal,
HPLC-DAD-MS (single ion extraction) analysis of all three
sponge extracts also successfully detected trace metabolites
consistent with putative intermediates (−)-ircinianin lactone A
sulfate (m/z 491) and (−)-oxoircinianin lactone A (m/z 428). To
assist in GlyR structure activity relationship (SAR) investi-
gations, a sample of 1 was acetylated to yield (−)-ircinianin
acetate (8), which was subjected to detailed spectroscopic ana-
lysis (ESI Table S8†).
The sesterterpenes 1–8 were screened against human α1
and α3 GlyRs stably expressed in HEK293 cells via automated
planar chip whole cell patch-clamp recording. The effects of
compounds were quantified at −40 mV by inducing an inward
current flux by applying an EC20 glycine concentration (α1
GlyR EC20 = 15 μM; α3 GlyR EC20 = 100 μM). GlyRs were first
activated with a 2 s pulse of glycine, and then with a 2 s pulse
of the same concentration of glycine plus a defined concen-
tration of 1 to 8, with a 1 min pause between successive appli-
cations. Full electrophysiology results are documented in the
ESI (Fig. S9 and S10 and Table S9†), and are summarized in
Fig. 3. Analysis of the α1 GlyR data confirmed the glycinyl-
lactam 6 as a selective potentiator of α1 GlyRs (110 ± 8% at
100 μM), while 2 was a modest antagonist (IC50 38.4 ± 2.8 μM,
Hill slope nH 0.76 ± 0.6), 1 and 4 were modest potentiators
(80 ± 10% and 70 ± 7%, at 100 μM), and 3, 5, 7 and 8 exerted
no significant effect (Fig. 3). Analysis of the α3 GlyR data con-
firmed the glycinyl-lactam 3 as an exceptionally potent and
selective α3 GlyR potentiator (260 ± 15% at 100 μM, EC50 8.5 ±
2.1 μM, nH 1.3 ± 0.3), while 2 was an antagonist (IC50 3.2 ±
1.3 μM, Hill slope nH 0.48 ± 0.12), and 1, 4, 5, 7 and 8 exerted
no significant effect (Fig. 3). An SAR analysis of all these data
established that the glycinyl-lactam moiety is optimal for a
potentiating effect, with the level of tetronic acid oxidation dic-
tating α1 versus α3 GlyR selectivity.
Experimental
General experimental details
Optical rotations were measured on a JASCO P-1010 polarimeter
with a 10 cm length cell. UV spectra were obtained on a Cary 50
UV-visible spectrophotometer with 1 cm pathway cell. NMR
experiments were performed on a Bruker Avance DRX600
spectrometer and referenced to residual non-deuterated signals
in the deuterated solvents. ESI-MS analyses were carried out on
an Agilent 1100 series LC/MSD instrument. HR-ESI-MS data were
acquired on a Bruker micrOTOF mass spectrometer by direct
infusion in MeCN at 3 μL min−1 flow using sodium formate clus-
ters as an internal calibrant. All HPLC analyses and separations
were performed on Agilent 1100 series LC instruments with
corresponding detectors, collectors and software inclusive. All
chemicals were purchased from Merck, Sigma-Aldrich or Fluka.
Solvents used for general purposes were of at least analytical
grade, and solvents used for HPLC were of HPLC grade.
Marine extracts library
A library of >2500 marine invertebrate and alga samples, col-
lected from intertidal, coastal and deep sea locations across
southern Australia and Antarctica, were processed to generate
an extract library suitably formatted for medium to high
throughput bioassay. A portion (7 mL) of the archived EtOH
extract of each marine sample was decanted, concentrated in
vacuo, weighed and partitioned into n-BuOH (2 mL) and H2O
(2 mL). This pre-processing achieves a >10 fold concentration
of “drug-like” small molecules, while simultaneously desalting
and simplifying the solubility characteristics of, the n-BuOH
solubles. Aliquots (1 mL) of both n-BuOH and H2O phases
were transferred to deep 96-well plates, to generate a set of
extract library plates. These plates were subsequently used to
prepare 10- and 100-fold dilution plates.
Extraction and fractionation
Psammocinia sp. (CMB-01008). A portion (∼500 mL) of the
EtOH extract of Psammocinia sp. (CMB-01008) was decanted
and concentrated in vacuo to return a black solid (2.31 g),
which was subsequently partitioned between n-BuOH (3 ×
50 mL) and H2O (50 mL). GlyR bioassays established that all
activity was concentrated in the n-BuOH solubles (730.3 mg),
which were sequentially triturated with aliquots (2 × 15 mL) of
hexanes, CH2Cl2 and MeOH, and concentrated in vacuo to
return 5.6, 590.7 and 109.3 mg respectively. A portion
(298.0 mg) of the CH2Cl2 solubles was subjected to HPLC frac-
tionation (Zorbax SB-C18 250 × 9.4 mm, 5 μm column, 4 mL
min−1 gradient elution from 10–100% MeCN–H2O over
25 min, with isocratic 0.01% TFA modifier) to yield (−)-ircinia-
nin (1) (tR = 14.8 min; 46.6 mg, 12.0%), (−)-ircinianin sulfate
(2) (tR = 10.8 min; 99.2 mg, 13.6%) and a third fraction (tR =
8.2 min; 9.8 mg), which was subjected to further HPLC frac-
tionation (Zorbax SB-C18 150 × 4.6 mm, 5 μm column, 1 mL
min−1 gradient elution from 10–100% MeCN–H2O over
25 min, with isocratic 0.01% TFA modifier) to yield (−)-ircinia-
nin lactam A sulfate (4) (tR = 8.4 min; 1.1 mg, 0.14%).
Fig. 3 Maximal effects of 1–8 at α1 and α3 GlyRs as determined by whole-cell
electrophysiological recording. Compounds were tested on currents activated by
an EC20 glycine concentration and the effect of each drug is shown as a percen-
tage of this current magnitude. The degree of potentiation is highlighted by
grey shading.
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Psammocinia sp. (CMB-03344). A portion (∼250 mL) of the
EtOH extract from Psammocinia sp. (CMB-03344) was decanted
and concentrated in vacuo to return brown solid (1.74 g),
which was subsequently partitioned between n-BuOH (3 ×
50 mL) and H2O (50 mL), with GlyR bioassays confirming that
all activity was concentrated in the n-BuOH solubles (246 mg).
The n-BuOH soluble material was sequentially triturated with
aliquots (2 × 15 mL) of hexanes, CH2Cl2 and MeOH, and con-
centrated in vacuo to yield 0.6, 155.0 and 54.6 mg fractions
respectively. Following spectroscopic and chemical analysis
the combined CH2Cl2 and MeOH solubles were fractionated by
HPLC (Zorbax SB-C18 250 × 9.4 mm, 5 μm column, 4 mL min−1
gradient elution from 10–100% MeCN–H2O over 25 min, with iso-
cratic 0.01% TFA modifier) to yield (−)-ircinianin (1) (tR =
15.5 min; 28.7 mg, 11.6%), (−)-ircinianin sulfate (2) (tR = 11.8 min;
17.3 mg, 7.03%), (−)-oxoircinianin (5) (tR = 16.2 min; 1.2 mg,
0.48%) and a fourth fraction (tR = 9.5 min; 1.5 mg), which was
further purified by HPLC (Zorbax SB-C18 150 × 4.6 mm, 5 μm
column, 1 mL min−1 gradient elution from 10–100% MeCN–
H2O over 25 min, with isocratic 0.01% TFA modifier) to yield
(−)-ircinianin lactam A (3) (tR = 9.5 min; 0.3 mg, 0.12%).
Psammocinia sp. (CMB-02858). A portion (∼250 mL) of the
EtOH extract from Psammocinia sp. (CMB-02858) was decanted
and concentrated in vacuo to return a brown solid (315.0 mg),
which was subsequently partitioned between n-BuOH (3 ×
15 mL) and H2O (20 mL), with GlyR bioassays confirming that
all activity was concentrated in the n-BuOH solubles
(103.4 mg). The n-BuOH soluble material was sequentially tri-
turated with aliquots (2 × 15 mL) of hexanes, CH2Cl2 and
MeOH, and concentrated in vacuo to yield 3.0, 75.9 and
20.9 mg fractions respectively. The CH2Cl2 and MeOH frac-
tions were combined and fractionated by HPLC (Zorbax SB-C18
250 × 9.4 mm, 5 μm column, 4 mL min−1 gradient elution
from 10–100% MeCN–H2O over 25 min, with isocratic 0.01%
TFA modifier) to yield two subfractions (tR = 9.5 min; 18.5 mg
and tR = 12.5 min; 2.5 mg). The first subfraction was
subjected to HPLC (Zorbax SB-C18 250 × 9.4 mm, 5 μm
column, 4 mL min−1 gradient elution from 10–100% MeCN–
H2O over 25 min, with isocratic 0.01% TFA modifier) to yield
(−)-oxoircinianin lactam A (6) (tR = 10.2 min; 1.7 mg, 1.6%).
The second subfraction was subjected to HPLC (Zorbax SB-C18
150 × 4.6 mm, 5 μm column, 1 mL min−1 gradient elution
from 10–100% MeCN–H2O over 25 min, with isocratic 0.01%
TFA modifier) to yield a third subfraction (tR = 12.8 min;
0.4 mg), which was further purified by HPLC (Zorbax SB-C18
150 × 4.6 mm, 5 μm column, 1 mL min−1 gradient elution
from 50–100% MeCN–H2O over 15 min, with isocratic 0.01%
TFA modifier) to yield (−)-ircinianin lactone A (7) (tR = 13.0;
0.2 mg, 0.19%).
Characterization of natural products
(−)-Ircinianin (1).11 White solid; [α]D −206 (c = 0.5, MeOH);
UV-vis (MeOH) λmax (log ε) 208 nm (4.54); NMR (600 MHz,
methanol-d4) see Tables 1 and 2 and ESI Table S1 and Fig. S1;†
HRESI(+)MS m/z 419.2185 (calcd for C25H32O4Na+ 419.2193).
(−)-Ircinianin sulfate (2).13 Pale yellow solid; [α]D −108 (c =
0.5, MeOH); UV-vis (MeOH) λmax (log ε) nm 203 (4.28), 210
(4.22), 217 (4.12), 226 (3.96); NMR (600 MHz, methanol-d4) see
Tables 1 and 2 and ESI Table S2 and Fig. S2;† HRESI(−)MS m/z
475.1799 (calcd for C25H31O7S− 475.1796).
(−)-Ircinianin lactam A (3). Colorless oil; [α]D −17 (c = 0.1,
MeOH); UV-vis (MeOH) λmax (log ε) 205 nm (4.38) nm; NMR
(600 MHz, methanol-d4) see Tables 1 and 2 and ESI Table S3
and Fig. S3;† HRESI(+)MS m/z 492.2357 (calcd for
C27H35NO6Na+ 492.2357).
(−)-Ircinianin lactam A sulfate (4). Colorless oil; [α]D −33
(c = 0.1, MeOH); UV-vis (MeOH) λmax (log ε) 208 nm (4.06) nm;
NMR (600 MHz, methanol-d4) see Tables 1 and 2 and ESI
Table S4 and Fig. S4;† HRESI(−)MS m/z 548.1970 (calcd for
C27H34NO9S− 548.1973).
(−)-Oxoircinianin (5). Pale yellow oil; [α]D −62 (c = 0.07,
MeOH); UV-vis (MeOH) λmax (log ε) 205.0 (4.55), 261 nm (3.09);
NMR (600 MHz, methanol-d4) see Tables 1 and 2 and ESI
Table S5 and Fig. S5;† HRESI(+)MS m/z 435.2144 (calcd for
C25H32O5Na+ 435.2142).
(−)-Oxoircinianin lactam A (6). Pale yellow oil; [α]D −17 (c =
0.1, MeOH); UV-vis (MeOH) λmax (log ε) 205 nm (4.38), 196 nm
(3.74); NMR (600 MHz, methanol-d4) see Tables 1 and 2 and
ESI Table S6 and Fig. S6;† HRESI(+)MS m/z 508.2306 (calcd for
C27H35NO7Na+ 508.2306).
(−)-Ircinianin lactone A (7). Pale yellow oil; [α]D −74 (c = 0.1,
MeOH); UV-vis (MeOH) λmax (log ε) 204 nm (4.30); NMR
(600 MHz, methanol-d4) see Tables 1 and 2 and ESI Table S7
and Fig. S7;† HRESI(+)MS m/z 435.2142 (calcd for C25H32O5Na+
435.2142).
Synthetic transformations
(−)-Ircinianin acetate (8). A solution of (−)-ircinianin (1)
(2.0 mg) and acetic anhydride (0.2 mL) in pyridine (0.5 mL)
was stirred at room temperature overnight, after which it was
concentrated in vacuo and the residue subjected to HPLC frac-
tionation (Zorbax C18 5 μm, 150 × 4.6 mm column, 25 min gra-
dient elution at 1 mL min−1 from 90% H2O–MeOH to 100%
MeOH with isocratic 0.01% TFA–MeOH modifier) to yield
(−)-ircinianin acetate (8) (0.9 mg, 45%) as a colorless oil; [α]D
−87 (c = 0.1, MeOH); UV-vis (MeOH) λmax (log ε) 208 nm (4.32);
NMR (600 MHz, methanol-d4) see ESI Table S8 and Fig. S8;†
HRESI(+)MS m/z 461.2294 (calcd for C27H34O5Na+ 461.2298).
Primary GlyR screening of marine extracts
The initial screen of >2500 marine extracts against recombi-
nantly expressed α1 and α3 GlyRs was performed using a yellow
fluorescent protein-based anion flux assay as previously
described.9,16 In this bioassay, 90 μL of each 100-fold diluted
n-BuOH partition was transferred into one well of a 384-well plate,
and was dried under nitrogen. The plates containing dried
n-BuOH partitions were protected from light and stored at −30 °C
until required. On the day of the experiment an aliquot (30 μL)
of extracellular solution [NaCl (140 mM), KCl (5 mM), CaCl2
(2 mM), MgCl2 (1 mM), HEPES (10 mM), and glucose (10 mM)
(pH 7.4 using NaOH)] was added to each well and mixed/
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dissolved using a multi-channel pipette. Subsequently, an
aliquot (10 μL) of this solution was transferred into the corres-
ponding well of a 384-well plate containing approx. 5000 cells
and 15 μL of extracellular solution per well, and incubated at
room temperature for 30 min. The 384-well plates were then
placed onto the motorized stage of an in-house imaging
system16 and cells were imaged twice: once in 25 μL of extra-
cellular solution containing the n-BuOH partition and once 10
s after the injection of 50 μL NaI solution supplemented with
500 μM glycine. The NaI solution was similar in composition
to NaCl control solution except the NaCl was replaced by equi-
molar NaI.
Images of fluorescent cells were segmented and quantitat-
ively analyzed using a modified version of DetecTIFF software.17
In brief, images were segmented using an iterative size and
intensity-based thresholding algorithm and the fluorescence
signal of identified cells was calculated as the mean of all pixel
values within the area of a cell. GlyR activation response was
used as a measure of extract potency and was defined as (Finit −
Ffinal) × 100/Finit, where Finit and Ffinal were the initial and final
values of fluorescence, respectively. All experiments were per-
formed twice in neighboring wells. Hits were selected by visual
inspection of color maps generated by analysis software. For hit
confirmation, 24 μL of the corresponding 10-fold diluted
n-BuOH partition was transferred into a well of a 384-well plate,
and was dried and stored as described above. On the day of the
experiment the dried 10-fold diluted n-BuOH partitions were
resuspended in 80 μL extracellular solution as described above
and two aliquots each of 17 and 10 μL respectively were then
transferred in neighboring wells containing ∼5000 cells and
15 μL extracellular solution per well. Imaging and image analy-
sis were conducted as described above. The concentration
dependence of the drug effects was used as measure for extract
potency and level of prioritization.
Automated electrophysiology
Electrophysiological screening was performed using an auto-
mated planar patch-clamp device (Patchliner, Nanion Techno-
logies GmbH, Munich, Germany). Stable α1 and α3 GlyR-
expressing HEK293 cell lines, produced as previously
described,9,17 were maintained in minimal essential medium.
After 2–3 days in culture, cells were trypsinized and suspended
in extracellular solution [NaCl (140 mM), KCl (4 mM), CaCl2
(2 mM), MgCl2 (1 mM), HEPES–NaOH (10 mM) and glucose
(5 mM) (pH 7.4 adjusted with NaOH)] at a density of 1 × 106
cells per mL before injecting into the Patchliner chip. This stan-
dard extracellular solution was employed in all Patchliner experi-
ments. The internal solution contained KCl (50 mM), NaCl
(10 mM), KF (60 mM), MgCl2 (2 mM), EGTA (20 mM), HEPES–
KOH (10 mM) (pH 7.2). All experiments were performed at
room temperature (19–22 °C). 1 M glycine (Ajax Finechem,
Seven Hills, NSW, Australia) stocks were prepared in water and
stored at −20 °C. All test compounds were dissolved in DMSO
(Sigma-Aldrich) and stored at −20 °C. From these stocks, solu-
tions for experiments were prepared on the day of recording.
Data analysis
Results are expressed as mean ± standard error of the mean of
three or more independent experiments. The Hill equation
was used to calculate the half inhibitory concentration (IC50)
and Hill coefficient (nH) values of individual concentration–
response relationships. All curves were fitted using a
nonlinear least squares algorithm (Sigmaplot 11.0; Jandel
Scientific, San Rafael, CA, USA). Statistical significance was
determined by unpaired Student’s t-test, with p < 0.05 repre-
senting significance.
Conclusions
In summary, this study successfully demonstrated a high-
throughput marine biodiscovery approach capable of discover-
ing and evaluating potent new isoform selective small mole-
cule GlyR potentiators. The discovery and characterization of
1–8, and in particular the glycinyl-lactams 3 and 6, provides
valuable new insights into GlyR pharmacology. These insights
have the potential to inform and inspire the development of
new molecular tools to probe GlyR distribution and function,
and new therapeutics to treat chronic inflammatory pain and a
range of other neurological disorders.
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Collection and Taxonomy  
 
CMB-01008 was collected in 1986 by R. J Capon (SCUBA) off Durras, New South Wales, Australia. A 
description of the specimen is as follows: Growth form massive-irregular; color in EtOH sandy; texture spongy but 
tough to tear; oscules scattered with membranous lip; surface translucent, wrinkled; spicules none; ectosome a 
distinct layer of detritus 300–400 µm thick; choanosome rectangular reticulation of spongin fibres 50–100 µm thick 
cored by tracts of sand grains, mesohyl a dense mass of collagen fibrils. The sponge was identified as Psammocinia 
sp. (Order Dictyoceratida, Family Irciniidae) and a type specimen registered with the Museum of Victoria (Registry 
No. MVF166222).  
 
CMB-03344 was collected in 1990 by R. J Capon (SCUBA) off The Rip, Nepean Wall, Port Phillip Heads, 
Victoria, Australia (latitude 38° 18.13(, longitude 144° 38.12(). A description of the specimen is as follows: Growth 
form lamellate; color in EtOH sandy; texture hard, stony, arenaceous; oscules not seen; surface opaque, regular, 
sandy; spicules none; ectosome sand grains bound by spongin; choanosome a mass of sand grains bound by 
spongin with collagen fibrils evident between tracts. The sponge was identified as Psammocinia sp. (Order 
Dictyoceratida, Family Irciniidae) and a type specimen registered with the Museum of Victoria (Registry No. 
MVF166223). 
 
CMB-02858 was collected in 1999 by R. J Capon (SCUBA) off 12 Pound Reef, Barwon Heads, Victoria, Australia 
(latitude 38° 17.0(, longitude 144° 38.37(). A description of the specimen is as follows: Growth form lamellate; 
color in EtOH sandy; texture firm, barely compressible, arenaceous; oscules scattered; surface opaque, sandy, 
evenly pitted on one surface, porous on the other; spicules none; ectosome distinct fine layer of sand and foreign 
spicule fragments; choanosome a reticulation of fibres evenly cored by sand and detritus, primary fibres indistinct 
from secondary fibres, spongin evident connecting adjacent fibres with the appearance of stretched plastic. 
Collagen fibrils were evident throughout. The sponge was identified as Psammocinia sp. (Order Dictyoceratida, 
Family Irciniidae) and a type specimen registered with the Museum of Victoria (Registry No. MVF166216).  
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Chemical Profiling  
 
Psammocinia sp. (CMB-01008): An HPLC-DAD (210 nm) analysis (Zorbax C8 150 ' 4.6 mm, 1.0 mL/min 20 
min gradient elution from 10–100% MeCN/H2O with isocratic 0.01% TFA/MeCN modifier) of the crude n-BuOH 
soluble revealed an extract rich in chemical diversity. Chemical fractionation yielded (–)-ircinianin (1), (–)-
ircinianin sulfate (2) and (–)-ircinianin lactam A sulfate (4).  
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Psammocinia sp. (CMB-03344): An HPLC-DAD (210 nm) analysis (Zorbax C8 250 ' 9.4 mm, 4.0 mL/min 20 
min gradient elution from 90% H2O/MeCN to 100% MeCN with isocratic 0.01% TFA/MeCN modifier) of the 
crude n-BuOH soluble revealed an extract rich in chemical diversity. Chemical fractionation yielded (–)-ircinianin 
(1), (–)-ircinianin sulfate (2), (–)-ircinianin lactam A (3) and (–)-oxoircinianin (5). 
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Psammocinia sp. (CMB-02858): An HPLC-DAD (210 nm) analysis (Zorbax C8 250 ' 9.4 mm, 4.0 mL/min 20 
min gradient elution from 90% H2O/MeCN to 100% MeCN with isocratic 0.01% TFA/MeCN modifier) of the 
crude n-BuOH soluble revealed an extract rich in chemical diversity. However, due to a limited material and 
instability of some metabolites in this specimen, chemical fractionation only yielded (–)-oxoircinianin lactam A 
(6) and (–)-ircinianin lactone A (7).  
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HPLC-MS (single ion extraction) Profiling 
  
Psammocinia sp. (CMB-01008) HPLC-DAD-MS (Agilent Zorbax SB-C8, 5 µm, 150 ' 4.6 mm, 15 min gradient elution at 1 
mL/min, from 90% H2O/MeCN to 100% MeCN with isocratic 0.05% formic acid/MeCN modifier] of a 10 #L injection of the 
n-butanol solubles (5 mg/mL in MeOH). (a) HPLC-DAD (254 nm); (b) ESI(+)MS single ion extraction at m/z 413, indicating 
(–)-oxoircinianin (5) and (–)-ircinianin lactone A (7); (c) ESI(+)MS single ion extraction at m/z 397, indicating (–)-ircinianin 
(1); (d) ESI(–)MS single ion extraction at m/z 475, indicating (–)-ircinianin sulfate (2); (e) ESI(+)MS single ion extraction at 
m/z 486, indicating (–)-oxoircinianin lactam (6); (f) ESI(+)MS single ion extraction at m/z 470, indicating (–)-ircinianin lactam 
A (3); (g) ESI(–)MS single ion extraction at m/z 548, indicating (–)-ircinianin lactam A sulfate (4). 
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Psammocinia sp. (CMB-03344) HPLC-DAD-MS (Agilent Zorbax SB-C8, 5 µm, 150 ' 4.6 mm, 15 min gradient elution at 1 
mL/min, from 90% H2O/MeCN to 100% MeCN with isocratic 0.05% formic acid/MeCN modifier] of a 10 #L injection of the 
n-butanol solubles (5 mg/mL in MeOH). (a) HPLC-DAD (254 nm); (b) ESI(+)MS single ion extraction at m/z 413, indicating 
(–)-oxoircinianin (5) and (–)-ircinianin lactone A (7); (c) ESI(+)MS single ion extraction at m/z 397, indicating (–)-ircinianin 
(1); (d) ESI(–)MS single ion extraction at m/z 475, indicating (–)-ircinianin sulfate (2); (e) ESI(+)MS single ion extraction at 
m/z 486, indicating (–)-oxoircinianin lactam (6); (f) ESI(+)MS single ion extraction at m/z 470, indicating (–)-ircinianin lactam 
A (3); (g) ESI(–)MS single ion extraction at m/z 548, indicating (–)-ircinianin lactam A sulfate (4). 
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Psammocinia sp. (CMB-02858) HPLC-DAD-MS (Agilent Zorbax SB-C8, 5 µm, 150 ' 4.6, 15 min gradient elution at 1 
mL/min, from 90% H2O/MeCN to 100% MeCN with isocratic 0.05% formic acid/MeCN modifier] of a 10 #L injection of the 
n-butanol solubles (5 mg/mL in MeOH). (a) HPLC-DAD (254 nm); (b) ESI(+)MS single ion extraction at m/z 413, indicating 
(–)-oxoircinianin (5) and (–)-ircinianin lactone A (7); (c) ESI(+)MS single ion extraction at m/z 397, indicating (–)-ircinianin 
(1); (d) ESI(–)MS single ion extraction at m/z 475, indicating (–)-ircinianin sulfate (2); (e) ESI(+)MS single ion extraction at 
m/z 486, indicating (–)-oxoircinianin lactam (6); (f) ESI(+)MS single ion extraction at m/z 470, indicating (–)-ircinianin lactam 
A (3); (g) ESI(–)MS single ion extraction at m/z 548, indicating (–)-ircinianin lactam A sulfate (4). 
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Scheme 4S1. Extraction and purification of Psammocinia sp. (CMB-01008) 
(a)  Solvent partition into n-BuOH (-1) and H2O (-2) solubles. 
(b)  Sequential trituration of n-BuOH solubles into hexanes (-1-1), CH2Cl2 (-1-2), MeOH (-1-3) and H2O (-1-4) solubles. 
(c)  Sequential trituration of H2O soluble into MeOH (-2-1) and H2O (-2-2) solubles. 
(d)  Semi-preparative fractionation by HPLC (Zorbax C18 5 µm 250 ' 9.4 mm, 25 min gradient elution at 4.0 mL/min from 90%  
         H2O/MeCN to 100% MeCN with isocratic 0.01% TFA/MeCN modifier). 
(e)  Analytical fractionation by HPLC (Zorbax C8 5 µm, 150 ' 4.6 mm, 25 min gradient elution at 1.0 mL/min from 90% H2O/MeCN to  
         100% MeCN with isocratic 0.01% TFA/MeCN modifier). 
Blue and red indicate known and new compounds respectively while * were not investigated.  
Note – % yields for 1, 2 and 4 are estimated against the total n-BuOH solubles.   
 
n-BuOH H2O
Petrol MeOH H2O MeOH H2O
(a)
(b) (c)
785.5.8 mg 714.4 mg5.6 mg 109.3 mg 5.3 mg
(-1-1) (-1-3) (-1-4)
99.2 mg 46.6 mg
(-1-2-3)
 9.8 mg 153.7 mg* (-1-2-4)
(298.0 mg)
CMB-01008
2.31 g
730.3 mg (-1) 1.50 g (-2)
CH2Cl2
  1.1 mg
-1-2-1-1
  7.2 mg*
-1-2-1-2
(4)
(1)(2)
590.7 mg
(-1-2) (-2-1) (-2-2)
(-1-2-1) (-1-2-2)
(d)
(e)
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Scheme 4S2. Extraction and purification of Psammocinia sp. (CMB-03344) 
(a)  Solvent partition into n-BuOH (-1) and H2O (-2) solubles. 
(b)  Trituration of n-BuOH into hexanes (-1-1), CH2Cl2 (-1-2), MeOH (-1-3) and H2O (-1-4) solubles. 
(c)  Sequential trituration of H2O soluble into MeOH (-2-1) and H2O (-2-2) solubles. 
(d)  Semi-preparative fractionation by HPLC (Zorbax C8 5 µm, 250 ' 9.4 mm, 25 min gradient elution at 4.0 mL/min from 90% 
H2O/MeCN to 100% MeCN with isocratic 0.01% TFA/MeCN modifier). 
(e)    Analytical fractionation by HPLC (Zorbax C8 5 µm, 150 ' 4.6 mm, 25 min gradient elution at 1.0 mL/min from 90% H2O/MeCN to      
         100% MeCN with isocratic 0.01% TFA/MeCN modifier). 
(f)   Analytical fractionation by HPLC (Zorbax C8 5 µm, 150 ' 4.6 mm, 15 min gradient elution at 1.0 mL/min from 50% H2O/MeCN to      
         100% MeCN with isocratic 0.01% TFA/MeCN modifier).  
Blue and red indicate known and new compounds respectively while * means uninvestigated.  
  Note – % yields for 1–3 and 5 are estimated against the total n-BuOH solubles.   
n-BuOH H2O
Petrol MeOH H2O MeOH H2O
(a)
(b) (c)
451.8 mg 891.2 mg0.6  mg 54.6 mg 3.3 mg
(-1-1) (-1-3) (-1-4)
28.7 mg
(-1-2-3)
17.3 mg
(-1-2-4)
 1.2 mg
(-1-2-5)
 1.5 mg
(-1-2-2)
135.3 mg* 
(-1-2-7)
(d)
CMB-03344
1.74 g
246.0 mg (-1) 1.45 g (-2)
CH2Cl2
  0.3 mg
-1-2-1-1
  0.6 mg
-1-2-1-2
(3)
(1) (2) (5)
155.0 mg
(-1-2) (-2-1) (-2-2)
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Scheme 4S3. Extraction and purification of Psammocinia sp
 
n-BuOH H2O
Petrol MeOH H2O MeOH H2O
(a)
(b) (c)
116.8 mg
  (-2-1)
95.3 mg
  (-2-2)
 75.9  mg
  (-1-2)
 20.9 mg 5.3 mg
(-1-1) (-1-3) (-1-4)
7.5 mg*
(-1-2-2)
 18.5 mg
(-1-2-3)
  7.8 mg*
 (-1-2-4) 9.5 mg*-1-2-1
29.2 mg* 
(-1-2-7)
(d)
CMB-02858
CH2Cl2
315.0 mg
103.4 mg (-1) 213.0 mg (-2)
3.0 mg
  0.4 mg*
(-1-2-2-2)
   1.7 mg
(-1-2-3-3)
  0.7*
(-1-2-4) 0.5 mg*-1-2-1-1
12.3 mg* 
(-1-2-7)
2.5
(-1-2-5)
  0.4 mg
(-1-2-5-1)
   1.4 mg*
 (-1-2-5-2)
(e)
(f)
 0.2 mg*
(-1-2-4)    0.2 mg(-1-2-5-1-1)
(g)
 (6)
(7)
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Table 4S1: NMR (600 MHz, CD3OD) data for (–)-ircinianin (1) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.38 (dd, 1.7, 1.7) 144.0 2, 4 2, 3, 4 
2 6.30 (m) 112.1 1 1, 3, 4 
3  126.5   
4 7.26 (m) 140.3 1, 5 1, 2, 3 
5 2.41B (br t, 7.6) 25.3 4, 6 2, 3, 4, 6, 7 
6 1.68 (m) 29.5 5, 7 3, 5, 7, 8 
7 2.04 (m) 40.5 6, 10 5, 6, 8, 9, 10 
8  136.5   
9 1.57 (d, 1.3) 16.3 10 7, 8, 10 
10 5.12 (dm, 10.3) 125.1 7, 9, 11  7, 9, 11 
11 3.07 (m) 48.7 10, 12, 14 12, 13, 21 
12 5.03 (m) 123.6 11, 14, 15 11, 14, 15, 21 
13  137.1   
14 1.71 (dd, 2.8, 1.4) 20.8 11, 12 12, 13, 15 
15 2.42B (m) 46.2 12, 16a, 16b, 20  
16 a 1.89 (m) 
b 1.34 (m) 
27.3 
 
15, 16b, 17a 
15, 16a, 17b 
17, 18, 20 
18 
17 a 2.00 (m) 
b 1.30 (m) 
33.6 
 
16a, 17b 
16b, 17a, 18 15, 16, 19 
18 1.65 (m) 33.2 17b, 19, 20 15, 18, 19 
19 0.92 (d, 6.3) 20.7 18 17, 18, 20 
20 1.60 (dd, 11.1, 10.5) 52.0 15, 18 18, 21, 24 
21  86.9   
22  179.5C    
23  97.2   
24  177.7C   
25 1.64 (s) 6.1  22, 23, 24 
 
A Assignments supported by HSQC and HMBC; B Overlapping signals; C Assignments interchangeable  
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Table 4S2. NMR (600 MHz, CD3OD) data for (–)-ircinianin sulfate (2) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.35 (dd, 1.6, 1.6) 143.8 2, 4 2, 3, 4 
2 6.32 (br s) 112.3 1 1, 3, 4 
3  126.8   
4 7.26 (br s) 140.2 1, 5 1, 2, 3 
5 2.37B (m) 25.7 4, 6 2, 3, 4, 6, 7 
6 1.73 (m) 29.2 5, 7 3, 5, 7, 8 
7 2.08 (br t, 7.6) 40.7 6, 10 5, 6, 8, 9, 10 
8  137.1   
9 1.57 (br s) 16.5 10 7, 8, 10 
10 5.10 (br d, 10.4) 124.3 7, 9, 11 7, 8, 9, 11 
11 3.09 (m) 49.0 10, 12, 14 12, 13, 21 
12 5.02 (m) 124.1 11, 14, 15 11, 14, 15, 21 
13  137.2   
14 1.71 (br s) 20.5 11, 12 12, 13, 15 
15 2.39B (m) 46.5 12, 16a, 16b, 20 20 
16 a 1.88 (m) 
b 1.38 (m)  
27.3 
 
15, 16b, 17a 
15, 16a, 17a, 17b 
15, 18, 20 
15, 17 
17 a 1.99C (m) 
b 1.31 (m) 
33.8 
 
16a, 16b, 17b 
16b, 17a, 18 
16, 20 
15, 16, 18, 19 
18 1.68 (m) 33.4 17b, 19, 20 16, 17, 20, 21 
19 1.00 (d, 6.4) 21.0 18 17, 18, 20 
20 1.62 (dd, 10.8, 10.8) 52.3 15, 18 18, 21, 24 
21  87.5   
22  177.7D   
23  102.6   
24  171.1D   
25 2.00C (s) 9.4  22, 23, 24 
A Assignments supported by HSQC and HMBC; B,C Overlapping signals; D Assignments interchangeable  
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Table 4S3. NMR (600 MHz, CD3OD) data for ircinianin lactam A (3) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 4.07D (br s) 53.0 2, 5 2 
2 6.89 (br s) 138.0 1, 5 1, 4 
3  139.0   
4  173.2   
5 2.26 (m) 25.8 6 3    
6 1.71B (m) 26.9 5, 7 3, 5, 7, 8 
7 2.08 (br t, 7.3) 40.4 6 6, 8, 9, 10 
8  135.1   
9 1.58 (d, 1.4) 16.2 10 7, 8, 10 
10 5.14 (dm, 10.4) 125.5 9, 11  
11 3.07 (m) 48.6 10, 12, 14  
12 5.03 (m) 123.5 11, 14  
13  137.2   
14 1.71B (dd, 2.9, 1.4) 20.74E 11, 12 12, 13, 15 
15 2.42 (m) 46.2 16a, 20  
16 a 1.91 (m) 
b 1.34C (m) 
27.3 17a, 17b 
15 
 
17 a 1.98 (m) 
b 1.31 (m) 
33.6 17b 
17a, 18 
 
 
18 1.67 (m) 33.2 19  
19 0.92 (d, 6.3) 20.66E 18 17, 18, 20 
20 1.61 (dd, 11.1, 10.4) 51.9 15  
21  ND   
22  179.5   
23  97.4   
24  ND   
25 1.64 (s) 6.1  22, 23 
1( 4.07D (br s) 47.1   
2(  ND   
A Assignments supported by HSQC and HMBC; B–D Overlapping signals; E Assignments interchangeable  
ND not detected 
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Table 4S4. NMR (600 MHz, CD3OD) data for (–)-ircinianin lactam A sulfate (4) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 4.05 (s) 54.4 2, 5 2 
2 6.92 (s) 137.8 1, 5 1 
3  139.3   
4  173.4   
5 2.23 (m) 26.6 2, 6 3, 7 
6 1.80 (m) 26.8 5, 7 7 
7 2.13 (t, 7.5) 40.5 6, 9 8, 9, 10 
8  137.1   
9 1.59 (s) 16.4 7 7, 8, 10 
10 5.12 (d, 7.2) 124.2 7, 9, 11  
11 3.08 (m) 49.3 10, 12, 14 8, 10 
12 5.02 (br s) 123.8 11, 14, 15 7, 9 
13  137.1   
14 1.71 (s) 20.4 11, 15, 20 12, 13, 15 
15 2.41 (m) 46.4 16, 20 12, 14 
16 1.90 (m)  27.0 15, 17 20 
17 1.30 (m) 33.6 16, 18 15, 16 
18 1.75B (m) 33.0 17, 19, 20 15, 16 
19 1.01 (d, 6.6) 21.0 18 18, 20 
20 1.74B (m) 52.0 15, 19 18 
21  87.5   
22  177.7   
23  102.7   
24  171.0   
25 2.01 (s) 9.7  22, 23, 24 
1( 4.03 (s) 46.8  1 
2(  173.0   
               A Assignments supported by HSQC and HMBC. B Overlapping signals. 
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Table 4S5. NMR (600 MHz, CD3OD) data for (–)-oxoircinianin (5) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.38 (dd, 1.6, 1.6) 144.0 2, 4 2, 3, 4 
2  6.32 (m) 112.1 1 1, 3, 4 
3  126.6   
4 7.29 (m) 140.4 1, 5 1, 2, 3 
5 2.42B (br t, 7.4) 25.0 4, 6 2, 3, 4, 6, 7 
6 1.67C (m) 29.3 5, 7  
7 2.01 (br t, 7.4) 40.3 6 5, 6, 8, 9, 10 
8  137.9   
9 1.57 (d, 1.3) 16.5 10 7, 8, 10 
10 4.98 (dm, 10.2) 121.6 9, 11 7, 9 
11 3.34 (m) 48.2 10, 12, 14  
12 5.03 (m) 123.9 11, 14 15 
13  137.2   
14 1.73C (dd, 2.7, 1.4) 21.3 11, 12 12, 13, 15 
15 2.42B (m) 45.7 16a, 16b, 20  
16 a 1.92 (m) 
b 1.36 (m) 
26.9 
 
15, 16b, 17a 
15, 16b, 17b 
18, 20 
 
17 a 2.05 (m) 
b 1.33 (m) 
34.1 
 
16a, 17b 
16b, 17a, 18 
16 
 
18 1.73C (m) 33.0 17b, 19  
19 0.84 (d, 6.3) 20.8 18 17, 18, 20 
20 1.70C (m) 52.0 15 18 
21  ND   
22  208.1   
23  70.2   
24  175.8    
25 1.39 (s) 19.8  22, 23, 24 
               A Assignments supported by HSQC and HMBC; B,C Overlapping signals; ND Signals not detected 
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Table 4S6. NMR (600 MHz, CD3OD) data for (–)-oxoircinianin lactam A (6) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 4.07 (td, 1.7, 1.7) 53.1 2, 5 2, 4 
2 6.96 (tt, 1.7, 1.7) 139.0 1, 5 1, 4 
3  140.1   
4  174.5   
5 2.26 (br t, 7.7) 26.3 1, 2, 6 3   2, 3, 4, 6, 7 
6 1.67 (m) 26.9D 5, 7 3, 5, 7, 8 
7 2.04 (br t, 7.3) 40.4 6 6, 8, 9, 10 
8  137.8   
9 1.58 (d, 1.3) 16.5 10 7, 8, 10 
10 5.02 (dm, 10.3) 124.1 9, 11 7, 9 
11 3.34 (m) 48.2 10, 12, 14 21 
12 5.03 (m) 121.6 11, 14 11 
13  137.2   
14 1.73B (dd, 2.8, 1.4) 21.3 11, 12 12, 13, 15 
15 2.42 (m) 45.6 16a, 16b, 20  
16 a 1.92 (m) 
b 1.33C (m) 
26.8D 
 
15, 16b, 17a 
15, 16a, 17b 
18, 20 
15 
17 a 2.05 (m) 
b 1.35C (m) 
34.1 
 
16a, 17b 
16b, 17a, 18 
 
 
18 1.73B (m) 33.0 19  
19 0.83 (d, 6.2) 20.8 18 17, 18, 20 
20 1.71B 52.0 15 18 
21  92.9   
22  208.1   
23  70.2   
24  175.7   
25 1.38 (s) 19.8  22, 23, 24 
1( 4.23 (s) 44.5  1, 4, 2' 
2(  172.5   
              A Assignments supported by HSQC and HMBC; B,C Overlapping signals; D Assignments interchangeable. 
 
 
N
H
OH
O
O
H
CO2H
OHO
14
8
14
9
19
21
24
25
5
12
16
15
11
22
1'
 
        Chapter 4: Ircinianin Supporting Information  
  
    107 
Table 4S7. NMR (600 MHz, CD3OD) data for (–)-ircinianin lactone A (7)  
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 4.83 (td, 1.8, 1.6) 72.2 2, 5 2, 3, 4 
2 7.37 (tt, 1.6, 1.6) 148.0 1, 4 1, 4 
3  134.6   
4  177.2   
5 2.26 (m) 25.8 1, 2, 6 2, 3, 4, 6, 7 
6 1.71B (m) 26.9 5, 7 3, 5, 7 
7 2.08 (br t, 7.3) 40.4 6 5, 6, 8, 9, 10 
8  136.1   
9 1.58 (d, 1.4) 16.2 10 7, 8, 10 
10 5.14 (dm, 10.4) 125.5 9, 11 7, 9 
11 3.07 (m) 48.6 10, 12, 14  
12 5.03 (m) 123.5 11, 14 15 
13  137.2   
14 1.71B (dd, 2.9, 1.4) 20.74C 11, 12 12, 13, 15 
15 2.42 (m) 46.2 16a, 16b, 20  
16 a 1.91 (m) 
b 1.34 (m) 
27.3 
 
15, 16b, 17a 
15, 16a, 17a, 17b 
18, 20 
 
17 a 2.01 (m) 
b 1.31 (m) 
33.6 
 
16a, 16b, 17b 
16b, 17a, 18 
16 
 
18 1.67 (m) 33.2 17b, 19  
19 0.92 (d, 6.3) 20.66C 18 17, 18, 20 
20 1.61 (dd, 11.1, 10.4) 51.9 15 15, 18 
21  86.9   
22  179.5D   
23  97.4   
24  177.7D   
25 1.64 (s) 6.1  22, 23, 24 
A Assignments supported by HSQC and HMBC; B Overlapping signals; C,D Assignments interchangeable 
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Table 4S8. NMR (600 MHz, CD3OD) data for (–)-ircinianin acetate (8) 
# !H (mult., J (Hz)) !CA COSY HMBC (1H-13C) 
1 7.39 (dd, 1.6, 1.6) 144.2 2, 4 3, 4 
2 6.30 (m) 112.1 1 1, 3, 4 
3  126.3   
4 7.26 (m) 140.3 1 1, 2, 3 
5 2.38B (m) 25.3 6 2, 3, 4, 6, 7 
6 1.65C (m) 29.4 5, 7 3, 5, 7, 8 
7 2.01D (m) 40.8 6 5, 6, 8, 9, 10 
8  137.6   
9 1.54 (d, 1.2) 16.1 10 7, 8, 10 
10 5.02 (br d, 10.5) 124.1 9, 11 7, 9 
11 3.09 (m) 48.7 10, 12, 14  
12 4.98 (m) 123.0 11, 14  
13  137.2   
14 1.72 (dd, 2.9, 1.5) 20.6 11, 12 12, 13, 15 
15 2.41B (m) 46.5 16a, 16b, 20  
16 a 1.93 (m) 
b 1.37 (m) 
27.4 
 
15, 16b, 17a 
15, 16a, 17a, 17b 
20 
 
17 a 2.03D (m) 
b 1.34 (m) 
33.5 
 
16a, 16b, 17b 
16b, 17a, 18 
 
 
18 1.63C (m) 33.0 17b, 19, 20  
19 0.95 (d, 6.5) 20.7 18 17, 18, 20 
20 1.68 (dd, 11.1, 10.5) 51.7 15, 18 18 
21  ND   
22  174.3E   
23  114.7   
24  169.1E   
25 1.65C (s) 9.3  22, 23, 24 
CH3CO 2.17 (s) 21.0  CH3CO 
CH3CO  165.5   
A 13C NMR assignments supported by HSQC experiment; B–D Overlapping signals within the column; 
E Interchangeable signals within the column; ND Signals not detected 
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Figure 4S1: 1H NMR (600 MHz, CD3OD) spectrum of (–)-ircinianin (1) 
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Figure 4S2. 1H NMR (600 MHz, CD3OD) spectrum of (–)-ircinianin sulfate (2) 
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Figure 4S3. 1H NMR (600 MHz, CD3OD) spectrum of (–)-ircinianin lactam A (3) 
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Figure 4S4. 1H NMR (600 MHz, methanol-d4) spectrum of (–)-ircinianin lactam A sulfate (4) 
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Figure 4S5. 1H NMR (600 MHz, CD3OD) spectrum of (–)-oxoircinianin (5) 
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 Figure 4S6. 1H NMR (600 MHz, CD3OD) spectrum of (–)-oxoircinianin lactam A (6) 
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Figure 4S7. 1H NMR (600 MHz, CD3OD) spectrum of (–)-ircinianin lactone A (7) 
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Figure 4S8. 1H NMR (600 MHz, CD3OD) spectrum of (–)-ircinianin acetate A (8) 
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 Pharmacology 
 
           
 
Figure 4S9. The effects of 1–8 on "1 GlyRs using whole-cell electrophysiological recording. All traces on a given line were 
recorded from the same cell with the periods of glycine and drug application indicated by unfilled and filled bars, respectively. 
The drug concentrations and glycine EC values are also indicated. Scale bars represent current in nA (vertical line) and time in 
sec (horizontal line). The averaged maximum effects of each compound are summarized in Table S9. 
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Figure 4S10. The effects of 1–8 on "3 GlyRs using whole-cell electrophysiological recording. All traces on a given line were recorded 
from the same cell with the periods of glycine and drug application indicated by unfilled and filled bars, respectively. The drug 
concentrations and glycine EC values are also indicated. Scale bars represent current in nA (vertical line) and time in sec (horizontal line). 
The averaged maximum effects of each compound are summarized in Table S9. 
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Table 4S9. Averaged maximum effects of 1–8 on "1 and "3 GlyRs. All effects were quantitated via whole-cell patch clamp. The mean 
percentage change in control glycine-gated current was determined at a concentration of 100 µM of each compound. All results were 
averaged from 4–6 cells, with the exception of 3 which was averaged from 10 cells at both receptors. 
 
"1 GlyR "3 GlyR Compound I/Imax (%) SEM I/Imax (%) SEM 
1 175 10 41 3 
2 34 5 17 2 
3 123 9 367 15 
4 190 6 190 5 
5 115 3 48 4 
6 211 6 57 2 
7 118 5 84 8 
8 121 7 74 3 
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                  CHAPTER 5 
                               IANTHELLALACTAMS  & APLYSINOPSINS 
 
 
5.1. Declaration  
Ianthellalactams and aplysinopsins were discovered from one of the priority extracts, Australian Ianthella cf. 
flabelliformis. Chemical profiling revealed the presence of two different structure classes, sesquiterpene and 
indole alkaloids in the metabolites of the specimen. The terpenoids featured several unreported molecular 
weights which upon 1H NMR and HRESIMS and suggested the presence of new metabolites (Table 2.2). 
Although similar investigation indicated the alkaloids as known molecules (Table 2.2), biological profiling 
showed them as the active component of the Australian I. flabelliformis, capable of modulating GlyR"1 at low 
sub micromolar concentration. Together, these results inspired further investigations leading to the discovery 
of two new sesquiterepenes, a moderate antagonist of and a potent potentiator of GlyR"1. A paper describing 
this discovery was recently published in Bioorganic & Medicinal Chemistry139. This is the third paper 
published from research collaboration on GlyR Modulators from Australian Marine Resource between the 
Capon Group of Institute for Molecular Bioscience (IMB) and the Lynch Group of Queensland Brain (QBI) of 
The University of Queensland Australia.  
The two-research groups contributed equally to the publication of the paper. As in the first two papers, I was 
responsible for chemical investigation (isolation, purification and structure elucidation) of all metabolites 
discovered from the Australian Ianthella cf. flabelliformis (CMB-03322). During my lab work at the IMB, I 
received technical assistance (lab work and data analysis) from Dr. Hua Zhang, Dr. Xiao Xue and Dr. Andrew 
M. Piggott and was supervised by Professor Robert J. Capon as the head of chemistry lab. Similarly, other co-
authors have contributed to this work. Dr. Robiul Islam performed bioassays (Yellow Fluorescence Protein 
and Patch Clamp assays) at the QBI. He received technical assistance from Dr. Daniel F. Gilbert, Dr. Frank 
Fontaine and Dr. Timothy I. Webb and was under the supervision of Professor Joseph W. Lynch as the head of 
pharmacology lab. The contributions of all co-authors to the publication of the paper were listed in the table 
below.   
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Balansa, W.; Islam, R.; Fontaine, F.; Piggott, A. M.; Xiao, X.; Zhang, H.; Gilbert, D.F.; Lynch, J. W.; Capon, 
R. J. Australian Marine Sponge Alkaloids as a New Class of Glycine Gated Chloride Channel Receptor 
(GlyR) Modulator. Bioorg. Med. Chem. 2013, 21, 4420-4425.   
 
Con       Contributor State     Statement of contribution 
Balansa, Walter Responsible for chemistry (100% working)  
Islam, Robiul Responsible for bioassay (100% working) 
Fontaine, Frank Assisted with lab work and data analysis 
Zhang, Hua Assisted with lab work and data analysis 
Piggott, Andrew M. Assisted with lab work and data analysis 
Webb, Timothy, I.  Assisted with lab work and data analysis 
Gilbert, Daniel F. Assisted with lab work and data analysis 
Lynch, Joseph W. Head of pharmacology lab.  
Capon, Robert J. Head of chemistry lab.  
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 5.2. Introduction  
The class of marine natural products indole alkaloids known as the aplysinopsins, including both mono and 
dimeric forms, have been the subject of much attention since first discovered almost four decades ago.  From 
several marine taxa such as sponge140-143, scleractinian coral144-147, anemone148 and mollusc149, dozen monomeric 
aplysinopsins have been reported featuring a diverse pattern of bromination and methylation as well as different 
levels of oxidation and geometry (E vs. Z)146,149. Monomeric aplysinopsins are known to exert a range of 
biological activities particularly as anticancer and antidepressant agents150-152, inspiring numerous total 
syntheses153-156. More recently, the discovery of asymmetric and symmetric dimers has generated renewed 
interest in this structure class. Asymmetric dimers were originally thought to be derived from Diels Alder 
cycloaddition146,147 of two monomers but the most recent discovery of symmetric aplysinopsins157 prompted  
consideration of an alternate biosynthetic hypothesis, a cyclobutane rearrangement. In addition to their cryptic 
biogenetic origin and intriguing structures, almost nothing is known about biological activity of the dimeric 
aplysinopsins. 
  
                                                                                      
        Figure 5.1. Aplysinopsin Structure  
 
5.2.1 Monomeric Aplysinopsins  
Aplysinopsin features three distinctive moieties (indole, 8-1( olefin and 2-aminoimidazole units, Figure 5.1) 
whose variations particularly at 8-1( olefin and ring C allow the classification of monomeric aplysinopsin into 
three main groups. In 1977, Wells et al first reported E/Z-aplysinopsin (5.1, 5.2) and E/Z-3(-deimino-3(-
oxoaplysinopsin (5.3, 5.4) from eight Australian Thorecta spp158. Aplysinopsin and oxo-aplysinopsin differ only 
in ring C, featuring iminoimidazolidinone for the previous and imidazolidinedione for the latter.  
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Following the original report, aplysinopsins were reported from taxonomically unrelated marine invertebrates, 
with a consistent preference for the E over Z configuration. Examples include aplysinopsin reported by 
Hollenbeak and Schmit in 1977 from a Florida Keys Verongia spengelii141, and by Djura and Faulkner from a 
Belize Decritus sp. in 1980142. The latter report also described 2(-deimino-methylaplysinopsin (5.5) and 6-
bromo-2(-deimino-methylaplysinopsin (5.6). In 1982, Taylor at al reported methylaplysinopsin (5.7), which 
underwent a rapid equilibrium in solution to (Z)-methyl aplysinopsin (5.8), from an Australian Aplysinopsis 
reticulata152, while Scheuer et al discovered (E)-aplysinopsin (5.1) along with dihydroaplysinopsin (5.9) from a 
Hawaiian scleractinian coral Tubastraea cocinea159. The NMR data for dihydroaplysinopsin were not reported 
until recently by Crews at al who also reported a series of other new dihydroaplysinopsins (5.11-5.13) from a 
Papua New Guinean Thorectandra and Smenospongia sp160. In 1985, (E)-aplysinopsin was reisolated by 
Fattorusso et al from a Naples Bay anthozoan Astroides calaycularis161 together with 6-bromo-aplysinopsin 
(5.14) and N-propionyl derivatives (5.15-5.16)161. 
In the late 1980s, Guella et al reported a series of E/Z geometrical of oxo-aplysinopsins from Mediterranean and 
Pilipino scleractinian corals144,145. In 1988, these same authors discovered 3(-deimino-3(-oxoaplysinopsin (5.17, 
5.18) and 6-bromo-3(-deimino-3(-oxoaplysinopsin (5.19, 5.20) existing as 5:2 mixture E:Z conformational 
isomers from a Philippine Tubastrea sp., and 3(-deimino-2(-4(-bis(demethyl)-3(-oxoaplysinopsin (5.21, 5.22)145 
and 6-bromo-3(-deimino-2(-4(-bis(demethyl)-3(-oxoaplysinopsin (5.23, 5.24) as 2:3 and 1:1 mixtures 
respectively of E:Z conformational isomers from a Mediterranean Leptopsammia pruvoti144. A year later, the 
same research group also discovered similar geometrical isomers (5.25-5.28) from a Philippine Dendrophyllia 
sp145. In both reports, Guella et al assigned the configuration about 8-1( olefin based on long range heteronuclear 
13C-1H coupling constants (3JC-H) using 2D HMBC correlation technique. This technique differentiated the 
magnitude of coupling constant (3JC-H) for E and Z configuration around 8-1( of aplysinopsins with the previous 
being smaller (2-6 Hz) than the latter (8-12 Hz). Of interest, the two reports featured typical chemical shifts of 
H-2 and C-8 being more downfield in E than in Z isomers, a characteristic used by the same authors in assigning 
the E vs. Z configurations to oxo-aplysinopsin145. A similar technique was also used by Selic et al in resolving 
geometrical configuration for synthetic aplysinopsins in 2000162 and by Kobayashi et al in assigning natural 
product aplysinopsins isolated from an Okinawan Hyrtios erecta in 2001151.  
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Apart from geometric isomers, monomeric aplysinopsin derivatives also arise from different patterns of 
bromination and methylation. Aplysinopsins are typically brominated at C-6, although C-5 bromination is also 
known such as compounds 5.28-5.30. Methylation in monomeric aplysinopsins has been reported to occur on 
the indole (i.e. 5.15-.5.16) and iminoimidazole moieties (i.e. 5.1-5.14, 5.17-5.20 and 5.25-5.32) with the latter 
varying from mono methyl (5.5-5.6, 5.25-5.31), dimethyl (5.1-5.4, 5.10-5.11, 5.14-5.20, 5.32) and tri-methyls 
(5.7-5.9). Aplysinopsins methylated at N-2( exist predominantly as E isomer144,145. The isomer configuration and 
methylation pattern were also reported to play an important role in bioactivity, particularly in serotonin receptor 
modulation (described more detail in bioactivity section, page 129)149,150.   
 
5.2.2 Dimeric Aplysinopsin  
Perhaps the most unusual members of aplysinopsins are the dimeric aplysinopsins initially foreshadowed but 
not documented by NMR in a 2000 report by Koh and Sweatman163. It took another three years before the first 
aplysinopsin dimer was unambiguously documented. In 2003, Iwaga et al reported asymmetric dimeric 
aplysinopsins tubastrindoles A-C (5.33-5.35) from a Japanese scleractinian coral Tubastraea sp147. The co-
occurrence of and structural resemblance between aplysinopsin and tubastrindoles prompted the authors to 
propose that tubastrindoles were Diels Alder cycloaddition adduct of aplysinopsins147.        
The same year, Mancini et al reported on cycloaplysinopsins A-B (5.36-5.37) from a Philippine 
Dendrophyliidae scleractinian coral. Cycloaplysinopsins A-B feature bisspiroiminoimidazolidione suggestive of 
Diels Alder adducts of oxoaplysinopsin146. Interestingly, the authors showed that tubastrindoles and 
cycloaplysinopsins exist as diastereomers and as such proposed the formation of tubastrindole B and 
cycloaplysinopsins A and B via a Diels Alder cycloaddition proceeded with oxidation146 (discussed in more 
detail in the synthetic achievement part, page 136).  
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In 2008, two research groups isolated new asymmetric dimers from a scleractinian coral of the genus 
Tubastraea. Iwagawa et al isolated tubastrindoles D-H (5.38-5.42) from a Japanese scleractinian coral 
Tubastraea sp164 while William et al reported tubastrindole B and C together dictazolines A and B (5.43-5.44) 
from a Panamanian Smenospongia cerebriformis165. In early 2009, Meyer et al re-isolated aplysinopsin along 
with cycloaplysinopsin C (5.45), a new aplysinopsin from a Comoro Island Tubastraea sp166. The latter authors 
reported cycloaplysinopsin as having a very similar structure with cycloaplysinopsin B (5.37) but with different 
configuration at the spiro cyclohexyl configuration suggesting a new diastereomer166.  
In early 2010, William et al re-examined in detail and discovered dictazolines C-E (5.46-5.48) along with 
dictazole A (5.49) and B (5.50)157. Compounds 5.49 and 5.50 featured a cyclobutyl instead of a cyclohexyl 
structure, representing the first symmetric dimeric aplysinopsin. The discovery of dictazoles A and B have given 
a dimension to the aplysinopsin structure class as the authors proposed a new biosynthetic pathway for the 
formation of dimeric aplysinopsin, cyclobutane rearrangement (discussed in detail in the synthetic achievement 
for dimeric aplysinopsin, page 136)157.   
Interestingly, both asymmetric and symmetric aplysinopsin dimers are capable of isomerisation with their 
stereochemistry mainly assigned on the basis of NOE analysis. To date, three diastereoisomers have been 
reported in the literature for asymmetric dimers proposed as cycloaddition of two aplysinopsin monomers one 
acting as diene and the other as dienophile such as in two E monomers in cycloaplysinopsin A (5.36), Z and E 
monomers in tubastrindole B (5.33)146 and E and Z monomers in cycloaplysinopsin C (5.45)166 (see Scheme 5.1, 
page 135). Similarly, two epimers for the symmetric aplysinopsins are known today including dictazole A 
(5.49) and dictazole B (5.50). These epimers are distinguishable both from their optical rotation values (positive 
vs. negative for dictazole A and B respectively) and NOE correlations157 (the presence vs.  absence of NOE 
coupling between two methines in the cyclobutane rings for dictazole A and B respectively)157,165.  
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5.2.3 Biological Activity  
Despite their intriguing structural features, little is known about biological activity of dimeric aplysinopsins 
other than the fact that cycloaplysinopsin C (5.45) and dictazole A (5.49) exerted antiplasmodial166 and BACE 
("-secretase inhibitor screening) modulating157 activities respectively. In contrast, many biological activities 
have been reported for the monomeric aplysinopsin including antibacterial, antiplasmodial, anticancer and 
antidepressant agents with anticancer and antidepressant being the most interesting feature. Apart from 
bromination, methylation also plays a key role in dictating the bioactivity of the monomeric aplysinopsins149-151 
(see Table 5.1 for detail).  
 
5.2.3.1 Monomer Aplysinopsins   
Aplysinopsins have been evaluated against antidepressant targets such as monoamine oxidase (MAO), nitric 
oxidase synthase (NOS) and the uptake of serotonin receptors. Several serotonin receptors reside in nerve and 
other cells mediating the effect of serotonin, endogenous ligands and many pharmaceuticals. In particular, 5-
TH2 type receptor (specifically 5-TH2A and 5-TH2C) are drug targets for antidepressant and antiobesity 
therapeutics149. Excessive production of nitric oxide (NO) has been associated with various diseases including 
post ischemic stroke damage, development of colitis, schizophrenia, tissue damage and pathological 
inflammation with specific inhibitors of NO production deemed an efficient approach to treat the above-
mentioned diseases151. MAO inhibitor has a long story of use as an effective treatment for Parkinson’s disease, 
as well as several other diseases including depression. Some aplysinopsins that are active against the above 
biological targets include 5.5-5.7, 5.9-5.14, 5.29-5.32 and 5.51 (Figure 5.1).  
The pharmacological potential of methylaplysinopsin (5.7) in inhibiting monoamine oxidase (MAO) has been 
intensively studied with an in vitro study reporting inhibition of MAO from mouse brain homogenate at 0.1-100 
µM167. Following an oral administration in mice and rats, 5.7 exhibited relatively short-term and reversible 
inhibition against MAO. In pharmacokinetic studies on rats, it was shown that after intravenous administration, 
the concentration of methylaplysinopsin in plasma declined rapidly over 4.8 h, reaching the level of below 1 
ng/mL 8 h after treatment167. 
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           Figure 5.2. Examples of active monomeric aplysinopsins as antimicrobial, anticancer and neuromodulator agents.  
  
 
Three geometric isomers of aplysinopsins were evaluated as inhibitors of NOS, in particular neuronal and 
inducible isozymes of nitric oxide synthase, nNOS and iNOS respectively. Examples include the geometrical 
isomers E/Z-5,6-dibromo-8Z,2(-demethyl aplysinopsins (5.29-5.30) reported by Kobayashi and co-workers from 
an Okinawan Hirtois aurecta168. These aplysinopsins showed specific inhibitory activity against nNOS, an 
activity that was absent from known NOS inhibitor such as N-monomethyl-L-arginine (L-NMMA)168.  
Hamman and co-workers reported several aplysinopsins from a Jamaican sponge Smenospongia sp. and three 
sponges of the family Thorecta150. These metabolites included 2(-demethylaplysinopsin (5.5), 6-bromo-2(-
demethyl-aplysinopsin (5.6), methylaplysinopsin (5.7), 6-bromo-aplysinopsin (5.14), ethyl aplysinopsin (5.9) 
and isoplysin (5.32). These monomeric aplysinopsins were evaluated against Plasmodium falciparum and 
serotonin receptors types 2 (5-HT2) particularly 5-HT2A and 5-HT2C150.  
N
H
NMe
H
N
O
NH
2'-demethyl 
aplysinopsin (5.5)
N
H
NMe
H
N
O
NH
6 bromo-2'-demethyl
aplysinopsin (5.6)
Br
Methylaplysinopsin (5.7)
N
H
NMe
Me
N
O
NMe
8,1'-hydroxy-6-bromo
dihydroaplysinopsin (5.11)
N
H
NMe
Me
N
O
NH
8,1'-methoxy-
dihydroaplysinopsin (5.12)
N
H
NMe
Me
N
O
NH
8,1'-ethoxy
dihydroaplysinopsin (5.13)
N
H
NMe
Me
N
O
NH
Br
HO MeO EtO
N
H
NMe
Me
N
O
NH
6 bromo-
aplysinopsin (5.14)
Br N
H
NMe
H
N
O
NH
E-5,6 dibromo
-3'-deimino-2'-demethyl
aplysinopsin (5.29)
Br
N
H
NMe
N
H
O
NH
6 bromo-3'-deimino
-2'-demethyl
aplysinopsin (5.31)
Br
Br
N
H
NMe
N
H
O
NH
Z-5,6-dibromo
-3'-deimino-2'-demethyl
aplysinopsin (5.30)
Br
Br
N
H
NH
Me
N
O
NMe
isoplysin (5.32)
1'
1'
1'8
8 8
N
H
NMe
Me
N
O
NEt
N
H
NMe
Me
N
O
NH
8,1'-dihydro
aplysinopsin (5.10
8 1'
N-3'-ethyl aplysinopsin (5.9)
N
H
NH
Me
N
O
NH
6 bromo-4'-demethyl
aplysinopsin (5.51)
Br
!
                  Chapter 5: Ianthellalactams and Aplysinopsins Introduction  
 
    130 
On evaluation against human serotonin receptor subtype 5-HT2A and 5-HT2C, half of the six monomeric 
aplysinopsins were active against the receptors including 6-bromo-2(-demethylaplysinopsin (5.6), 
ethylaplysinopsin (5.9) and 6-bromo aplysinopsin (5.14). Although these three compounds showed high affinity 
antagonist binding towards 5-HT2C receptor subtype, only 5.9 and 5.14 showed potent activity against receptor 
5-HT2A subtype150. Of these, 5.14 showed the highest affinity against 5-HT2C receptor subtype resembling the 
equilibrium affinity constant (Ki) value of the indigenous receptor, KI = 0.13 µM and 0.33 µM for serotonin and 
5.14 respectively. In terms of specificity, however, 5.6 revealed >40 fold selectivity for 5-HT2C over 5-HT2A150. 
The authors argued that these results indicated the important role of alkyl chain at N-3( and bromination position 
at C-6 in increasing binding property and specificity of aplysinopsin type compounds towards the serotonin 5-
HT2 receptor150 (Table 5.1).  
Upon evaluation for antiplasmodial activity, it was shown in vitro that 6-bromo-2(-demethylaplysinopsin (5.6), 
6-bromo-aplysinopsin (5.14) and isoplysin (5.32) were active against the D6 clone of Plasmodium 
falciparum150. Compound 5.14 revealed strong antimalarial activity at 0.34 µg/mL with a selectivity index of 14 
while isoplysin (5.32) and 6-bromo-2(-demethylaplysinopsin (5.6) exhibited moderate activity at 0.97 and 1.1 
µg/mL and with a selectivity index of >4.9 and >43 respectively. It was also proven that compound 5.6 inhibited 
the antimalarial target plasmepsin II enzyme with IC50 values of 53 µM (FRET) and 66 µM (FP)150.  
A series of monomeric aplysinopsins have also been evaluated against various pathogenic microbes many of 
which were inactive and/or with modest antimicrobial activity. Tymiak and Rinehart reported that a mixture of 
6-bromo-aplysinopsin (5.14) and 6-bromo-4(-demethylaplysinospin (5.51) modestly inhibited Bacillus subtilis 
but were inactive against Escherichia coli, Saccharomyces cerevisiae and Penicillium atrovenetum169. When 
screening aplysinopsin (5.1) and 6-bromoaplysinopsin (5.14) for antibacterial, antiviral and antifungal activities, 
Gulati et al discovered 5.1 as the active compound modestly inhibiting only the fungus Trichophyton 
mentagrophytes170. In addition, Koh and Sweatman discovered aplysinopsin (5.1) and 6-bromoaplysinopsin 
(5.14) from an Australian scleractinian Tubastraea faulkneri as weak antimicrobial agents against 
Staphylococcus aureus163 while Seagraves and Crews isolated a series dihydroaplysinopsins (5.9-5.12) from 
Papua New Guinean sponges Thorectandra sp. and Smenospongia sp. as having modest antibacterial activity 
against Staphylococcus epidermis (MIC = 6.25 to 100 ug/mL)160.  
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Finally, monomeric aplysinopsin are also known as anticancer agents. According to Hollenbeak and Schmitz, 
aplysinopsin (5.1) showed cytotoxic activity against P388 lymphocytic leukaemia at 200 mg/kg in mice and 
appeared to be active against P338, human epidermoid carcinoma KB and murine lymphoma LH-1220 cancer 
cell lines141. Together with methylaplysinopsin (5.7), aplysinopsin (5.1) was also shown to inhibit LH-1220 (IC50 
11.5 mg/mL and KB (31% inhibition at 20 µg/mL) cancer cell lines respectively171. Isoplysin discovered from 
an Okinawan Aplysina sp. was reported as a weak cytotoxic agent against murine lymphoma L-1210 (IC50 11.5 
µg/mL) and human epidermoid carcinoma KB (30% inhibition at 20 µg/mL) cell lines171.  
 
5.2.3.2 Dimeric Aplysinopsin 
Unlike monomeric aplysinopsin, most of the dimeric aplysinopsins have been repeatedly reported as inactive in 
many bioassays such as antibacterial, antiviral, cytotoxic and BACE1 inhibitor tests with the exception being 
the antimalarial activity (inhibitor of Plasmodium falciparum, IC50 = 1.2 µg/mL) attributed to cycloaplysinopsin 
C (5.45)166 and inhibitory property against BACE1 (IC50 = 50 µg/mL) attributed to dictazole A (5.49) (Table 
5.1)157.   
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Table 5.1 Bioactivity of monomeric and dimeric aplysinopsin  
No Compound  Biological Target Activity /References 
Anticancer  Inhibited fungus Trichophyton mengographytes  5.1 
 
Aplysinopsin/monomer 
M 
Anticancer 
Inhibited P388 lymphocytic leukaemia in mice, 
cytotoxic against P338 human epidemoide 
carcinoma and LH-1220 cancer cell lines. Cytotoxic 
against LH-1220 (IC50 2.3 mg/mL). 
Antidepressant  
Stronger displacer of 5-HT2A than 5-HT2c (>100 
mM vs. 2.3 µM)150, weak inhibitor of iNOS (7.5% at 
125 mg/mL 168. 
5.6 
 
6-bromo-2(-
demethylaplysinopsin/monomer 
M 
Antiplasmodial 
Moderate inhibitor of D6 clone (1.1 mg/mL, SI >4.3 
). Strong inhibitor of antimalarial target plasmepsin 
II enzyme (IC50 53 µM (FRET) and 6.6 µM (FP) 
Antidepressant  
Tetrabenazine-induced ptosis158, weak displacer of 
serotonin but more potent displacer of [3H]-
serotonin 
5.7 Methylaplysinopsin/monomer 
M 
Anticancer  Cytotoxic against LH-1220 (IC50 3.5 mg/mL)167.  
5.9 Ethylaplysinopsin/monomer  M Antidepressant  Strong modulator of 5-HT2A and 5-HT2C (1.7 vs. 3.5 
µM). 
5.10 8-1(-
dihydroaplysinopsin/monomer  
M Antibacterial Weak antibacterial against Staphylococcus aureus (mg/mL) )160 
5.10 6-bromo-8-1(-
dihydroaplysinopsin /monomer  Antibacterial  
Weak antibacterial against Staphylococcus aureus 
(mg/mL) )160 
5.11 8-1(-methoxy-
dihydroaplysinopsin/monomer 
M Antibacterial  Weak antibacterial against Staphylococcus aureus (mg/mL) )160 
5.12 8-1(-ethoxy 
dihydroaplysinopsin/monomer  
M Antibacterial  Weak antibacterial against Staphylococcus aureus (mg/mL) )160 
Antibacterial Weak antibacterial against Staphylococcus aureus (mg/mL) )160 
5.13 6-bromo-aplysinopsin/monomer 
 
M Antiplasmodial  Inhibited D6 clone of Plasmodium falciparum (0.34 mg/mL, SI=14 but inactive in vivo studies.  
5.29 E-5,6-dibromo-2-
demethylaplysinoposin/monomer 
 
 Strong inhibitor of nNOZ (100% and 32% at 125 and 5 µg/mL respectively168.    
5.30 Z-5,6-dibromo-2-
demethylaplysinoposin/monomer 
M  Stung inhibitor of nNOZ (100% and 22% at 125 and 5 µg/mL respectively168. 
5.31 Isoplysin/monomer 
 
  M 
Anticancer 
Antiplasmodial 
Inhibited LH-1220 (IC50 11.5 µg/mL) and KB (31% 
at 20 µg/mL).  
Moderate inhibitor of D6 clone 0.97 mg/mL and Si 
>4.9 
 6-bromo-4’-demethyl-
aplysinopsin/monomer M  
Weak inhibition against Bacillus subtills but was 
inactive against E. coli, S. carevisiae and 
Pencicillium airovenetum.  
5.33 Tubastrindole A/dimer 
 
Antibacterial, 
antifungal, cytotoxicity, 
#-secretase 
Inactive 147 
5.34 Tubastrindole B/dimer 
M Antibacterial, antifungal, cytotoxicity, 
#-secretase 
Inactive 147 
5.35 Tubastrindole C/dimer   D Antibacterial, 
antifungal, cytotoxicity, 
#-secretase 
Inactive 147 
5.36 Cycloaplysinopsin A/dimer   D NA NA146 
5.37 Cycloaplysinopsin B/dimer   D NA NA146 
Note: M = monomer, D = dimer 
!
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No Compound  Biological Target Activity /References 
5.38 Tubastrindole D/dimer   D Antibacterial, 
antifungal, cytotoxicity Inactive 
164 
5.39 Tubastrindole E/dimer D Antibacterial, antifungal, cytotoxicity 
Inactive 164 
5.40 Tubastrindole F/dimer D Antibacterial, antifungal, cytotoxicity 
Inactive 164 
5.41 Tubastrindole G/dimer D Antibacterial, antifungal, cytotoxicity 
Inactive 164 
5.42 Tubastrindole H/dimer D Antibacterial, antifungal, cytotoxicity 
Inactive 164 
5.43 Dictazoline A/dimer D BACE assay Inactive165 
5.44 Dictazoline B/dimer D BACE assay  Inactive 165 
5.45 Cycloaplysinopsin C/dimer 
D 
Antiplasmodial  Inhibitor of two Plasmodium falciparum strains, a 
chloroquine-sensitive (F32/Tanzania, IC50 2.7 µM) 
and chloroquine-resistence (FcB1 Columbia, IC50 
1.8 µM)166  
5.46 Dictazoline C/dimer D BACE assay Inactive 165 
5.47 Dictazoline D/dimer D BACE assay  Inactive 165 
5.48 Dictazoline E/dimer D BACE assay Inactive 165 
5.49 Dictazole A/dimer D BACE inhibitor (mamapcin 2) 
Inhibited BACE1-mediated cleavage of amyloid 
precursor with an IC50 value of 50 μg/mL157 
5.50 Dictazole B/dimer D BACE assay  Inactive  
         Note: M = monomer, D = dimer 
 
 
5.2.4 Synthetic Achievement 
Despite their intriguing structures, to date there is no synthetic report on dimeric aplysinopsin. Synthetically 
inaccessible and the absence of bioactivity of dimer aplysinopsin may have been a major factor in impeding the 
exploration of aplysinopsin biological properties. In contrast, monomeric aplysinopsins have been reported to 
exert a range of bioactivities in particular antidepressant, anticancer and antilehsmanial inspiring many synthesis 
efforts. 
 
5.2.4.1 Monomeric Aplysinopsin  
One of such synthetic efforts included the incorporation of aplysinopsin into known drug fragment such as 
antilehsmanial drug pentamidine (5.53) to improve potency and efficacy of the known drug. The rationale 
behind this synthetic effort rested on the dicationic nature of aplysinopsins and pentamidine154, a pharmachopore 
responsible for the activity of these alkaloids against plasmepsin II and serotonin receptors150,154. This fragment-
!
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based discovery yielded a hit molecule (5.54) with IC50 value of 18.2 µM, which upon optimisation resulted in 
5.55 and 5.56 with IC50 values of 6.5 and 2.0 µM for the Z and E aplysinopsin hybrids respectively154. In 
particular the E isomer 5.56 (the most promising compound in this study) showed 10 times stronger than 
pentamidine in intracellular amastigote assay and 401 times less toxic for human macrophage than the known 
drug154.  
Another approach was the evaluation and synthesis of monomeric aplysinopsin serotonin receptor particularly 
type 2-serotonin receptor (5-HT2a and 5HT-2c) due their structural similarity.  In 2006, Hamman et al reported 
on aplysinopsin that revealed higher inhibitory selectivity towards 5-HT2A over 5-HT2C encouraged synthesis 
efforts to discover more selective and potent inhibitors of 5-HT2A over 5-HT2C150. Inspired by this discovery, in 
2010 Schetz et al synthesized more than 20 aplysinopsin derivatives three of which 5.57-5.60 exhibited 
selectivity for 5-HT2A over 5-HT2C153. The aplysinopsin analogue 5.60 was approximately 2100-fold more 
selective at inhibiting the serotonin 5-HT2C receptor subtype: an affinity for 5-HT2C was of 46 µM and no 
detectable affinity for the 5-HT1A or 5-HT2A receptor subtypes. Also discussed in the paper153 was structure 
activity relationship significance of alkylation of the imidazolidinone and bromination of the indole ring153. 
Aplysinopsins have also inspired the discovery of anticancer agents156. In 2011, Crooks et al synthesized a series 
of aplysinopsin analogues. These compounds were tested for cytotoxicity against 60 human tumour cell lines 
including leukaemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate and brest cancers. Of 
these, compounds 5.61 inhibited melanoma UACC-257 (GI50 = 13.3 µM) and OVCAR-8 (GI50 = 19.5 µM) 
cancer cells. A second analogue 5.62 exhibited cytotoxicity against 60 cancer cell lines (GI50 0.3 to 6.0 µM). 
Thus, aplysinopsin hybrids 5.61 and 5.62 can be regarded as useful lead compounds for further structural 
optimization as antitumor agent156.  
                                                                     
!
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5.2.4.2 Dimeric Aplysinopsins  
The co-existence of and striking structural similarities between monomeric and dimeric aplysinopsins have led 
to the hypothesis that the latter were biosynthetically derived from the former by a Diels Alder cycloaddition 
process, although the specifics of this mechanism are yet to be agreed (Scheme 5.1)146.  
Although this Diels Alder hypothesis seems creditable, all efforts at synthetically initiating Diels Alder coupling 
between aplysinopsin monomers have failed. Although the chiral nature of the natural products demands an 
enzymatic process, the failure to chemically activate a Diels Alder coupling is certainly surprising, and could 
suggest that the original biosynthetic hypothesis is flawed.  
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                                       Scheme 5.1. Plausible formation of dimers from monomers adapted from Mancini et al 2003146  
 
 
The discovery of dictazoles A-B in early 2010 prompted an alternative biosynthetic hypothesis, one 
transitioning through a 2+2 cycloaddition leading to the cyclobutyl dictazoles, with concomitant radical ring 
expansion to deliver the cyclohexyl aplysinopsin dimers157 (Scheme 5.2 below). It was inspired by an early 
study on the cyclohexyl moiety in sceptrin (5.65)172 which although initially believed to be derived from a Diels 
Alder cycloaddition was later determined to be generated by ring expansion in sceptrin (Scheme 5.2). This 
hypothesis was further supported by the detection of higher levels of the cyclobutyl dictazoles A and B in a 
Panamanian Smenospongia sp160. 
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Scheme 5.2. Plausible formation of dictazolines C from dictazole A through a cyclobutane rearrangement (below) inspired by the same 
reaction in sceptrin172 (above) adapted from Dai et al 2009157.  
 
 
 
 
 
 
This chapter describes the discovery of new, potent and selective modulators of glycine receptors (GlyRs) from 
an Australian Ianthella cf flabelliformis. Chemical profiling (LCMS, 1H NMR and literature studies) showed the 
presence of two distinct metabolites in the specimen, terpenes and indole alkaloids. Two unreported 
pseudomolecular ions were detected in the terpenoid containing fractions (tR = 10.73 and 11.21 min., Table 2.2) 
while the non-terpenoid fraction revealed pseudomolecular ions correspond to monomeric (tR = 5.67-9.49 min.) 
and dimeric aplysinopsins (tR = 5.60 min., Table 2.2). Primary screening revealed indole alkaloid fractions as 
the active component of the Australian Ianthella cf. flabelliformis. In particular, a fraction (tR = 5.60 and 9.13 
min., Table 2.2) corresponding to molecular weights of 508 and 254 (dimeric and monomeric aplysinopsins) 
showed potent potentiating activity against GlyR"1. These data prompted a more detailed investigation of the 
metabolites of Ianthella cf. flabelliformis as new source of novel, potent and selective GlyR modulators.  
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The following paper details our discovery of two new nitrogenous sesquiterpenes ianthellalactam A (5.66) and 
B (5.67), an artefact ethyldictyondendrilin (5.68) and 5 known indole alkaloids aplysinopsin (5.1), 8E-3(-
deimino-3(-oxo-aplysinopsin (5.3), 8Z-3(-deimino-3(-oxo-aplysinopsin (5.4), dihydroaplysinopsin (5.10) and 
tubastrindole B (5.34), three of which were novel GlyR modulators (5.3-5.4 and 5.34). The activity of these 
GlyR modulators inspired one-pot synthesis giving rise to four synthetic compounds 8E-3(-deimino-2(-4(-
bisdemethyl-3(-oxoaplysinopsin (5.69), 8E-3(-deimino-4(-bisdemethyl-3(-oxoaplysinopsin (5.70), 8Z-3(-
deimino-4(-bisdemethyl-3(-oxoaplysinopsin (5.71), 8E-4(-demethylaplysinopsin (5.72) and 8Z-4(-
demethylaplysinopsin (5.73), two of which (5.70-5.71) showing strong antagonist activity against GlyR"1.   
Note: The numbering system for all metabolites of Ianthella cf. flabelliformis in this introduction and conclusion of this 
thesis is different from the ones at the paper and its supporting information.  
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a b s t r a c t
Chemical analysis of a specimen of the sponge Ianthella cf. flabelliformis returned two new sesquiterpene
glycinyl lactams, ianthellalactams A (1) and B (2), the known sponge sesquiterpene dictyodendrillin (3)
and its ethanolysis artifact ethyl dictyodendrillin (4), and five known sponge indole alkaloids, aplysinopsin
(5), 8E-30-deimino-30-oxoaplysinopsin (6), 8Z-30-deimino-30-oxoaplysinopsin (7), dihydroaplysinopsin (8)
and tubastrindole B (9). The equilibrated mixture 6/7 exhibited glycine-gated chloride channel receptor
(GlyR) antagonist activity with a bias towards a3 over a1 GlyR, while tubastrindole B (9) exhibited a bias
towards a1 over a3 GlyR. At low- to sub-micromolar concentrations, 9was also a selective potentiator of
a1 GlyR, with no effect on a3 GlyR—a pharmacology that could prove useful in the treatment of
movement disorders such as spasticity and hyperekplexia. Our investigations into the GlyR modulatory
properties of 1–9 were further supported by the synthesis of a number of structurally related indole
alkaloids.
! 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Glycine-gated chloride channel receptors (GlyRs) are members
of the Cys-loop ion channel receptor family comprising subunits
a1–a4 and b. They play a pivotal role in orchestrating inhibitory
neurotransmission in the spinal cord, brainstem and retina,1 with
functional GlyRs being formed either as pentameric homomers or
as ab heteromers. GlyR subunits exhibit differential central ner-
vous system distributions that are particularly evident in the
superficial dorsal horn of the spinal cord2 and the retina.3–6 The
physiological consequences of differential distribution patterns
are difficult to establish as there are currently few pharmacological
probes that can selectively inhibit different GlyR isoforms,7 and
therefore small molecule isoform-selective GlyRs modulators (ago-
nists, antagonists, potentiators) would have significant value as
both pharmacological tools and as lead compounds for inflamma-
tory pain,2,8 opioid-induced breathing disorders,9 epilepsy10 and
movement disorders.11 In an attempt to address this need, we
recently screened a library of >2500 southern Australian and
Antarctic marine invertebrates and algae for metabolites display-
ing GlyR-modulating properties. This approach successfully identi-
fied a number of promising extracts, and in a preliminary report12
we described sesterterpene tetronic acid glycinyl-lactams from
several Ircinia spp., as a new class of isoform selective GlyR modu-
lators. This report extends on our earlier findings and details the
chemical analysis of a specimen of the GlyR-active sponge Ianthella
cf. flabelliformis.
2. Results and discussion
A portion of the EtOH extract of Ianthella cf. flabelliformis was
decanted, dried in vacuo and subjected to solvent partitioning
and trituration. The GlyR-modulatory CH2Cl2- and MeOH-soluble
materials were further fractionated by reversed phase HPLC to
yield two new sesquiterpene lactams ianthellalactams A (1) and
B (2), the known sponge sesquiterpene dictyodendrillin13 (3), its
ethanolysis artifact ethyl dictyodendrillin (4), and five known sponge
indole alkaloids, aplysinopsin14 (5), 8E-30-deimino-30-oxoaplysinop-
sin15 (6), 8Z-30-deimino-30-oxoaplysinopsin15 (7), dihydroaplysinop-
sin16 (8) and tubastrindole B17 (9) (Fig. 1). The compounds 3–9
were characterized by detailed spectroscopic analysis and compari-
son with literature data (see Supplementary data).
High resolution ESI(+)MS analysis of 1 and 2 revealed quasi-
molecular ions [M+H]+ consistent with isomeric molecular
formulae (C17H25NO3) incorporating six double bond equivalents
0968-0896/$ - see front matter ! 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bmc.2013.04.061
⇑ Corresponding authors. Tel.: +61 7 3346 6375; fax: +61 7 3346 6301 (J.W.L.);
tel.: +61 7 3346 2979; fax: +61 7 3346 2090 (R.J.C.).
E-mail addresses: j.lynch@uq.edu.au (J.W. Lynch), r.capon@uq.edu.au
(R.J. Capon).
! These authors contributed equally to this work.
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(DBE). Analysis of the 1D and 2D NMR (methanol-d4) data for 1 and
2 (Table 1 and Fig. 2) revealed resonances and correlations consis-
tent with common geranyl and glycinyl residues, and differing tri-
substituted a,b-unsaturated esters/lactones. These observations
account for five DBE and require that both 1 and 2 be monocyclic.
Diagnostic deshielded C-9 resonances supported assignment of
E D7,8 configurations for 1 (dC 16.3) and 2 (dC 16.3), further con-
firmed by comparison to authentic samples of the closely related
dictyodendrillin (3) and dendrolasin (13). HMBC correlations and
significant deshielding of H-3 in 1 (dH 6.88) compared to H-2 in 2
(dH 5.85) confirmed the presence of regioisomeric glycinyl lactam
moieties. Thus the complete structures for ianthellalactams A (1)
and B (2) were assigned as shown.
Although 1 and 2 possess a rare glycinyl lactam moiety in com-
mon with the ircinialactams12 (marine sponge metabolites previ-
ously reported by us as potent GlyR modulators), neither 1 nor 2
exhibited any effect against either a1 or a3 GlyRs. Indeed, follow-
ing a comprehensive testing of all metabolites the GlyR modula-
tory activity detected in the crude Ianthella cf. flabelliformis
extract was attributed solely to 6/7, and 9 (Fig. 3 and Table 2).
Whereas the (photo-activated) equilibrating mixture of geometric
isomers 6/7 exhibited weak GlyR antagonist activity with a modest
bias towards a3 over a1, the dimeric analog tubastrindole B (9)
proved to be a more potent GlyR antagonist with a bias towards
a1 over a3. Of interest, 9 was found to be a selective potentiator
of a1 GlyR at low- to sub-lM concentrations (126 ± 5% at 1 lM),
while exhibiting no such effect on a3 GlyR—a pharmacology that
could prove useful as a treatment for movement disorders such
as spasticity and hyperekplexia (pronounced startle response). This
unusual difference in activity at lower and high concentrations
suggests 9 may have two distinct a1 GlyR binding sites.
To further probe the indole alkaloid GlyR pharmacophore
exemplified by 6/7 and 9, we employed aldol condensations to cou-
ple indole-3-carboxaldehyde with hydantoin, methyl hydantoin
and creatinine, to synthesize the analogs 10, 11a/b and 12a/b
respectively (Fig. 4). Significantly, whereas the unmethylated
hydantoin derived alkaloid 10was prepared as the stable E isomer,
the methylated analogs 11a and 11b derived from methyl hydan-
toin, and 12a and 12b derived from creatinine, existed as photo-
labile equilibrating mixtures of geometric isomers. These analogs
were exposed to UV light for 3 h prior to bioassay to generate
!1:1 mixtures of the E/Z isomers. Of note, only the mixture 11a/
b exhibited significant GlyR modulatory activity, being a more po-
tent GlyR antagonist than either 6/7 or 9, with a bias favoring a1
over a3 (Fig. 3 and Table 2).
A structure–activity relationship analysis inspired by the mono-
meric alkaloid natural products 5–8, and further informed by the
synthetic alkaloid analogs 10, 11a/b and 12a/b, provides a sense
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Figure 1. Ianthella cf. flabelliformis metabolites 1–9, and dendrolasin (13).
Table 1
1H (600 MHz) and 13C (150 MHz) NMR data for ianthellalactams A (1) and B (2) in
methanol-d4
Position Ianthellalactam A (1) Ianthellalactam B (2)
dH, mult. (J in Hz) dCa dH, mult. (J in Hz) dCa
1 174.4 175.0
2 139.7 5.85, tt (1.4, 1.4) 121.5
3 6.88, tt (1.6, 1.6) 138.9 164.6
4 4.05, dt (1.6, 1.6) 53.1 4.11, d (1.4) 56.8
5 2.29b 27.1 2.48, td (7.4, 1.4) 30.8
6 2.27b 27.2 2.30, br td (7.4, 7.1) 27.4
7 5.16, tq (6.9, 1.3) 124.8 5.16, tq (7.1, 1.3) 124.3
8 137.3 137.9
9 1.60, br s 16.3 1.64, br s 16.3
10 1.99, br t (7.6) 41.0 2.00, br t (7.6) 40.9
11 2.08, br td (7.6, 7.0) 27.9 2.08, br td (7.6, 7.0) 27.8
12 5.09, tqq (7.0, 1.4, 1.4) 125.6 5.08, tqq (7.0, 1.4, 1.4) 125.4
13 132.3 132.4
14 1.60, br s 17.9 1.60, br s 17.9
15 1.67, br s 26.0 1.66, br s 26.0
10 4.21, s 44.9 4.17, s 44.4
20 173.0 172.9
a 13C NMR assignments supported by HSQC data.
b Overlapping resonances.
ianthellalactam A (1)
ianthellalactam B (2)
N
O
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N
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O
C 16.3
C 16.3
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Figure 2. Diagnostic NMR (methanol-d4) resonances and correlations for 1 and 2.
W. Balansa et al. / Bioorg. Med. Chem. 21 (2013) 4420–4425 4421
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250 ! 9.4 mm columns were used for HPLC analyses and
separations.
4.2. Marine extracts library
A library of >2500 marine invertebrate and alga samples, col-
lected from intertidal, coastal and deep sea locations across south-
ern Australia and Antarctica, were processed to generate an extract
library suitably formatted for medium to high throughput bioas-
say. A portion (7 mL) of the archived EtOH extract of each marine
sample was decanted, concentrated in vacuo, weighed and parti-
tioned into n-BuOH (2 mL) and H2O (2 mL). This pre-processing
achieves a >10-fold concentration of ‘drug-like’ small molecules,
while simultaneously desalting and simplifying the solubility char-
acteristics of, the n-BuOH solubles. Aliquots (1 mL) of both n-BuOH
and H2O phases were transferred to deep 96-well plates, to gener-
ate a set of extract library plates. These plates were subsequently
used to prepare 10- and 100-fold dilution plates.
4.3. Sponge collection and taxonomy
Sponge specimen CMB-03322 was collected by SCUBA from
Lonsdale Wall, The Rip, Port Phillip Heads, Victoria (38! 170 5500 S,
144! 370.4600 E). A description of the specimen is as follows: Growth
form massive-thickly flabelliform; colour in EtOH likely to be an
aerophobic colour change to dark purple; texture barely compress-
ible, harsh, fibrous; oscules scattered, sunken; surface opaque,
glossy, conulose; spicules none; ectosome thick collagen with fi-
bres tangential or protruding the surface; choanosome a reticula-
tion of fibres strongly laminated and pith visible. Large primary
fibres cored by single column of sand grains, smaller fibres clear
of detritus. The sponge was identified as Ianthella cf. flabelliformis
(Order Verongida, Family Ianthellidae) and a type specimen regis-
tered with Museum Victoria (Registry No. MVF166222).
4.4. Extraction and fractionation
A portion (350 mL) of the aqueous EtOH extract of the Ianthella
cf. flabelliformis was decanted and concentrated in vacuo to return
a black solid (1.74 g), which was subsequently partitioned between
n-BuOH (3 ! 50 mL) and H2O (50.0 mL). GlyR bioassays (see below)
established that all activity was concentrated in the n-BuOH solu-
bles (519.7 mg), which were sequentially triturated with
2 ! 15 mL aliquots of hexane, CH2Cl2 and MeOH, and concentrated
in vacuo to return 9.0, 283.0 and 74.6 mg yields respectively. A por-
tion of the CH2Cl2 soluble fraction (130 mg) was subjected to HPLC
fractionation (Zorbax C8 5 lm 250 ! 9.4 mm column, 4 mL/min,
gradient elution of 10–100% MeCN/H2O over 25 min, with an iso-
cratic 0.01% TFA/H2O modifier) to yield ianthellalactam A (1)
(tR = 12.9 min; 2.6 mg, 0.056%), ianthellalactam B (2)
(tR = 13.3 min; 1.7 mg, 0.032%), dictyodendrillin (3) (tR = 13.9 min;
0.2 mg, 0.003%), aplysinopsin (5) (tR = 7.0 min; 2.4 mg, 0.041%), 8E-
30-deimino-30-oxoaplysinopin (6) (tR = 10.1 min; 2.7 mg, 0.051%),
8Z-30-deimino-30-oxoaplysinopin (7) (tR = 10.6 min; 3.5 mg,
0.067%), dihydroaplysinopsin (8) (tR = 6.4 min; 1.8 mg, 0.034%)
and tubastrindole B (9) (tR = 5.8 min; 1.7 mg, 0.029%). Since the
MeOH soluble fraction exhibited a similar HPLC-DAD and 1H
NMR profile to the CH2Cl2 soluble fraction, the remaining CH2Cl2
(153.0 mg) and MeOH solubles (74.6 mg) were combined and frac-
tionated using the method outlined above, to yield 1–3 and 5–9 to-
gether with a newminor metabolite/artifact, ethyl dictyodendrillin
(4) (tR = 14.2 min; 1.7 mg, 0.029%). Although the geometric isomers
8E-30-deimino-30-oxoaplysinopsin (6) and 8Z-30-deimino-30-
oxoaplysinopsin (7) were well resolved by HPLC, the isomers rap-
idly isomerized during handling (and on exposure to light). Isola-
tion in a darkened laboratory, followed by rapid data acquisition,
did permit independent characterization of these photolabile iso-
mers. Note—yields for all isolated compounds were calculated as
a weight-to-weight estimate against the crude n-BuOH solubles
4.5. Characterization of natural products
4.5.1. Ianthellalactam A (1)
Pale yellow oil. UV–vis (MeOH) kmax (loge) 203 nm (4.33); NMR
(600 MHz, methanol-d4) see Table 1 and Supplementary Figures
S1a and b and Table S1; HRESI(+)MS m/z 314.1721 (calcd for
C17H25NO3 Na 314.1727).
4.5.2. Ianthellalactam B (2)
Pale yellow oil. UV–vis (MeOH) kmax (loge) 202 nm (4.40); NMR
(600 MHz, methanol-d4) see Table 1 and Supplementary Figures
S2a and b and Table S2; HRESI(+)MS m/z 314.1725 (calcd for
C17H25NO3Na 314.1727).
4.5.3. Dictyodendrillin13 (3)
Colorless oil. 1H NMR (600 MHz, CDCl3) see Supplementary Fig-
ures S3a and b. ESI(+)MS m/z 251 [M+H]+, ESI(")MS m/z 249
[M"H]". Identical with an authentic sample of dictyodendrillin.13
4.5.4. Ethyl dictyodendrillin (4)
Colorless oil. UV–vis (MeOH) kmax (loge) 204.9 (4.27), 201
(4.27); NMR (600 MHz, CDCl3) see Supplementary Figures S4a
and b and Table S4.
4.5.5. Aplysinopsin14 (5)
Yellow solid. UV–vis (MeOH) kmax (loge) 217 (4.0), 279 (3.49),
391 (3.67); NMR (600 MHz, DMSO-d6) see Supplementary Figures
S5a and b and Table S5; HRESI(+)MS m/z 255.1247 (calcd for
C14H15N4O 255.1240). Identical with an authentic sample of
aplysinopsin.14
4.5.6. 8E-30-Deimino-30-oxoaplysinopsin15 (6)
Yellow solid. UV–vis (MeOH) kmax (loge) 203 (4.01), 278 (3.49),
367 (3.83) nm; NMR (600 MHz, DMSO-d6) see Supplementary Fig-
ures S6a and b and Table S6; HRESIMS m/z 278.0909 (calcd for
C14H13N3O2Na 278.0900).
4.5.7. 8Z-30-Deimino-30-oxoaplysinopsin15 (7)
Yellow solid. UV–vis (MeOH) kmax (loge) 203 (4.01), 218 (4.23),
278 (3.49), 367 (3.83) nm; NMR (600 MHz, DMSO-d6) see Supple-
mentary Figures S6a and b and Table S7; HRESIMS m/z 278.0909
(calcd for C14H13N3O2Na 278.0900).
4.5.8. Dihydroaplysinopsin16 (8)
Yellow solid. ½a$23D "86 (c 0.05 MeOH); UV–vis (MeOH) kmax
(loge) 202 (3.98), 218 (3.93), 280 (3.12) nm; NMR (600 MHz,
DMSO-d6) see Supplementary Figures S8a and b and Table S8;
HRESI(+)MS m/z 257.1393 (calcd for C14H17N4O 257.1397).
4.5.9. Tubastrindole B17 (9)
Yellow solid. ½a$23D "44 (c 0.1 MeOH); UV–vis (MeOH) kmax (loge)
202 (4.21), 217 (4.27), 205 (4.24), 268 (3.55) nm; NMR (600 MHz,
DMSO-d6) see Supplementary Figures S9a and b and Table S9;
HRESI(+)MS m/z 509.2415 (calcd for C28H29N8O2 509.2408).
4.6. Synthesis of analogs
4.6.1. General synthetic procedures
Solutions of indole-3-carboxaldehyde (1.0 g, 6.9 mmol) and
either hydantoin, methyl hydantoin or creatinine (17 mmol,
2.5 equiv) in piperidine (5 mL) were refluxed for 45 min under ar-
gon. The solutions were then cooled to room temperature and di-
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luted with acetone (10 mL). The resulting yellow precipitates were
filtered and washed with cold acetone (10 mL) to yield the essen-
tially pure 8E isomers (10, 11a and 12a). Suspensions of 11a and
12a in methanol were exposed to UV light for 3 h, yielding !1:1
mixtures of the 8E and 8Z (11b and 12b) isomers.
4.6.2. 8E-30-Deimino-20,40-bisdemethyl-30-oxoaplysinopsin18
(10)
Yellow solid (0.90 g, 57%). UV–vis (MeOH) kmax (loge) 227.1
(4.03), 277.9 (3.55), 364 (4.09) nm; NMR (600 MHz, methanol-d4)
see Supplementary Figures S10a and b and Table S10; HRESIMS
m/z 250.0593 (calcd for C12H9N3O2Na 250.0587).
4.6.3. 8E-30-Deimino-40-demethyl-30-oxoaplysinopsin19 (11a)
Yellow solid (0.76 g, 46%). UV–vis (MeOH) kmax (loge) 228.9
(4.01), 276 (3.49) 336.9 (3.83) nm; NMR (600 MHz, methanol-d4)
see Supplementary Figure S11a and Table S11a; HRESIMS m/z
264.0746 (calcd for C13H11N3O2Na 264.0743).
4.6.4. 8Z-30-Deimino-40-demethyl-30-oxoaplysinopsin19 (11b)
Yellow solid. UV–vis (MeOH) kmax (loge) 228.9 (4.01), 276 (3.49)
336.9 (3.83) nm; NMR (600 MHz, methanol-d4) see Supplementary
Figure S11b and Table S11b; HRESIMS m/z 264.0746 (calcd for
C13H11N3O2Na 264.0743).
4.6.5. 8E-40-Demethylaplysinopsin20 (12a)
Yellow solid. (0.70 g, 42%). UV–vis (MeOH) kmax (loge) 228.9
(3.93), 277.9 (3.49), 387 (3.90) nm; NMR (600 MHz, DMSO-d6)
see Supplementary Figure 12a and Table S12a; HRESIMS m/z
241.1085 (calcd for C13H13N3O 241.1084).
4.6.6. 8Z-40-Demethylaplysinopsin20 (12b)
Yellow solid. UV–vis (MeOH) kmax (loge) 228.9 (3.93), 277.9
(3.49), 387 (3.90) nm; NMR (600 MHz, DMSO-d6) see Supplemen-
tary Figure 12b and Table S12b; HRESIMS m/z 241.1085 (calcd
for C13H13N4O 241.1084).
4.7. Bioassays
4.7.1. Primary GlyR screening of marine extracts
The initial screen of >2500 marine extracts against recombi-
nantly expressed a1 and a3 GlyRs was performed using a yellow
fluorescent protein-based anion flux assay as previously de-
scribed.12,21 In this bioassay, 90 lL of each 100-fold diluted n-BuOH
partition was transferred into one well of a 384-well plate, and was
dried under nitrogen. The plates containing dried n-BuOH parti-
tions were protected from light and stored at"30 !C until required.
On the day of the experiment an aliquot (30 lL) of extracellular
solution [NaCl (140 mM), KCl (5 mM), CaCl2 (2 mM), MgCl2
(1 mM), HEPES (10 mM), and glucose (10 mM) (pH 7.4 using
NaOH)] was added to each well and mixed/dissolved using a
multi-channel pipette. Subsequently, an aliquot (10 lL) of this solu-
tionwas transferred into the corresponding well of a 384-well plate
containing approx. 5000 cells and 15 lL of extracellular solution
per well, and incubated at room temperature for 30 min. The 384-
well plates were then placed onto the motorized stage of an in-
house imaging system21 and cells were imaged twice: once in
25 lL of extracellular solution containing the n-BuOH partition
and once 10 s after the injection of 50 lL NaI solution supple-
mented with 500 lM glycine. The NaI solution was similar in com-
position to NaCl control solution except the NaCl was replaced by
equimolar NaI. Images of fluorescent cells were segmented and
quantitatively analyzed using a modified version of DetecTIFF soft-
ware.22 In brief, images were segmented using an iterative size and
intensity-based thresholding algorithm and the fluorescence signal
of identified cells was calculated as the mean of all pixel values
within the area of a cell. GlyR activation response was used
as a measure of extract potency and was defined as
(Finit " Ffinal) # 100/Finit, where Finit and Ffinal were the initial and fi-
nal values of fluorescence, respectively. All experiments were per-
formed twice in neighboring wells. Hits were selected by visual
inspection of color maps generated by analysis software. For hit
confirmation, 24 lL of the corresponding 10-fold diluted n-BuOH
partition was transferred into a well of a 384-well plate, and was
dried and stored as described above. On the day of the experiment
the dried 10-fold diluted n-BuOH partitions were resuspended in
80 lL extracellular solution as described above and two aliquots
each of 17 and 10 lL respectively were then transferred in neigh-
boring wells containing !5000 cells and 15 lL extracellular solu-
tion per well. Imaging and image analysis were conducted as
described above. The concentration dependence of the drug effects
was used as measure for extract potency and level of prioritization.
From these experiments we identified Ianthella cf. flabelliformis
(CMB-03322) as an extract with antagonist activity on a1 and a3
GlyRs.
4.7.2. Automated electrophysiology
Electrophysiological screening was performed using an auto-
mated planar patch-clamp device (Patchliner, Nanion Technologies
GmbH, Munich, Germany). Stable a1 and a3 GlyR expressing
HEK293 cell lines, produced as previously described,12,22 were
maintained in Minimal Essential medium. After 2–3 days in cul-
ture, cells were trypsinized and suspended in extracellular solution
[NaCl (140 mM), KCl (4 mM), CaCl2 (2 mM), MgCl2 (1 mM), HEPES/
NaOH (10 mM) and glucose (5 mM) (pH 7.4 adjusted with NaOH)]
at a density of 1 # 106 cells/mL before injecting into the Patchliner
chip. This standard extracellular solution was employed in all
Patchliner experiments. The internal solution contained KCl
(50 mM), NaCl (10 mM), KF (60 mM), MgCl2 (2 mM), EGTA
(20 mM), HEPES/KOH (10 mM) (pH 7.2). All experiments were per-
formed at room temperature. 1 M glycine (Ajax Finechem, Seven
Hills, NSW, Australia) stocks were prepared in water and stored
at "20 !C. All test compounds (marine natural products and syn-
thetics) were dissolved in DMSO (Sigma–Aldrich) and stored at
"20 !C. From these stocks, solutions for experiments were pre-
pared on the day of recording.
4.7.3. Data analysis
Results are expressed as mean ± standard error of the mean of
three or more independent experiments. The Hill equation was
used to calculate the half inhibitory concentration (IC50) and Hill
coefficient (nH) values of individual concentration–response rela-
tionships. All curves were fitted using a nonlinear least squares
algorithm (Sigmaplot 11.0; Jandel Scientific, San Rafael, CA, USA).
Statistical significance was determined by unpaired Student’s t-
test, with p <0.05 representing significance.
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Chemical Profiling 
 
An HPLC analysis (Zorbax C8 250 ' 9.4 mm, 4.0 mL/min, gradient elution from 10–100% MeCN/H2O over 25 
min, with an isocratic 0.01% TFA/H2O modifier) of the crude n-BuOH solubles from sponge CMB-03322 
revealed an extract rich in chemical diversity. 
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Isolation Scheme  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.1. Extraction and purification of CMB-03322 
 
(a) Partition into n-BuOH (-1) and H2O (-2) solubles 
(b) Sequentially triturate n-BuOH solubles into hexane (-1-1), CH2Cl2 (-1-2), MeOH (-1-3) and H2O (-1-4) 
(c) Sequentially triturate water solubles into MeOH (-2-1) and H2O (-2-2) 
(d) HPLC [Zorbax C8 (250 ' 9.4 mm), 4.0 mL/min, gradient 10-100% MeCN/H2O over 25 min, with isocratic 0.01% TFA  
               modifier] 
(e) HPLC [Zorbax C8 (250 ' 9.4 mm), 4.0 mL/min, gradient 10-100% MeCN/H2O over 25 min, with isocratic 0.01% TFA  
 modifier] 
(f) Blue and red indicate known vs. new compounds respectively, while * indicates equilibrating isomers. 
 
CMB-03322
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n-BuOH H2O
Petrol DCM MeOH MeOH H2O
(a)
(b) (c)
519.7 mg (-1) 2.71mg (-2)
294.1 mg
  (-2-1)
 2.39 mg
  (-2-2)
9.0 mg 283.0 mg
  (-1-2)  74.6 mg
 3.3 mg
(-1-1)  (-1-3) (-1-4)
  0.7 mg
(-1-2-1)
 0.8 mg
(-1-2-2)
 1.5 mg
(-1-2-3)
 1.8 mg*
(-1-2-4)
 1.6 mg*
(-1-2-5)
(d)
 1.8 mg
(-1-3-2)
 3.5 mg
(-1-3-3)
  2.9 mg*
(-1-3-4)   1.7 mg(-1-3-6)
  0.2 mg
(-1-3-8)
(e)
H2O
 1.1 mg
(-1-2-8)
 1.5 mg
(-1-3-1)
153.0 mg (-1-2) + 74.6 mg (-1-3)
  2.6 mg
(-1-3-7)
   1.4 mg
(-1-2-7)
9 8 5 7 2 1 3
95.6 mg
(-1-2-10)
163.5 mg
(-1-3-9)
  2.4 mg*
(-1-3-5)
6
9 8 5 7 1 46
130.0 mg (half of the fraction)
2
  0.8 mg
(-1-2-7)
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 Figure 5S1a. 1H NMR (600 MHz, methanol-d4) spectrum of ianthellalactam A (1) 
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 Figure 5S1b 13C NMR (150 MHz, methanol-d4) spectrum of ianthellalactam A (1) 
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            Figure 5S1c. UV-vis (MeOH) spectrum of ianthellalactam A (1) 
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  Figure 5S1d: Selected 2D NMR correlations for ianthellalactam A (1) 
 
 
 
  Table 5S1: NMR (600 MHz, CD3OD) data for ianthellalactam A (1) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
1  174.4   
2  139.7   
3 6.88 (tt, 1.6, 1.6)  138.9 4, 5 1, 2, 4, 5 
4 4.05 (dt, 1.6, 1.6) 53.1 3, 5 1, 2, 3 
5 2.29B  27.1 3, 4, 6 1, 2, 3, 6, 7  
6 2.27B 27.2 5, 7, 9 2, 5, 7, 8 
7 5.16 (tq, 6.9, 1.3) 124.8 6, 9 5, 6, 9, 10 
8  137.3   
9 1.60 (br s)  16.3 6, 7 7, 8, 10 
10 1.99 (br t, 7.6) 41.0 11 7, 8, 9, 11 
11 2.08 (br td, 7.6, 7.0)  27.9 10, 12, 14, 15 8, 10, 12, 13 
12 5.09 (tqq, 7.0, 1.4, 1.4) 125.6 11, 14, 15 14, 15 
13  132.3   
14 1.60 (br s) 17.9 11, 12 12, 13, 15 
15 1.67 (br s) 26.0 11, 12 12, 13, 14 
1( 4.21 (s) 44.9  1, 2(, 4 
2(  173.0   
              A 13C NMR assignments supported by HSQC data. B Overlapping signals. 
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 Figure 5S2a. 1H NMR (600 MHz, methanol-d4) spectrum of ianthellalactam B (2) 
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 Figure 5S2b. 13C NMR (150 MHz, methanol-d4) spectrum of ianthellalactam B (2) 
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           Figure 5S2c. UV-vis (MeOH) spectrum of ianthellalactam B (2) 
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Figure 5S2d: Selected 2D NMR correlations for ianthellalactam B (2) 
 
 
 
 
 
 
 
 
 
 
Table 5S2: NMR (600 MHz, CD3OD) data for ianthellalactam B (2) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
1  175.0   
2 5.85 (tt, 1.4, 1.4)  121.5 4, 5 1, 3, 4, 5 
3  164.6   
4 4.11 (d, 1.4) 56.8 2 1, 2, 3 
5 2.48 (td, 7.4, 1.4) 30.8 2, 6 2, 3, 4, 6, 7  
6 2.30 (br td, 7.4, 7.1) 27.4 5, 7, 9 3, 5, 7, 8 
7 5.16 (tq, 7.1, 1.3) 124.3 6, 9 5, 6, 9, 10 
8  137.9   
9 1.64 (br s)  16.3 6, 7 7, 8, 10 
10 2.00 (br t, 7.6) 40.9 11 7, 8, 9, 11, 12 
11 2.08 (br td, 7.6, 7.0)  27.8 10, 12, 14, 15 8, 10, 12, 13 
12 5.08 (tqq, 7.0, 1.4, 1.4) 125.4 11, 14, 15 14, 15 
13  132.4   
14 1.60 (br s) 17.9 11, 12 12, 13, 15 
15 1.66 (br s) 26.0 11, 12 12, 13, 14 
1( 4.17 (s)  44.4  1, 4, 2( 
2(  172.9   
              A 13C NMR assignments supported by HSQC data.  
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         Figure 5S3a. 1H NMR (600 MHz, CDCl3) spectrum for dictyodendrillin (3) 
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            Figure 5S3b. 1H NMR (600 MHz, DMSO-d6) spectrum for dictyodendrillin (3)  
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         Figure 5S4a. 1H NMR (600 MHz, CDCl3) spectrum for ethyl dictyodendrillin (4) 
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        Figure 5S4b. 13C NMR (150 MHz, CDCl3) spectrum for ethyl dictyodendrillin (4) 
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           Figure 5S4c. UV-vis (MeOH) spectrum for ethyl dictyodendrillin (4) 
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Figure 5S4d: Selected 2D NMR correlations for ethyl dictyodendrillin (4) 
 
 
Table 5S4.  NMR (600 MHz, CDCl3) data for ethyl dictyodendrillin (4) 
 
No.  %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
1 5.78 (br s) 101.2 2, 5 1(, 3, 4 
2 6.75 (d, 1.3) 142.0 4, 5 1, 3, 4, 5 
3  138.2   
4  172.2   
5 2.32 (t, 7.4) 25.1 2, 6 2, 3, 4, 6, 7  
6 2.25 (dt, 7.1, 7.3) 26.1 5, 7 3, 5, 7 
7 5.07 (t, 7.4, 7.6) 121.9 6, 9 5, 9, 10 
8  137.2   
9 1.57 (br s)  16.8 7 7, 8, 10 
10 1.96 (t, 7.6) 40.5 11 8, 9, 11, 12 
11 2.04 (dt, 7.1, 7.6)  27.3 10, 12 8, 10, 12, 13 
12 5.05 (t, 7.1) 124.0 11, 14, 15 14, 15 
13  132.4   
14 1.57 (br s) 16.5 12 13, 15 
15 1.65 (br s) 26.0 12 12, 13, 14 
1(a 3.89 (m)  65.0 2(, 1(b 1 
1(b 3.70 (m)   2(, 1(a  
2( 1.25 (t, 7.3) 15.2 1( 1 
             A 13C NMR assignments supported by HSQC data 
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       Figure 5S5a. 1H NMR (600 MHz, DMSO-d6) spectrum of aplysinopsin TFA salt (5) 
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         Figure 5S5b 13C NMR (150 MHz, DMSO-d6) spectrum of aplysinopsin TFA salt (5) 
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           Figure 5S5c. UV-vis (MeOH) spectrum of aplysinopsin TFA salt (5) 
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 Table 5S5: NMR (600 MHz, DMSO-d6) data for aplysinopsin TFA salt (5)  
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 8.99 (d, 3.0) 131.2  3, 3a, 7a 
3  108.5   
3a  127.7   
4 8.06 (br d, 7.6) 118.5 5 6, 7a 
5 7.22 (br dd, 7.6, 7.1) 120.8 4, 6 3a, 7 
6 7.25 (br dd, 7.8, 7.1) 122.8 5, 7 4, 7a 
7 7.52 (br d, 7.8) 112.4 6 3a, 5 
7a  135.8   
8 7.34 (s) 115.8  2, 3, 3a, 1(, 5( 
1(  121.9   
2(-NMe 3.52 (s) 28.8  1(, 3( 
3(  152.0   
4(-NMe 3.22 (s) 26.2  3(, 5( 
5(   161.2   
1-NH 9.36 (br s)    
             A 13C NMR assignments supported by HSQC data 
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Figure 5S6a. 1H NMR (600 MHz, DMSO-d6) spectrum of a mixture of 8E/Z-3(-deimino-3(-oxoaplysinopsins (6/7).  
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     Figure 5S6b. 13C NMR (150 MHz, DMSO-d6) spectrum of a mixture of 8E/Z-3(-deimino-3(-oxoaplysinopsins (6/7).  
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          Figure 5S6c. UV-vis (MeOH) spectrum of a mixture of 8E/Z-3(-deimino-3(-oxoaplysinopsins (6/7). 
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       Table 5S6. NMR (600 MHz, DMSO-d6) data for 8E-3(-deimino-3(-oxoaplysinopsin (6)  
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 8.85 (d, 2.7) 128.6   3, 3a, 7a 
3  108.5   
3a  127.7   
4 7.95 (br d, 7.8)  118.2 5 3, 3a, 6, 7, 7a 
5 7.14 (br dd, 7.8, 7.4) 119.9 4, 6 3a, 4, 6, 7 
6 7.19 (br dd, 7.9, 7.4) 122.1 5, 7 4, 7, 7a 
7 7.46 (br d, 7.9) 111.9 6 3a, 4, 5 
7a  135.6   
8 6.78 (s) 108.3  2, 3, 3a, 1(, 5( 
1(  124.5   
2(-Me 3.01 (s) 24.3  1(, 3( 
3(  152.8   
4(-Me 3.25 (s) 26.2  3(, 5( 
5(  161.9   
            A 13C NMR assignments supported by HSQC data 
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        Table 5S7. NMR (600 MHz, DMSO-d6) data for 8Z-3(-deimino-3(-oxoaplysinopsin (7) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 7.70 (d, 2.6) 127.5   3, 3a, 7a, 8 
3  106.9   
3a  127.4   
4 7.62 (br d, 7.9) 118.5 5 3, 3a, 6, 7, 7a 
5 7.12 (br dd, 7.9, 7.2) 120.1 4, 6 3a, 4, 6, 7 
6 7.19 (br dd, 8.0, 7.2) 122.2 5, 7 4, 7, 7a 
7 7.44 (br d, 8.0) 112.0 6 3a, 4, 5 
7a  135.9   
8 6.90 (s) 104.7  2, 3, 1(, 5( 
1(  126.7   
2(-Me 3.11 (s) 29.6  1(, 3( 
3(  155.7   
4(-Me 2.99 (s) 24.7  3(, 5( 
5(  163.6   
             A 13C NMR assignments supported by HSQC data 
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 Figure 5S8a. 1H NMR (600 MHz, DMSO-d6) spectrum for dihydroaplysinopsins TFA salt (8).  
 
 
 
N H
N
N
NH
2
O
           Chapter 5: Ianthellalacams and aplysinoposins Supporting Information 
    173 
[p
pm
]
 16
0 
 14
0 
 12
0 
 10
0 
 80
 
 60
 
 40
 
172.29
157.41
135.89
126.92
124.33
121.19
118.64
118.12
111.55
63.55
25.99
24.10
30.34
106.36
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Figure 5S8b. 13C NMR (150 MHz, DMSO-d6) spectrum for dihydroaplysinopsins TFA salt (8).  
 
 
 
N H
N
N
NH
2
O
           Chapter 5: Ianthellalacams and aplysinoposins Supporting Information 
    174 
        
Figure 5S8C. UV-vis (MEOH) spectrum for dihydroaplysinopsin TFA salt (8) 
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       Table 5S8. NMR (600 MHz, DMSO-d6) data for dihydroaplysinopsin TFA salt (8) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 7.14 (d, 2.4) 124.3  3, 3a, 7a 
3  106.4   
3a  126.9   
4 7.49 (br d, 8.0) 118.1 5 3, 3a, 6, 7a 
5 6.99 (ddd, 8.0, 8.0, 1.0) 118.7 4, 6 3a, 7 
6 7.07 (ddd, 8.0, 8.0, 1.0) 121.2 5, 7 4, 7a 
7 7.34 (ddd, 8.0, 1.0, 0.8) 111.6 6 3a, 5 
7a  135.9   
8" 3.40B 24.1 1(, 8# 2, 3, 3a, 1(, 5( 
8# 3.29 (dd, 15.5, 4.2)  1(, 8" 2, 3, 1( 
1( 4.58 (dd, 5.2, 4.2) 63.6 8"/# 3, 3(, 5(, 8 
2(-Me 3.08 (s) 30.3  1(, 3( 
3(  157.5   
4(-Me 2.86 (s) 26.0  3(, 5( 
5(  172.3   
3(-NH2 9.17 (br s)    
             A 13C NMR assignments supported by HSQC data; B obscured by H2O signal 
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            Figure 5S9a. 1H NMR (600 MHz, DMSO-d6) spectrum for tubastrindole B TFA salt (9) 
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Figure 5S9b. 13C NMR (150 MHz, DMSO-d6) spectrum for tubastrindole B TFA salt (9) 
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            Figure 5S9c. UV-vis (MEOH) spectrum for tubastrindole B TFA salt (9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Figure 5S9d. Selccted 2D NMR correlations for tubastrindole B TFA salt (9) 
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        Table 5S9. NMR (600 MHz, DMSO-d6) data for tubastrindole B TFA salt (9) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) ROESY 
2  123.4    
3  117.0    
3a  127.3    
4 7.60 (d, 8.0) 118.7 5 3a, 6, 7a 8" 
5 7.17 (dd, 8.0, 1.0) 119.4 4, 6  3a, 7  
6 7.29 (dd, 8.3, 1.0) 123.6 5, 7 5, 7, 7a  
7 7.44 (dd, 8.3, 1.0) 111.7 6 3a, 6  
7a  137.4    
8" 3.69 (d, 17.2) 25.8 8# 2, 3, 8(, 9 4, 14 
8# 3.63 (d, 17.0)  8" 3, 9, 13 4, 8(, 15( 
9  70.2    
11  161.0    
13  172.8    
14 3.16 (s) 32.1  9, 11 2( 
15 2.58 (s) 26.0  11, 13  
1-NH 9.65 (br s)     
2( 6.9 (d, 2.7) 123.4 3( 3(, 3(a, 7(a 14(, 15( 
3(  102.4    
3(a  127.3    
4( 7.52 (d, 8.0) 116.6 5( 3(, 6(, 7(a 8(, 14( 
5( 7.13 (dd, 8.1, 1.0) 121.6 4(, 6( 3(a, 4(, 7(  
6( 7.15 (dd, 8.1, 1.0) 119.4 5, 6( 7(a, 3a  
7( 7.40 (dd, 9.0, 1.0) 111.6 6( 3(a, 6(  
7(a  134.7    
8( 4.45 (s) 42.2  2(, 3(, 3(a, 9(, 13( 4(, 8#, 14( 
9(  70.3    
11(  159.7    
13(  171.2    
14( 3.05 (s) 27.5   9, 11( 4( 
15( 2.83 (s)  26.3  11(, 13(  
1(-NH 9.50 (d, 0.6)      
              A 13C NMR assignments supported by HSQC data. 
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           Figure 5S10a. 1H NMR (600 MHz, DMSO-d6) spectrum for 8E-3(-deimino-2(-4(-bisdemethyl-3(-oxoaplysinopsin  (10) 
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            Figure 5S10b. 13C NMR (150 MHz, DMSO-d6) spectrum for 8E-3(-deimino-2(,4(-bisdemethyl-3(-oxoaplysinopsin  (10) 
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            Figure 5S10c. UV-vis (MeOH) spectrum for 8E-3(-deimino-2(,4(-bisdemethyl-3(-oxoaplysinopsin (10) 
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        Table 5S10: NMR (600 MHz, DMSO-d6) data for 8E-3(-deimino-2(,4(-bisdemethyl-3(-oxoaplysinopsin (10) 
 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 8.14 (d, 2.4) 128.0  3, 3a, 7a 
3  108.0   
3a  127.0   
4 7.75 (br d, 8.0) 118.1 5 3, 3a, 6, 7a 
5 6.99 (ddd, 8.0, 8.0, 1.0) 120.1 4, 6 3a, 7 
6 7.15 (ddd, 8.0, 8.0, 1.0) 123.0 5, 7 4, 7a 
7 7.41 (ddd, 8.0, 1.0, 0.8) 112.0 6 3a, 5 
7a  136.0   
8 6.76 (s) 102.0  2, 3, 3a, 1(, 5( 
1(  127.0   
3(  165.0   
5(  165.0   
1-NH 11.8 (br s)   3, 3a, 7a 
             A 13C NMR assignments supported by HSQC data. 
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 Figure 5S11a. 1H NMR (600 MHz, DMSO-d6) spectrum for 8E-3(-deimino-4(-demethyl-3(-oxoaplysinopsin  (11a) 
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Figure 5S11b. 1H NMR (600 MHz, DMSO-d6) spectrum for a mixture of 8E/Z-3(-deimino-4(-demethyl-3( 
oxoaplysinopsins  (11a/b) 
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              Figure 5S11c. UV-vis (MeOH) spectrum for a mixture of 8E/Z-3(-deimino-4(-demethyl-3(-oxoaplysinopsins (11a/b) 
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       Table 5S11a. NMR (600 MHz DMSO-d6) data for 8E-3(-deimino-4(-demethyl-3(-oxoaplysinopsin (11a) 
 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 8.78 (d, 2.2) 128.6  3, 3a, 7a 
3  108.8   
3a  126.0   
4 7.93 (d, 7.98) 117.9 5 3, 3a, 7a 
5 7.18 (ddd, 8.1, 8.0, 1.0) 119.8 4, 6 3a, 7 
6 7.13 (ddd, 8.0, 7.9, 1.0) 122.0 5, 7 4, 7a 
7 7.48 (d, 7.98) 111.8 6 3a, 5 
7a  135.4   
8 6.68 (s) 107.6  1(, 2, 3, 5( 
9  125.9   
2(-Me 3.19 (s) 27.6  1(, 3( 
3(  153.3   
4(-
NH 11.61 (br s)   3, 3a, 7a 
5(  163.5   
              A 13C NMR assignments supported by HSQC data. 
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        Table 5S11b. NMR (600 MHz, DMSO-d6) data for 8Z-3(-deimino-4(-demethyl-3(-oxoaplysinopsin (11b) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 7.68 (br s) 128.5  3, 3a, 7a 
3  108.8   
3a  127.6   
4 7.61 (d, 7.86) 117.6 5 3, 3a, 7a 
5 7.18 (ddd, 8.0, 8.0, 1.0) 119.5 4, 6 3a, 7 
6 7.13 (dd, 8.1, 8.0, 1.0) 121.0 5, 7 4, 7a 
7 7.44 (dd, 8.1, 1.0) 111.5 6 3a, 5 
7a  135.4   
8 6.68 (s) 102.1   
1(  130.0  3, 3(, 5(, 8 
2(-Me 3.07 (s) 27.5  1(, 3( 
3(  165.0   
4(-NH    3(, 5( 
5(  177.0   
1-NH 11.51 (br s)    
              A 13C NMR assignments supported by HSQC data. 
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           Figure 5S12a. 1H NMR (600 MHz, DMSO-d6) spectrum for 8E-4(-demethylaplysinopsin (12a)  
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Figure 5S12a. 1H NMR (600 MHz, DMSO-d6) spectrum for mixture of 8E-4(-demethylaplysinopsin (12a) and 8Z-4(-
demethylaplysinopsin (12b) 
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Figure 5S12c. UV-vis (MeOH) spectrum of a mixture of 8E-4(-demethylaplysinopsin (12a) and 8Z-4(-
demethylaplysinopsin (12b) 
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Table 5S12a. NMR (600 MHz, DMSO-d6) data for 8E-4(-demethylaplysinopsin (12a) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 8.78 (d, 2.2) 128.6  3, 3a, 7a 
3  108.8   
3a  126.0   
4 7.93 (d, 8.0) 117.9 5 3, 3a, 7a 
5 7.18 (ddd, 8.1, 8.0, 1.0) 119.8 4, 6 3a, 7 
6 
7.13 (ddd, 8.0, 7.9, 1.0) 122.0 5, 7 4, 7a 
7 7.48 (d, 8.0) 111.8 6 3a, 5 
7a  135.4   
8 6.68 (s) 107.6  1(, 2, 3, 5( 
1(  125.9   
2(-Me 3.19 (s) 27.6  1(, 3( 
3(  153.3   
4(-NH 11.61 (br s)   3, 3a, 7a 
5(  163.5   
             A 13C NMR assignments supported by HSQC data. 
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       Table 5S12b. NMR (600 MHz, DMSO-d6) data for 8Z-4(-demethylaplysinopsin (12b) 
No. %H (mult., J (Hz)) %CA COSY  HMBC (1H to 13C) 
2 7.59 (d, 1.74) 126.5  3, 3a, 7a 
3  108.8   
3a  127.4   
4 7.57 (d, 7.92) 118.4 5 3, 3a, 7a 
5 7.10 (ddd, 8.0, 8.0, 1.0) 119.0 4, 6 3a, 7 
6 7.11 (ddd, 7.56, 8.0, 1.0) 121.5 5, 7 4, 7a 
7 7.42 (d, 8.94, 0.9) 111.5 6 3a, 5 
7a  136.0   
8 6.64 (d, 0.96) 102.4  1(, 2, 3, 5 
1(  132.5   
2(-Me 3.10 (s)   31.2  1(, 3( 
3(  169.5   
4(-NH     
5(  177.5   
1-NH 11.51 (brs)   3, 3a, 7a 
             A 13C NMR assignments supported by HSQC data. 
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 Figure 5S13. 1H NMR (600 MHz, CDCl3) spectrum for dendrolasin (13)  
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CHAPTER 6 
           CONCLUSION & OUTLOOK 
 
6.1. Conclusion  
In summary, chemical and biological investigations successfully challenged a library of more than 2,500 marine 
extracts to focus our attention on extracts of 7 southern Australian sponges including 3 members of Irciniidae 
family (CMB-03363, CMB-01064 and CMB-03231), 3 members of Psammocinia genus (CMB-01008, CMB-
02858 and CMB-03344) and 1 member of genus Ianthella (CB-03322). Bioassay guided fractionations using YFP 
assay on the 7-priority specimens yielded 24 compounds, 13 of which were new metabolites. They included 
ircinialactam A (3.45), 8-hydroxyircinialactam A (3.46), 8-hydroxyircinialactam B (3.47), ircinialactam C (3.48), 
ent-ircinialactam C (3.49) and ircinialactam D (3.50), (!)-ircinianinlactam A (4.11), (!)-ircinianinlactam A sulfate 
(4.12), (!)-oxo-ircinianin (4.13), (!)-oxo-ircinianin lactam (4.14), (!)-ircinianin lactone (4.15), ianthellalactam A 
(5.1) and ianthellalactam B (5.2) (Table 6.1). Two of these new metabolites (4.13-4.14) featured an 
unprecedented moiety, a modified tetronic acid hitherto unknown in natural products, and eleven of them (3.45-
3.50, 4.11-4.12, 4.14, 5.1-5.2) contained the rare glycinyl lactam functionality. Curiously, all priority specimens 
produced at least one compound with glycinyl lactam moiety (Table 6.1), a functional group that mimics glycine 
and N-arachidonyl glycine (NAGly), which are known to exert anti-inflammatory activity with glycine acting as 
an anti-inflammatory micronutrient174, and NAGly as an inhibitor of anandamide173,174 (see page 207 for NAGly).  
To confirm the activity observed in the primary screening using YFP, we screened 24 MNPs against "1 and "3 
GlyRs with an automated patch clamp electrophysiology. This gold standard method in screening ion channel 
modulators confirmed the presence of 14 GlyR modulators further grouped into 7 potentiators (3.45-3.47, 3.53, 
4.1, 4.14 & 5.34) and 2 antagonists  (4.2 & 5.34) of GlyR"1, 2 potentiators (4.11 & 4.12) and 7 antagonists (3.45, 
3.48-3.50, 3.53, 4.2, 5.3 & 5.4) of GlyR"3 (Table 6.1). The level of activity against GlyRs varied among the 
modulators and was classified as weak GlyRs modulators such as 4.1, 4.2, 5.3, and 5.4, modest GlyR modulators 
including 3. 45-3.50 and strong GlyR modulators such as 3.46, 3.47, 3.53, 4.11, 4.14 and 5.34. One pot synthesis 
inspired by the activity of 4.2, 4.3 and 5.34 gave two potent GlyR"1 antagonists (5.70 & 5.71) (Figure 6.1a) 
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Table 6.1. Natural products discovered from seven priority samples and their synthetic derivatives  
Activity against GlyRs 
No Compound/Source 
Molecular 
weight/Molecul
ar Formula 
Status 
GlyR"1 GlyR"3 
3.45 ircinialactam A/ 
CMB-01064 and CMB-03363 
471/C27H37NO6 New/MNPs MP  (140% at 
100 µM) 
MA   (IC50 = )30) 
3.46 8-hydroxyircinilactam A/  
CMB-01064 and CMB-03363 
489/C27H39NO7 New/MNPs SP (sub to low 
micromolar 
range)101 
 
$ 
3.47 8-hydroxyircinialactam B/ 
CMB-01064 
489/C27H39NO7 New/MNPs SP (EC50 = 0.5 
µM)101 
 
$ 
3.48 ircinialactam C/  
CMB-01064 and CMB-03363 
405/C23H35NO5 New/MNPs $ MA (IC50 = )30 
µM)101 
3.49 ent-ircinialactam C/ 
CMB-03231 
405/C23H35NO5 New/MNPs $ MA (IC50 = )30 
µM)101 
3.50 ircinialactam D/ 
CMB-03363 
551/C29H45NO9 New/MNPs $ MA (IC50 = )30 
µM)101 
3.51 7E,12E,20Z,18S-variabilin/ CMB-
01064 and CMB-03363 
398/C25H34O4 Known/MNPs  
$ 
 
$ 
3.52 7E,12Z,20Z,18S-variabilin/ CMB-
01064 and CMB-03363 
398/C25H34O4 Known/MNPs  
$ 
 
$ 
3.53 12E,20Z,18S-hydroxyvariabilin/ 
CMB-01064 and CMB-03363 
416/C25H36O5 Known/MNPs $ $ 
4.1 ($)-ircinianin/ 
CMB-01064 and CMB-03363 
396/C25H32O4 Known /MNPs WP (~80% at 100 
µM)133 
    
            $ 
4.2 ($)-ircinianin sulfate/ 
CMB-01064 and CMB-03363 
475/C25H31O7S– Known /MNPs MA (IC50 = 38.4 
µM) 
SA ((IC50 = 3.2 
µ*)133 
4.11 ($)-ircinianinlactam A/ 
CMB-01064 and CMB-03363 
469/C27H35NO6 New /MNPs $ SP (EC50 = 8.5 µM)133 
4.12 ($)-ircinianinlactam A sulfate/ 
CMB-01008 
548/C27H34NO9S– New/MNPs $ WP  (~70%  at 100 
µM)133 
4.13 ($)-oxoircinianin/CMB-03344 412/C25H32O5 New/MNPs $ $ 
4.14 ($)-oxoircinianin lactam A/ 
CMB-02858 
485/C27H35NO7 New/MNPs MP (~110% at 
100 µM)133 
$ 
4.15 ($)-ircinianin lactone/ 
CMB-02858 
412/C25H32O5 New/MNPs  
$ 
 
$ 
4.16 ($)-ircinianin acetate 438/C27H34O5 New/synthetic  $ $ 
5.1 aplysinopsin/CMB-03322 254/C14H15N4O Known/MNPs  
$ 
 
5.3 8E-3’-deimino-3’-oxoaplysinopsin/ 
CMB-03322 
255/C14H13N3O2 Known /MNPs   
              $ 
WA (IC50 = 67 µM)139 
5.4 8Z-3’-deimino-3’-oxoaplysinopsin 
/CMB-03322 
255/C14H13N3O2 Known /MNPs  
$ 
WA (IC50 = 67 µM)139 
5.10 dihydroaplysinopsin TFA salt 
/CMB-03322 
256/C14H17N4O Known /MNPs  
$ 
 
$ 
5.34 tubastrindole B/CMB-03322 508/C28H29N8O2 Known /MNPs SP (+ 1.0 µM), 
MA (IC50 = 25.9 
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µM)139, 
 
             $ 
5.66 ianthellalactam A/CMB-03322 291/C17H25NO3 New/MNPs $ $ 
5.67 ianthellalactam B/CMB-03322 291/C17H25NO3 New/MNPs $ $ 
5.68 ethyldictyondendrilin/ 
CMB-03322 
278/ New/artefact   
$ 
 
$ 
5.69 8E-3(-deimino-2(-4(-
bisdemethyl-3(-oxoaplysinopsin  
250/C12H9N3O2 Known/Synthetic   
$ 
 
$ 
5.70 8E-3(-deimino-4(-demethyl-3(-
oxoaplysinopsin 
250/C13H13N3O2 Known/Synthetic SA (IC50 = 8.8 
µM) 
 
$ 
5.71 8Z-3(-deimino-4(-demethyl-3(-
oxoaplysinopsin  
250/C13H13N3O2 Known/Synthetic SA (IC50 = 8.8 
µM) 
 
$ 
5.72 8E-4(-demethyl-3(-
oxoaplysinopsin 
241/C13H13N4O Known/Synthetic  
$ 
 
$ 
5.73 8E-4(-demethyl-3(-
oxoaplysinopsin 
241/C13H13N4O Known/Synthetic  
$ 
 
$ 
      
Note : WA, MA and SA = weak, modest and strong antagonists respectively. WP, MP and SP = weak, moderate  
          and strong potentiators respectively 
 
  
 
 
 
 
 
 
 
Figure 6.1a. Strong modulators of GlyRs  
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Figure 6.1b. Moderate (orange box) and weak (yellow bow) GlyR modulators as well as inactive molecules  
                    (black box) against GlyRs.  
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Many of the above GlyR modulators may inspire the development of new pharmacological tools capable of 
probing the distribution and function of GlyR isoforms, potentially advancing the development of GlyR targeting 
therapeutics to treat epilepsy, spasticity, hyperekplexia and chronic inflammatory pain. For example, at low 
concentration 12E,20Z,18S-hydroxyvariabilin (3.53) and tubastrindole B (5.34) strongly potentiated GlyR"1 with 
IC50 value of 1.2 µM for the sesterterpene tetronic acid and 120% glycine enhancement at 1.0 µM for the indole 
alkaloid. At higher concentration, they also showed antagonist activity but against different GlyR subunits with 
the former acting as a strong GlyR"1 antagonist (IC50 = 7.0 µM) while the latter as a modest GlyR"3 inhibitor 
(25.9 µM) (Table 6.1). This bifunctional activity particularly for 5.34 indicates that the dimeric aplysinopsin may 
have two different GlyR"1 binding sites. As pointed out in general introduction (page 11 and the ircinialactam 
paper), potent antagonist of 3.53 against GlyR"3 may be useful in identifying the function of GlyR"3 signaling 
in the spinal cord and/or treatment of temporal lobe epilepsy101. Similarly, in addition to being crucial in 
uncovering pharmacological functions of GlyR"1, potent and/or selective GlyR"1 potentiators attributed to 3.46, 
3.47 and 4.14 (Table 6.1) may play a key role in the development of therapeutics for movement disorders such as 
hyperekplexia, spasticity and chronic anti-inflammatory pain101,133,139 although as a target for pain treatment 
GlyR"1 is less favorable than GlyR"3 due to the risk of side effects attributed to GlyR"11. Hence, a potent and 
specific activity of ($)-ircinianinlactam A (4.11) (IC50 = 8.5 µM) against GlyR"3, the emerging pain target, 
renders 4.11 as the most interesting lead for the development of novel chronic anti-inflammatory pain 
drug(s)1,19,21,44.  
Together, the medical potentials of the above GlyR modulators, the absence of specific and potent GlyR 
modulator particularly GlyR"31,44 and the availability of synthetic methods for variabilin129, glycinyl lactam126 and 
ircinianin136 type compounds offer an excellent opportunity for the development of GlyR pharmacological probes 
and/or novel, potent and specific drugs for treating hyperekplexia, spasticity, epilepsy and particularly chronic 
anti-inflammatory pain. The latter target attributes to the potent and/or specific modulating activity of 8-
hydroxyircinialactam A (3.46) and B (3.47), ($)-oxo-ircinianinlactam A (4.14) against GlyR"1 and importantly of 
potent and selective activity of ($)-ircinianinlactam A (4.11) GlyR"3. The potential of these lead molecules to 
inspire the discovery of novel, specific and potent anti-inflammatory drug(s) is worth further research attention 
and is the subject of the following viewpoint.  
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6.2. Outlook  
Over the years, drug discovery including anti inflammatory pain and marine derived drugs (MDDs) has always 
been challenging45,66. Conspicuously, material supply, structural complexity of the present GlyR modulators and 
lack of support from pharmaceutical companies remain the major hurdles faced by academia and industry in 
developing MDDs67,69,87 leading to low rate of drug discovery from marine resource66. The same issues are posing 
a serious challenge to the development of current GlyR modulators discovered from Australian marine sponges. 
However, it is worth noting that most marine derived bioactive molecules in the pipeline (clinical trials) have 
their origin in academia research87 with salinosporamide A (1.38) being the fastest MDDs to enter the pipeline 
due to its strategic research development87. In addition, widespread use of analgesics such as strong opioids, 
NSAIDs and COX inhibitors has been the subject for many debates presenting a challenge as well as providing an 
opportunity for the development of analgesic with new mode of actions45. The following section is a description 
of the possibility of bringing the novel, potent and specific GlyR"1 potentiators (3.46, 3.47 and 4.14) and 
particularly the novel, potent and selective GlyR"3 potentiator, ($)-ircinianinlactam A (4.11), to the pipeline by 
considering a number of drug development aspects through a SWOT (strength weakness opportunity and threat) 
analysis.  
 
 
6.2.1. Strength Weakness Opportunity and Threat (SWOT) Analysis 
Although mainly applied in business ventures, SWOT analysis is also applicable for analyzing a product, place, 
industry or person175. It provides a systematic approach for identifying factors affecting the internal strength and 
weakness as well as external opportunity and threat allowing the internal factors to effectively meet the external 
ones176. Identification of SWOT is crucial in that it allows one to determine the benefit of the process or the 
necessity to enhance different aspects prior to detailed economic evaluation177. With this regards, SWOT analysis 
is undertaken to identify internal strength and weakness as well as external opportunity and threat regarding the 
possibility of bringing GlyR modulators discovered from Australian marine sponges in particular ($)-
ircinianinlactam A (4.11) to the pipeline.  
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Strength. GlyR is an emerging target for pain treatment5,21 safer than opioid receptors due to its discrete 
distribution at the nociceptive neurons in the spinal cord of the dorsal horn, the pain terminal1. Interestingly, 
recent study has shown cannabinoid-GlyRs interaction as playing a crucial role in cannabis-induced analgesia 
underscoring the importance of GlyR in particular GlyR!3 as a promising target for pain treatment. Also, unlike 
the known GlyR modulators, all GlyR modulators discovered in this study were novel (Table 6.1 and Figure 6.1). 
Of interest, the rare molecule (")-ircinialactam A (4.11) has emerged as the most interesting lead compound for 
the discovery of novel, potent and specific GlyR modulators due to its potent and specific modulating activity 
against the GlyR!3. Apart from being rare, ircinialactam A and other glycinyl lactams are synthetically 
accessible which are of great interest to the drug discovery.  
Weakness: Several weaknesses in developing current GlyR modulators include material supply, structural 
complexity, the absence of in vivo study and the lack of industrial support. For example, all GlyR modulators 
existed as minor components with purification of 12E,18S-8-hydroxyvariabilin A and 8-hydroxyvariabilin B 
requiring the use of LC-SPE-NMR. In addition, synthetically inaccessible GlyR modulator such as tubastrindole 
B is hampering the development of this promising GlyR!1 potentiator. Moreover, apart from the absence of in 
vivo study, the specificity of all GlyR modulators for particular subunit of the chloride channel receptors has not 
been confirmed, as they have not been evaluated against other receptor members of cys-loop LGIC superfamily. 
Importantly, marine drug discovery is still academia-based research that lacks in industrial support. Furthermore, 
although several anticancer in clinical pipeline have their origin in academia, the lack of support from 
pharmaceutical company remains one of the major hurdles in the development of marine based drugs.  
Opportunities: The current analgesics give patients only 25% of pain relief with many of these pain relief drugs 
having adverse side effects including addiction45. Based on the U$50 billion global value for pain market in 2009, 
it was predicted the market would continue to grow in the future due to an increasing number of ageing 
population45. In addition, despite the widespread use of known analgesics, the unmet medical condition for pain 
treatments was predicted to potentially fill specific market for pain treatment. Moreover, as the understanding of 
pain mechanism grows, more specific pain targets are now available (Figure 6.2)45. Importantly, the most recent 
studies have shown that several tetrahydrocannabinoids (THCs) exerted anti-inflammatory activity by activating 
GlyR!3 instead of CB1 receptor21.  
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                  Figure 6.2. Pain classification and representative indications modified from Melnikova 201045  
 
Threat:  Two major threats to developing of new analgesic are upcoming regulations and the current trend in 
developing analgesics45. It was predicted that the safety issue of current analgesics in the market would result in 
future stricter regulations and give only narrow window of opportunity for analgesics with new mode of action. In 
contrast, pain drug development is still in favor of the known analgesics such as the modulators of cannabinoid 
receptors whose market sharing remains the highest among today’s approved analgesics. Also, recent pain market 
analysis strongly indicated that pharmaceutical companies are opting to reformulating the old analgesics (e.g. 
OxyContin and morphine/naltrexone combination) than discovering new drugs. Indeed, a 2010 figure showed that 
most of the pain relief marketed drugs derived from the known analgesics with Remoxy and Ofirmev as the only 
new comers (Figure 6.3)45.  
                            
Figure 6.3. Projected annual peak sells of selected pain drugs representative for various pain medications modified from Melnikova 201045 
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Figure 1 | Pain classification and representative indications. Distinguishing between different 
types of pain is critical for proper treatment. Pain can be classified by its duration into acute and 
chronic pain. Chronic pain is further classified by the source of pain production: nociceptive pain, 
which is transmitted by nociceptors from the site of injury or tissue damage (for example, inflamed 
joints in arthritis); neuropathic pain, which is initiated or caused by a primary lesion or dysfunction 
in the nervous system (further subdivided into central and peripheral, involving the central and 
peripheral nervous systems, respectively); visceral pain, which involves the internal organs; mixed 
pain, which is of mixed origin. Prevalence for selected chronic pain conditions in the United States 
is indicated. Sources: Centers for Disease Control and Prevention, National Center for Health 
Statistics, Arthritis Foundation, National Institutes of Di b tes and Digestive and Kidney Dise ses, 
American Pain Society, The American Pain Foundation.
Figure 2 | Total value and market share by 
sales in the seven major pharmaceutical 
markets of major pain drug classes in 2009. 
Market shares of major drug classes as sales 
percentages of the total are indicated. NSAIDs, 
non-steroidal anti-inflammatory drugs. Sources: 
Datamonitor, IMS Health, Decision Resources.
Figure 3 | Projected annual peak sales of selected pain drugs representative for the 
various categories of pain medications. OxyContin (controlled-release oxycodone;  
Purdue Pharma), Remoxy (long-acting oxycodone; King Pharma/Pain Therapeutics) and Embeda 
(morphine plus naltrexone; King Pharma) are oral formulations. Lidoderm (5% lidocaince patch; 
Endo) and Duragesic (transdermal fentanyl; Johnson & Johnson) are topical formulations. 
OFIRMEV (intravenous acetaminophen; Cadence) is an injectable. Lyrica (pregabalin; Pfizer)  
is an anticonvulsant. Cymbalta (duloxetine; Eli Lilly) and Savella (milnacipran; Forest/Cypress)  
are antidepressants. All drugs are on the market except for Remoxy and OFIRMEV; the new  
drug application for Remoxy is anticipated to be re-submitted in the fourth quarter this year,  
and OFIRMEV is anticipated to be approved in the third quarter of this year. Numbers for  
Lyrica and Cymbalta indicate sales in all indications. Approximately 30–35% of Lyrica 
prescriptions are estimated to be for neuropathic pain and fibromyalgia. Approximately  
20–25% of Cymbalta prescriptions are for neuropathic pain and fibromyalgia. Sources: company 
information, analyst reports.
The global pain market in 2009 was valued at 
over US$50 billion, including $27 billion in 
the seven major economies (the US, Japan, 
France, Germany, Italy, Spain and the UK) 
(FIG. 2). An ageing population, increases in the 
prevalence of chronic painful conditions, new 
product approvals, as well as improvements 
in education of both physician and patients 
regarding available treatment options should 
continue to sustain the growth and further 
development of this market.
Owing to the availability of generic 
compounds, pricing will become an important 
consideration and only a limited number 
of new products are projected to achieve 
blockbuster status (sales over $1 billion) 
(FIG. 3). Thus, novel agents are unlikely to 
displace any of the currently approved drug 
classes and are likely to be indicated for use  
in specific patient populations.
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Figure 1 | Pain classification and representative indications. Distinguishing between different 
types of pain is critical for proper treatment. Pain can be classified by its duration into acute and 
chroni  pain. Chronic pain is further classified by the source of pain roduction: nociceptive pain, 
which is transmitted by nociceptors from the site of injury or tissue damage (for example, inflamed 
joints in arthritis); neuropathic pain, which is initiated or caused by a primary lesion or dysfunction 
in the nervous system (further subdivided into central and peripheral, involving the central and 
peripheral nervous systems, respectively); visceral pain, which involves the internal organs; mixed 
pain, which is of mixed origin. Prevalence for selected chronic pain conditions in the United States 
is indicated. Sources: Centers for Disease Control and Prevention, National Center for Health 
Statistics, Arthritis Foundation, National Institutes of Diabetes and Digestive and Kidney Diseases, 
American Pain Society, The American Pain Foundation.
Figure 2 | Total value and market share by 
sales in the seven major pharmaceutical 
markets of major pain drug classes in 2009. 
Market shares of major drug classes as sales 
percentages of the total are indicated. NSAIDs, 
non-steroidal anti-inflammatory drugs. Sources: 
Datamonitor, IMS Health, Decision Resources.
Figure 3 | Projected annual peak sales of selected pain drugs representative for the 
various categories of pain medications. OxyContin (controlled-release oxycodone;  
Purdue Pharma), Remoxy (long-acting oxycodone; King Pharma/Pain Therapeutics) and Embeda 
(morphine plus naltrexone; King Pharma) are oral formulations. Lidoderm (5% lidocaince patch; 
Endo) and Duragesic (transdermal fentanyl; Johnson & Johnson) are topical formulations. 
OFIRMEV (intravenous acetaminophen; Cadence) is an injectable. Lyrica (pregabalin; Pfizer)  
is an anticonvulsant. Cymbalta (duloxetine; Eli Lilly) and Savella (milnacipran; Forest/Cypress)  
are antidepressants. All drugs are on the market except for Remoxy and OFIRMEV; the new  
drug application for Remoxy is anticipated to be re-submitted in the fourth quarter this year,  
and OFIRMEV is anticipated to be approved in the third quarter of this year. Numbers for  
Lyrica and Cymbalta indicate sales in all indications. Approximately 30–35% of Lyrica 
prescriptions are estimated to be for neuropathic pain and fibromyalgia. Approximately  
20–25% of Cymbalta prescriptions are for neuropathic pain and fibromyalgia. Sources: company 
information, analyst reports.
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Considering the SWOT, the development of GlyR modulators for pharmacological probes/drug include 
prioritizing target molecules, tackling supply issue, evaluating current GlyR modulators against other members of 
cys-loop ligand gated ion channel and/or other receptors as well as conducting in vivo assay focusing on specific 
pain target (i.e. neuropathic pain) and establishing a partnership with a pharmaceutical company.  
Prioritization of a target molecule for discovering anti-inflammatory pain from the recent discovery takes into 
consideration bioactivity, specificity and synthetic accessibility of current GlyR modulators. For example, 
although aplysinopsin type compounds, both monomers and dimer, strongly antagonized GlyR"1139, they also 
inhibited GlyR"3 suggesting their unspecific activity against either GlyR"1 or GlyR"3. Also, as mentioned in 
the introduction of Chapter 5, dimeric aplysinopsin has not been synthetically accessible and therefore is not 
considered as lead compound for the development of pain relief drugs at this moment. In contrast, apart from 
being synthetically accessible126,136, both linear (8-hydroxyircinialactam A (3.46), 8-hydroxyircinialactam B (3.47) 
and cyclic sesterterpene glycinyl lactams (ircinianinlactam (4.11) and oxo-ircinianinlactam A (4.14) showed 
potent and specific modulation activity against GlyR"1 (3.46-3.47 and 4.14) and GlyRa3 (4.11)101,133 rendering 
them feasible target for the development of pharmacological tools and/or drugs for treating inflammatory pain. 
The following describes two plausible synthetic strategies in generating novel anti-inflammatory pharmacological 
tools and/or drugs inspired by both linear and cyclic glycinyl lactams. 
 
 
6.2.2 Synthetic Strategy  
6.2.2.1 First Approach  
The first approach incorporates wistarin and ircinianin synthesis136 followed by the conjugation of the tetra- and 
pentacyclic sesterterpenes with several amines such as glycine, taurine, ethanolamine and dopamine126. Also our 
preliminary study suggested that the oxo-ircinianin and other ircinianin derivatives could be generated through 
oxidation of ircinianin under UV in the presence of Rose Bengal suggesting the possibility to generate oxo-
ircinianin and other ircinianin derivatives through oxidation. Once ircinianin is obtained, it will be oxidized to 
yield regioisomers hydroxy-!-lactones (6.2 and 6.3). Conjugation of 6.2 and 6.3 with glycine will produce 
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hemiaminals (6.4-6.5) and reduction of 6.4 and 6.5 with NaBH3CN will give both " and #-substituted !-lactams, 
ircinianin lactams (ILMs) (6.6-6.7). Similarly, conjugations between regioisomer-!-lactones with ethanolamine, 
dopamine or taurine are expected to yield both regioisomers of ircinianin-ethanolaminyls (IELs) (6.10-6.11), 
ircinianin-taurinyls (ITLs) (6.14-6.15) and ircinianin-dopaminyls (IDLs) (6.18-6.19) (Scheme 6.1). The same 
treatments to oxo-ircinianins and wistarins are predicted to yield oxo-ircinianin lactaminyls (OLLs) (6.20-6.21), 
oxoircinianin-ethanolaminyls (OELs) (6.22-6.23), oxo-ircinianintaurinyls (OTLs) (6.24-6.25), oxoircinianin-
dopaminyls (ODLs) (6.26-6.27), wistarin-lactaminyls (WLLs) (6.28-6.29), wistarin-ethanolaminyls (WELs) 
(6.30-6.31), wistarin-taurinyls (WTLs) (6.32-6.33) and wistarin-dopaminyls (WDLs) (6.34-6.35) (Figure 6.2).  
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Scheme 6.1.  Synthesis of ircinianin lactams and derivatives. MCPBA, NaOAc and AcOH, (2a) glycine, (2b) ethanolamine, (2c) taurine 
and (2d) dopamine (3a-d) NaBH3CN, HCl, MeOH. 
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6.2.2.2 Second Approach  
Alerted by the inactivity of ircinialactam C, ent-ircinialactam C, ircinialactam D (Chapter 3)101, ianthellalactam A 
and ianthellalactam B (Chapter 5)133 and inspired by anti-inflammatory activity of as N-arachidonyl glycine 
(NAGly)174 and potent activity of sesterterpene glycinyl lactams against GlyRs101,133, a second approach involves 
coupling between glycinyl moiety and a range of fatty acids such as arachidonic, linolenic, and lenoleic acids 
instead of linear terpene units.  
The premise is that fatty lipoaminoacid such as N-arachidonyl glycine (NAGly) (6.36) was abundant in the rat 
skin and spinal cord, exerting a strong anti-nociceptive effects in vivo21. The anti-inflammatory activity of NAGly 
was linked with its ability in inhibiting the hydrolysis of anandamide or N-arachidonyl-ethanolamine (AEA) 
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(6.37)—an endogenous ligand for the brain receptors of marijuana’s active principle &9-tetrahydrocannabinol, the 
type-1 cannabinoid receptor (CB1)21—by fatty acid amide hydrolase (FAAH), the regulator of AEA signaling in 
vivo. NAGly was also not recognized by AEA membrane receptor and more importantly was inactive against 
cannabinoid receptors178,179 suggesting not only that NAGly’s inflammatory activity was independent of CB1 
receptor but also that it was deprived of adverse effects related to CB1 such as drug abuse and addiction21. 
Interestingly, several tetrahydrocannabinoids were very recently reported to exert their analgesic effect by 
modulating, not CB1, but GlyRs in particular GlyR"3 strongly suggesting that cannabis-induced analgesia was 
correlated with potentiation of GlyRs by cannabinoid, a mechanism currently largely unexplored due to the lack 
of understanding regarding mechanism and behavioral implication of cannabinoid potentiation of GlyRs21. 
Unfortunately like other fatty acid amides such as arachidonilglycerol (6.38), N-acyl taurine (6.39), N-
palmitolethanolamine (6.40) and oleamide (6.41), NAGly was prone to FAAH hydrolysis174 with its  rapid 
metabolism by the enzyme leading to the low level of AEA which in turn diminished anti-inflam=[matory 
activity. 
Over the years, many studies have addressed this issue by replacing the acylic amide or ester with cyclic 
substituent with A9-octadeceynoil-a-keto-N4-oxazolopyridine (6.42) as a good example exerting Ki value of 140 
pM against FAAH174. Curiously, our results strongly indicated that glycinyl lactam moiety dictated the activity of 
both linear and cyclic sesterterpenes towards "1 and "3 GlyRs (Chapter 3 and Chapter 4)101,133 and that N-acyl 
glycine (6.43) can be viewed as the cyclic version of N-arachidonic glycine. Therefore, we propose that 
replacement of the glycine with glycinyl lactam moiety will result in N-arachidonic acid lactams (NALs) that are 
more resistant to FAAH hydrolysis and can maintain high level of AEA in the spinal cord which in turn exert 
more potent anti-inflammatory activity.  
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The preparation of NALs proceeds from alkyl furan analogues through the corresponding Grignard reagent via 
a coupling with primary alcohols prepared from readily available fatty acids (i.e. arachidonic, linolenic, 
linoleic and oleic acids) to yield a library of 3-alkylfurans that can be transformed by photo-oxidation and/or 
NBS to alkylbutenolides (Figure 6. 4A). Treatment of alkylbutenolides with glycine will yield the target N-
glycinyl lactams (NGLs). With a successful synthetic methodology in place as shown in Figure 6.4A, 
replacement of glycine with other amines will lead to N-glycinyl lactams (NGL), N-ethanolaminyl (NEL), N-
taurinyl (NTL) and N-dopaminyl (NDL) structure class (Figure 6.4B). The following steps would be to 
couple NGL, NEL, NTL and NDL with a range of fatty acids such as arachidonic acid, linolenic acid, 
linoleic acid and oleic acid (Scheme 6.2a). Treatment of acyl chloride of arachidonic acid with NGL, NEL, 
NDL and NTL will give N-acyl glycinyl lactam (NAGL) (6.43), N-acyl ethanolaminnyl lactam (NAEL) 
(6.44), N-acyl dopaminyl lactam (NADL) (6.45) and N-acyl taurinyl lactam (NATL) (6.46) respectively 
(Scheme 6.2a). Alternatively, these compounds can be prepared from direct condensation between the 
arachidonic acid and the corresponding amine or alcohol in the presence of dicyclohexylcarbodiimide (DCC) 
and catalytic amounts of N,N-dimethyl-4-4-aminopyridine (DAMP) (Scheme 6.2b). Reacting a series of fatty 
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acids (linoleic, linolenic and oleic acids) and NGL, NEL, NTL and NDL will generate NAGL (6.43), NAEL 
(6.44), NATL (6.45) and NADL (6.46) (Figure 6.2b). 
 
 
 
  
                  
                     (A) 
 
 
 
 
 
             (B)                                                  (A) 
 
 
 
 
                     (C) 
 
                     
 
 
Figure 6.4.  Synthesis of glycine moiety from alkyl furan and fatty acids (A), NEL, NTL and NDL (B) and faty acids (C) 
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                                  Scheme 6.2. The synthesis of glycine moiety from alkyl furan and fatty acids 
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Scheme 6.2.  Synthesis of NAGL, NEGL, NDGL and NTGL. (a) oxalyl chloride, DMF CH2Cl2, rt (b) DCC, DAMP, CH2Cl2, rt.  
 
 
Once synthetic analogues have been produced, their biological activities need to be evaluated in vitro and in vivo 
studies. To determine their specificity towards GlyR"1 and/or GlyR"3, all synthetic compounds obtained from 
the first and second approaches will be evaluated in SAR studies against all GlyR subunits and/or other members 
of cys-loop LGIC. Promising candidates will be further evaluated in enzymatic catalytic against FAAH to 
evaluate their specificity against GlyR. Furthermore, Tail Flick Reflex (TFR) and Hot Plate Test (HPT) should be 
conducted for promising candidates with the previous aiming at evaluating spinal reflex while the latter assessing 
supraspinal processing180. All these evaluations need to be performed prior to establishing research collaboration 
with a pharmaceutical company as this approach was shown to be effective in bringing salinosporamide A in to 
the pipeline, the fastest MDDs to enter the clinical trials70.  
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Toward this end, screening of >2,500 southern Australia and Antarctic marine invertebrates against GlyRs using 
YFP and automated patch clamp electrophysiology successfully identified a series of GlyR modulators from 7 
priority specimens, featuring three main pharmacophores such as aplysinopsin, linear and cyclic sesterterpene 
glycinyl lactams. In particular, the latter two pharmachopores may contribute to the discovery of new GlyR 
pharmacological tools and/or therapeutics to treat CNS diseases. For example, in addition to having potential in 
treating hyperekplexia, spasticity and other movement disorders, 8-hydroxyircinialctam A (3.46), 8-
hydroxyircinialctam B (3.47), ($)-oxo-ircinianin lactam (4.14) can inspire the development of GlyR"1 
pharmacological probes and/or pain relief drug(s) due to their specific and/or potent potentiation activity against 
GlyR"1. More importantly, ($)-ircinianinlactam A (4.11)133 potently and specifically potentiated GlyR"3, the 
emerging pain target whose activation by cannabinoid was recently shown to contribute to analgesia21, rendering 
4.11 as the most interesting lead molecule for the development of both GlyR pharmacological probe(s) and/or 
chronic anti-inflammatory pain drug(s).  
Despite their promising anti-inflammatory potential, limited material remains the major challenge for the 
development of these lead compounds precluding, at the moment, intensive pharmacological studies such as in 
vitro against other receptor members of LGIC superfamily or in vivo in animal models133. Fortunately, both 
ircinianin136 and glycinyl lactam126 type compounds are now synthetically accessible suggesting the feasibility of 
developing anti-inflammatory pain drugs by mimicking both linear and cyclic glycinyl lactam pharmacophores. 
Hence, two synthetic approaches are proposed to achieve this goal including derivatisation of ircinianinlactams 
and incorporation of glycinyl lactam moiety to fatty acids. Following on the synthetic applications, it is 
recommended that comprehensive in vitro and in vivo studies are conducted before establishing partnership with a 
pharmaceutical company, a successfully applied strategy in rapidly advancing salinosporamide A to the 
pipeline70.  
Therefore, provided that synthetic plans are well-addressed, high potency and specificity towards GlyRs in 
particular GlyR"3 are confirmed both in vitro and in vivo assays and partnership with a pharmaceutical company 
is established, novel, potent and specific GlyR"1 and GlyR"3 modulators have a fighting chance of advancing to 
the pipeline and hopefully to the clinic.  
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